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ABSTRACT 
 
Mitochondrial dysfunction accounts for an important and heterogeneous group of inherited 
metabolic disorders with hitherto no effective therapeutic options. Most of the known 
mitochondrial disorders are caused primarily by a dysfunctional oxidative phosphorylation 
system (OXPHOS) and consequently a deficient energy production. OXPHOS depends 
on the coordinated expression of both nuclear and mitochondrial genomes. Therefore, 
mitochondrial diseases can be caused by genetic defects in the mitochondrial or the 
nuclear genome. This may affect the interplay between the two genomes, causing 
nuclear-mitochondrial intergenomic communication disorders. The organelle/nucleus 
cross-talk has gained increased relevance in the past years and since then many genes 
have been identified as being involved in these diseases. Mitochondrial cross-talk 
disorders are particularly severe and can be divided in two groups: i) mitochondrial DNA 
(mtDNA) multiple deletions syndrome, that share features such as ocular and limb 
myopathy, and ii) mtDNA depletion syndrome (MDS) which comprises a heterogeneous 
group of autosomal recessive disorders occurring in infancy or early childhood with three 
clinical categories: myopathic, encephalomyopathic and hepatocerebral MDS. 
In this work 47 patients clinically suspicious of intergenomic communication disorders 
were selected to be investigated at the molecular level. In 55% of these patients mtDNA 
depletion or multiple deletions were present. From these, “primary” mtDNA depletion was 
detected in 17 patients, whereas “secondary” mtDNA depletion was identified in eight 
cases and mtDNA multiple deletions were shown in only one patient. The spectrum of 
identified mutations encompasses the following genes: MPV17, DGUOK, SUCLA2, 
C10orf2, POLG, and TAZ, in patients with “primary” mtDNA depletion; TTC19 and RARS2 
in those with “secondary” mtDNA depletion; and TYMP in a patient with mtDNA multiple 
deletions. However, some of the studied patients still remain undefined, because no 
mutations were detected, demonstrating that whole exome sequencing could be an 
effective alternative to seek for new candidate genes. Additionaly, we tested some 
therapeutical agents in vitro in order to appreciate their efficacy in the enhancement of 
mitochondrial ATP generation and in the reduction of ROS production. These potential 
therapeutic compounds can have an impact on patients health and offer novel prospective 
against mitochondrial diseases. 
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RESUMO 
 
As citopatias mitocondriais constituem um importante grupo de doenças hereditárias do 
metabolismo de expressão clínica heterogénea, para as quais não existe uma terapia 
eficaz. A maioria das doenças mitocondriais descritas são causadas por uma disfunção 
ao nível do sistema da fosforilação oxidativa (OXPHOS), originando consequentemente 
uma deficiente produção de energia. O correto funcionamento do OXPHOS resulta de 
uma interação coordenada entre o genoma nuclear e mitocondrial. Assim, as doenças 
mitocondriais podem ser causadas por defeitos moleculares no genoma mitocondrial, no 
nuclear, ou em ambos, originando doenças da comunicação intergenómica. Estas 
doenças resultam da perda ou instabilidade do DNA mitocondrial (mtDNA), e podem ser 
devidas quer a deleções múltiplas, quer a depleção do genoma mitocondrial. As doenças 
da comunicação intergenómica adquiriram bastante relevância nos últimos anos tendo 
sido descritos um vasto número de genes associados a estas patologias. Estas doenças 
podem ser divididas em dois grandes grupos: i) o síndrome das deleções múltiplas do 
mtDNA, que se caracteriza pelo aparecimento de miopatias oculares e dos membros e ii) 
o síndrome da depleção do mtDNA, que constitui um grupo de doenças autossómicas 
recessivas que se manifestam durante a infância ou início da adolescência com três 
apresentações clínicas distintas, nomeadamente miopática, encefalomiopática e 
hepatocerebral. 
Neste trabalho foram selecionados para estudo molecular 47 doentes clinicamente 
suspeitos de doenças da comunicação intergenómica. Em 55% dos casos encontrou-se 
depleção do mtDNA ou deleções múltiplas, 17 dos quais apresentaram depleção 
“primária” do mtDNA, oito depleção “secundária” do mtDNA e apenas um doente 
apresentou deleções múltiplas do mtDNA. O espectro mutacional identificado neste 
estudo encontra-se distribuído pelos seguintes genes: MPV17, DGUOK, SUCLA2, 
C10orf2, POLG, e TAZ, nos casos com depleção “primária” do mtDNA; TTC19 e RARS2 
nos doentes com depleção “secundária” do mtDNA; e pelo gene TYMP, num doente com 
deleções múltiplas do mtDNA. Contudo, alguns dos casos estudados continuam sob 
investigação molecular, devido ao fato de não terem sido identificadas mutações causais, 
o que significa que a utilização da sequenciação do exoma, poderá permitir esclarecer a 
etiologia molecular destes doentes. Para além disso, foram testados alguns agentes 
terapêuticos in vitro, de modo a avaliar a sua eficácia, quer ao nível do aumento da 
produção de ATP, quer quanto à redução das espécies reativas de oxigénio. Estes 
compostos com potenciais efeitos terapêuticos poderão ter grande impacto na saúde dos 
doentes e estabelecer novas estratégias terapêuticas para o tratamento destas patologias. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
  
Chapter I Introduction 
 
3 
 
INTRODUCTION 
 
1.1. Mitochondria 
Mitochondria, from the Greek mitos (thread-like) and khondros (grain or granule), are 
bacterium-sized organelles found in all nucleated cells. They are dynamic subcellular 
organelles present in virtually all eukaryotic cells with numerous functions, but it is fair to 
say that what sets them apart is their role in energy production. To reiterate an often used 
term, mitochondria are the ‘powerhouses of the cell’ because they generate more than 
90% of a typical cell’s adenosine triphosphate (ATP), which is the ‘energy currency’ of the 
cell (Schon et al., 2012). They play an important role in various metabolic and 
developmental processes such as calcium homeostasis, apoptosis and programmed cell 
death, just to mention some. Mitochondria produce ATP by means of the mitochondrial 
respiratory chain (MRC) and oxidative phosphorylation (OXPHOS) system, a series of five 
enzyme complexes embedded in the inner mitochondrial membrane (IMM).  
 
 
1.1.1. Organization and function of mitochondria 
Mitochondria are large organelles, approximately one micron in size, found in the cytosol 
of all cells. Mitochondrial metabolism is compartmentalized by a two-membrane system: 
the outer mitochondrial membrane (OMM) and the IMM that envelop an aqueous 
compartment, the mitochondrial matrix (Figure 1). The space between the inner and outer 
membranes is referred to as the intermembrane space and has an ionic composition 
similar to the cytosol. The integrity of these membrane structures is essential for proper 
mitochondrial function. In addition, specialized domains within the membrane system 
provide interaction with the rest of the cell in order to coordinate its energy demands 
(Rosenberg, 2004). 
The OMM is responsible for interfacing with the cytosol and its interactions with 
cytoskeletal elements are important for movement of mitochondria within a cell. This 
mobility is essential for the distribution of mitochondria during cell division, differentiation, 
and possibly for positioning of mitochondria to cellular regions under intense demands for 
energy. This membrane contains a large number of integral proteins, termed porins, and 
is also involved in the transport of proteins from the cytosol to the interior of mitochondria. 
Small molecules less than 15 kD are freely diffusible to the intermembranous space, 
however, larger molecules only enter through the translocase of the outer membrane 
(TOM) complex, when a signalling sequence to the mitochondria is present. 
Chapter I Introduction 
 
4 
 
The IMM is much more selective than the OMM and fold into the matrix to form cristae. A 
translocase of the inner membrane (TIM) complex can be found, which facilitate the 
translocation of proteins into the matrix and also the insertion of proteins into the IMM. 
Here integral membrane proteins are found such as the five complexes of the MRC 
including the electron transport chains (complexes I-IV), ATP synthase (complex V), and 
the the adenine nucleotide translocator (ANT). Electron transport through the MRC 
generates the electrochemical gradient necessary to produce ATP. Key components of 
the electrochemical gradient include the membrane potential of IMM and the proton 
gradient . 
The matrix contains the mitochondrial genetic system as well as several enzymes, 
including those for the tricarboxylic acid (TCA) cycle, oxidation of pyruvate and fatty acids 
and the machinery used in macromolecular synthesis which is required for mitochondria to 
replicate and function properly (Rosenberg, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Schematic representation of mitochondria structure (figure adapted from 
http://commons.wikimedia.org/wiki/File:Mitochondrion_(standalone_version)-en.svg). 
 
These structural dynamics may serve to regulate mitochondrial metabolism (Dieteren et 
al., 2011). Mitochondrial internal and external structure varies with cell type and metabolic 
state and often becomes altered during mitochondrial dysfunction. Mitochondrial 
morphology also depends on the balance between mitochondrial motility, fission, and 
fusion. This equilibrium is regulated by dedicated proteins and plays a role in metabolic 
energy dissipation, turnover of damaged mitochondria, distribution of mitochondria 
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throughout the cell, induction of apoptosis, mitochondrial inheritance during cell division, 
and defense against aging (Westermann et al., 2010).  
The mitochondrial fundamental role is related with the cellular energy metabolism, which 
includes the TCA, the fatty acid β-oxidation, the urea cycle and the final common pathway 
for ATP production – OXPHOS (Friedkin and Lehninger 1949; Attardi and Schatz 1988). 
 
Inner mitochondrial membrane lipid milieu 
The phospholipid component of the IMM, in which the MRC resides, provides much more 
than a passive cell scaffold. Alterations of the lipid milieu are increasingly being 
associated with mitochondrial encephalomyopathies.  
Cardiolipin is a dimeric molecule composed of two phosphatidylglycerol moieties 
connected by a glycerol group (Schlame et al., 2005), is the signature mitochondrial 
phospholipid and a major component of the IMM, where it is synthesized. Cardiolipin 
contains four acyl chains, the composition of which depends on the deacylation–
reacylation activity of tafazzin, a phospholipid–lysophospholipid transacylase that confers 
cell-type and tissue specificity (Schlame et al., 2012; Claypool et al., 2012). 
The mitochondria-associated membrane (MAM) is a close physical and functional 
association between the endoplasmic reticulum and mitochondria. These membranes 
consist of specialized detergent-insoluble lipid raft domains that are rich in cholesterol and 
sphingolipids, and function as platforms for membrane proteins (Hayashi et al., 2009). 
MAMs are involved in multiple functions, including lipid transport, cholesterol metabolism, 
calcium signalling, energy metabolism, apoptosis and mitochondrial dynamics. MAM is a 
recently described subcellular structure. The structure, although not with the acronym 
MAM, was first described in 1990 (Vance, 1990). 
 
Mitochondrial transition pore 
Most mitochondrial functions involve proteins that control the movement of various 
molecules and ions across the IMM. The permeability transition defines an increase of 
IMM permeability to ions and solutes with molecular masses up to 1,500Da, and it is 
presumed to be mediated by opening of a channel, the permeability transition pore 
(Bernardi, 2013).  
One particularly important ion that must go through this membrane is calcium (Ca2+); once 
inside the mitochondria, Ca2+ regulate cell survival and generation of ATP. Although 
several Ca2+ import mechanisms exist, the best-studied pathway involves a pore-forming 
protein complex called the mitochondrial calcium uniporter (MCU). This ion channel has 
an exquisite selectivity, allowing only Ca2+ into mitochondria even when other ions 
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outnumber it a million-fold. Mitochondrial Ca2+ uptake via the uniporter is crucial to cell 
metabolism, signaling, and survival (Csordás et al., 2013). 
Previously, researchers had identified several genes that are required for the formation of 
the uniporter, but it had not been established which of those encode the central pore 
allowing Ca2+ to go through. Chaudhuri and collaborators have shown that one of these, a 
gene called MCU, codes for the protein subunit that creates the pore (Chaudhuri et al., 
2013). MCU is a transmembrane protein of the IMM with two predicted transmembrane 
domains connected by a loop that seems to contribute to the selectivity filter (Baughman 
et al., 2011; De Stefani et al., 2011). MCU likely oligomerizes to form a pore.  
 
 
1.1.1.1 Mitochondrial dynamics 
Mitochondrial network dynamics, much like mitochondrial DNA (mtDNA) replication, is 
controlled completely by nuclear DNA (nDNA), although likely involves mtDNA–nDNA 
communication (Youle et al., 2012). Mitochondria form a complex reticulum that is 
undergoing continual fusion and fission (Figure 2).   
Fusion (i) has evolved as a mechanism to promote inter-mitochondrial cooperation, 
allowing the sharing and dissemination of mtDNA and mitochondrial proteins.  
Fission (ii) promotes mitochondrial compartmentalization (Youle et al., 2012), a 
mechanism that is needed to distribute mitochondria during cell division. 
 
i) Mitochondrial fusion 
Mitochondrial fusion is essential to maintain a homogenous organelle population and 
ensures inter-complementation of mtDNA. Mitochondrial fusion is a two-step process, in 
which the outer and IMM fuse by separate events. In mammals OMM fusion is controlled 
by two large membrane GTPase proteins, Mitofusin1 (Mfn1) and Mitofusin2 (Mfn2), 
whereas IMM fusion is controlled by Optic atrophy 1 (OPA1). It is unknown how the fusion 
machineries are activated and how mitochondrial content, distribution and division timing 
are coordinated. The Mitofusins are essential for mitochondrial fusion and their loss of 
function results in fragmentation of the mitochondrial network (Osellame et al., 2012). 
 
ii) Mitochondrial fission 
Mitochondrial division is essential for organelle biogenesis and inheritance and left 
unregulated can lead to a heterogeneous population of organelles with non-uniform 
mtDNA distribution, varied ability to produce ATP, increased capacity to generate reactive 
oxygen species (ROS) and increased susceptibility of cells to undergo apoptosis. Fission 
is also required for the removal of aged or damaged mitochondria through a specialized 
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form of autophagy, termed mitophagy. While a number of different proteins have recently 
been proposed to actively contribute to the fission process, Dynamin related protein 1 
(Drp1) is almost the only conserved though evolution. Drp1 belongs to the large family of 
dynamin related GTPases, is dispersed in the cytosol and cycles on and off mitochondria 
in a guanosine-5'-triphosphate (GTP) dependent manner. It assembles on the OMM in 
multimeric ring-like structures to facilitate scission of the double membrane. (Osellame et 
al., 2012). 
Figure 2 - Mitochondrial dynamics. Steady state mitochondrial morphology requires a balance of fission and 
fusion events. Organelle division is mediated by Drp1 which forms high molecular weight oligomers on the 
mitochondrial surface. Once Drp1 is released fission is complete. Mitochondrial fusion is a two-step process 
that requires outer and inner membrane fusion. Outer membrane fusion is facilitated by mitofusin tethering of 
adjacent membranes. In high GTP environments, OPA1 isoforms allow inner membrane fusion (figure 
adapted from Osellame et al., 2012). 
 
 
1.1.1.2 Mitochondrial biogenesis 
Mitochondrial biogenesis is a complex process, driven by a set of nuclear-encoded 
transcription factors and assisted by transcriptional co-factors, through which the cell 
equilibrates its energy-harvesting capacity to meet its energetic demands during 
endurance exercise, caloric restriction, cold exposure, or other cellular stress, such as 
DNA damage (Andreux et al., 2013). 
Considering this transcriptional network, one can distinguish two approaches targeting 
mitochondrial biogenesis: i) the upstream regulators (for example, sensors), or ii) their 
downstream effector pathways (for example, transcription factors and co-factors). 
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i) Energy stress promotes the activation of AMP-activated protein kinase (AMPK) via an 
increase in the AMP/ATP ratio, whereas energy excess activates the mammalian target of 
rapamycin (mTOR) pathway either via an increase in levels of amino acids or via the 
activation of insulin signalling. Rapamycin, 5-aminoimidazole-4-carboxamide riboside 
(AICAR) and resveratrol simulate energy crisis by inhibiting mTOR or activating AMPK. 
AMPK-mediated phosphorylation of co-factors (such as peroxisome proliferator-activated 
receptors-Y (PPARγ) co-activator of proliferator-activated receptor gamma coactivator 1- 
1α (PGC1α)) and transcription factors (such as forkhead box O (FOXO) proteins) is a 
preliminary step required for their activation. AMPK also increases the levels of NAD+, 
which is a substrate for sirtuins. NAD+ levels can be increased either by supplying 
precursors or by inhibiting NAD+ consuming enzymes (CD38 and poly adenosine 
diphosphate (ADP) ribose polymerases (PARPs)). The increase in NAD+ levels activates 
sirtuin 1 (SIRT1), which subsequently deacetylates PGC1α and FOXO. The acetylation 
status of PGC1α is counterbalanced by the activity of the histone acetyltransferase GCN5, 
which is activated via the recruitment of steroid receptor co-activator protein 3 (SRC3). 
Sirtuin-activating compounds (STACs) can also activate SIRT1 directly (Figure 3A).  
Figure 3 - Pharmacological approaches for targeting mitochondrial biogenesis. A) Upstream sensors of 
energy status. B) Downstream transcriptional factors and co-factors (figure adapted from Andreux et al., 2013). 
FAO, fatty acid oxidation; NAMPT, nicotinamide phosphoribosyltransferase; NCOR1, nuclear receptor co-
repressor 1; OXPHOS, oxidative phosphorylation; RIP140, receptor-interacting protein 140; Rb, 
retinoblastoma protein; TCA, tricarboxylic acid. 
Chapter I Introduction 
 
9 
 
ii) The balance between the activity of co-repressors and co-activators determines the 
activation of transcription factors involved in mitochondrial biogenesis. Nuclear receptors 
such as PPARs are ideal drug targets as they are activated upon ligand binding. Likewise, 
agonist ligands for retinoid X receptor-α (RXRα), the heterodimerization partner of the 
PPARs, enhance mitochondrial function. Also, several compounds can induce the 
transcriptional activity of the oestrogen-related receptors (ERRs). The only approach 
described to modulate the activity of the transcription factor nuclear respiratory factor 1 
(NRF1) was a microRNA (miRNA)-based approach. Finally, a recombinant form of human 
mitochondrial transcription factor A (TFAM) was designed to stimulate the processing of 
mtDNA (Figure 3B). 
 
 
1.1.2. Mitochondrial respiratory chain / Oxidative phosphorylation 
The OXPHOS system is the main responsible for the production of energy in the cell and 
is carried out in IMM by the MRC complexes (I, II, III and IV) (Ghezzi et al., 2012). 
OXPHOS is composed of five enzymatic multiheteromeric, four from the MRC plus 
complex V, all embedded in the IMM, and two mobile electron shuttles, ubiquinone, a 
lipoidal quinone, and cytochrome c, a heme-containing small polypeptide. The protein 
subunits of the MRC complexes are assembled together with prosthetic groups and metal-
containing reactive centres by a set of chaperones and assembly factors, some of which 
are specific to each complex. Coenzyme Q (a lipoidal quinone) and cytochrome c are also 
involved in mitochondrial respiration, serving as ‘electron shuttles’ between the complexes 
(Wallace, 1999). The OXPHOS system is under the control of two separate genomes, the 
nuclear and the mitochondrial genomes, and all OXPHOS complexes, except complex II, 
contain both nDNA and mtDNA encoded polypeptides (Figure 4).  
In terms of function, the first two linked events of respiration, i.e. electron transfer and 
proton pumping, are carried out by the mitochondrial electron transport chain (mETC), a 
functional supramolecular structure located in the lipid bilayer of the membrane, and 
composed of four complexes (complex I–IV). In humans, complex I or reduced 
nicotinamide adenine dinucleotide (NADH) - ubiquinone oxidoreductase, which 
accomplishes the oxidation of NADH derived by the oxidation of fatty acids, pyruvate and 
amino acids, contains seven subunits encoded by the mtDNA (subunits ND1–ND6 and 
ND4L), plus at least 37 nDNA subunits (Smeitink, 2001; Carroll et al., 2003). Among these 
44 subunits, 14 are enzymatic ‘core subunits’ (7 from mtDNA and 7 from nDNA) (Hirst et 
al., 2011) and the remaing 30 are nDNA accessory subunits thought to maintain complex 
stability (Angerer et al., 2011). Complex II or succinate-ubiquinone oxidoreductase, which 
accomplishes the oxidation of flavine adenine dinucleotide (FADH2) derived from fatty acid 
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and the TCA cycle, is composed of only four subunits, all encoded by the nDNA. Complex 
III or ubiquinol-ferricytochrome c oxidoreductase holds one subunit, cytochrome b, 
encoded by the mtDNA and 10 subunits encoded by the nDNA (Smith et al., 2012). 
Complex IV or cytochrome c oxidase (COX) is composed of 14 subunits, three of which 
are encoded by mtDNA (COX I–III) and the other 11 by nDNA. In addition, mETC contains 
two highly hydrophobic, mobile, small electron carriers, coenzyme Q10 (CoQ10) and 
cytochrome c, both synthesized by nuclear genes. In substance the mETC is especially 
built to accept electrons from NADH and FADH2, transfer them through a series of 
oxidation–reduction reactions to molecular oxygen (O2) to produce water and 
simultaneously coupling this exergonic reaction to the translocation of protons across the 
IMM (Saraste, 1999; Di Donato, 2000). Synthesis of ATP from ADP is the second 
fundamental reaction of the MRC, a process performed by complex V or ATP synthase. 
ATP synthase is also a genetic mosaic, since it is composed of two mtDNA-encoded 
subunits (ATPase 6 and 8), and at least 17 nDNA-encoded subunits.  
 
Figure 4 – Schematic view of the OXPHOS complexes. Ninety-two structural OXPHOS subunit genes have 
been identified: 13 encoded by mtDNA and 79 encoded by the nuclear genome. Complex I consists of 44 
subunits, seven encoded bt mtDNA and 37 encoded by nDNA. Complex II is encoded entirely by four nDNA 
subunits. Complex III contains 11 subunits, one encoded by mtDNA and 10 encoded by nDNA. Complex IV 
consists of three mtDNA-encoded subunits and a further 11 nDNA-encoded subunits. Finally, complex V 
comprises 19 subunits, 2 encoded by mtDNA and the remaining 17 encoded by nDNA. In addition, nDNA 
encodes over 39 proteins required for the MRC assembly: 11 nDNA assembly factors of complex I, two of 
complex II, four of complex III, 18 of complex IV and four of complex V (figure adapted from Shon et al., 2012). 
 
 
As mentioned, the proton electrochemical gradient generated at the mETC level during 
electron transfer to O2 creates a polarization of the IMM which is changed back by the 
proton flux through a proton channel that resides in the F0 component of ATP synthase. 
The proton flux drives the condensation of ADP and inorganic phosphate into ATP 
(Saraste, 1999; Wallace, 1999). Electron transfer across the mETC and ATP synthesis is 
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coupled, or linked. In fact, the MRC works as a proton pump which generates a proton 
gradient and a membrane potential of about 180mV across the IMM with a negative 
polarity at the matrix side of the IMM. The proton gradient is utilized by the ATP synthase 
to phosphorylate matrix ADP. During this process the proton gradient decreases and this 
activates respiration, i.e. electron transfer (Saraste, 1999). 
Hence, the fundamental reaction of life, i.e. O2 activation and the conservation of energy 
in cell respiration, is essentially a function of the integrity of the MRC (Babcock and 
Wilkstrom, 1992). Notably, energy production in mitochondria requires not only a full 
assembly of functional protein at the level of the IMM, but also a bidirectional flow of 
information between the nuclear and the mitochondrial genomes to adjust energy 
production in tissues to different energetic demands (Poyton and McEwan, 1996). 
Accordingly, many different mutations in mtDNA and nDNA encoding subunits, including 
nuclear proteins necessary for the proper assembly/stability of the MRC complexes, can 
produce a wide range of OXPHOS diseases (DiMauro and Schon, 2003; Zeviani and 
Carelli, 2003; Ghezzi et al., 2012). 
 
 
1.1.3. The genetic system of mitochondria 
The MRC is the only metabolic pathway in the cell that is under the dual control of the 
mtDNA and nDNA. Therefore, a genetic classification of the mitochondrial diseases 
distinguishes disorders due to mutations in mtDNA, which are governed by the laxer rules 
of mitochondrial genetics, and disorders due to mutations in nDNA, which are governed 
by the stricter rules of Mendelian genetics. 
 
 
1.1.3.1. Human mitochondrial genome 
The human mtDNA is a circular, double-stranded molecule with a striking economy of 
sequence organization, compressing 37 genes into 16.6 kilobase pairs of DNA (Figure 5). 
Unsurprisingly, here are no introns and the genes are arranged end to end with little or no 
intergenic regions. However, there is one sizeable non-coding region (D-loop) that 
contains a number of important regulatory elements for replication and transcription. 
MtDNA is devoted to the synthesis of 13 subunits of respiratory complexes I, III, IV, and V. 
In addition mtDNA encodes the 22 transfer RNAs (tRNAs) and two ribosomal RNAs 
(rRNAs) necessary for translation within the organelle. The two strands of human mtDNA 
have different nucleotide compositions and are designated heavy (H) and light (L), 
according to their buoyant density on cesium chloride gradients. The H-strand contains 
most of the coding material, including 12 of the 13 protein-coding genes, both rRNAs, and 
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14 of the 22 tRNAs, whereas the DNA L-strand encodes a single protein and eigh tRNAs 
(Pearce  et al., 2013).  
 
 
 
 
 
 
 
Figure 5 – Mitochondrial DNA. The human 
mitochondrial genome. The 37 mtDNA - 
encoded genes include seven subunits of 
complex I (ND) 1, 2, 3, 4, 4L, 5 and 6, one 
subunit of complex III (Cyt b), three subunits 
of complex IV (COX) I, II and III, two subunits 
of complex V (A6 and A8), two rRNAs (12S 
and 16S) and 22 tRNAs (one-letter code). 
Also shown are the origins of replication of the 
heavy strand (OH) and the light strand (OL), 
and the promoters of transcription of the 
heavy strand (HSP) and light strand (LSP) 
(figure adapted from Schon et al., 2012). 
 
 
 
 
 
 
 
The fact that mtDNA is a compartmentalized extrachromosomal element contributes to its 
unique genetic features (Figure 6), such as: 
 
i) Heteroplasmy and threshold effects. In contrast to nuclear genes, each consisting of 
one maternal and one paternal allele, there are hundreds or thousands of mtDNA 
molecules in each cell (polyploidy) and at cell division the mtDNA is distributed randomly 
between the daughter cells. In normal tissues, all mtDNA molecules are essentially 
identical (homoplasmy). Deleterious mutations of mtDNA usually affect some but not all 
mtDNA (heteroplasmy), and disease expression is determined largely by the proportion of 
normal and mutant mitochondrial genomes. A critical proportion of mutated mtDNA is 
necessary before biochemical defects and tissue dysfunction become apparent. This 
threshold level varies for each mutation and differs between tissues, being lower in tissues 
highly dependent on OXPHOS metabolism.  
 
ii) Mitotic segregation. During mitosis, mitochondria appear to be randomly segregated. 
In heteroplasmic cells, the proportion of mutant mtDNA in the daughter cells can therefore 
change via random genetic drift, and the phenotype may change accordingly. This 
phenomenon, called mitotic segregation, explains how the clinical phenotype in patients 
 
Human Mitochondrial DNA 
16569 bp 
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with mtDNA-related disorders may change with age and why, in rapidly dividing cells, 
particular variants of mtDNA may be gained or lost. The situation is further complicated by 
counter-selection against deleterious mutant mtDNAs, based on mitochondrial function, 
and conversely the replicative advantage of some mutant mtDNAs (Holt, 2010). 
 
iii) Maternal inheritance. At fertilization, all mitochondria (and all mtDNA) in the zygote 
derive from the oocyte (Giles et al., 1980). Therefore  mothers carrying an mtDNA point 
mutation may transmit it to all their children (males and females), but only her daughters 
will transmit it to subsequent generations. The occurrence of paternal inheritance of 
mtDNA in humans is an extremely rare event. A single case of paternal transmission of a 
pathogenic mtDNA mutation have been described in the literature (Schwartz et al., 2002) 
and has not been noted in any other cases despite systematic investigation (Filosto et al., 
2003; Taylor et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            Figure 6 – Mitochondria genetics (figure adapted from http:// acessmedicine.com). 
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1.1.3.2. Nuclear genome 
 
The mitochondrial proteome is estimated to contain about 1,500 proteins (Calvo et al., 
2006). Mitochondria are dependent upon the nuclear genome for the majority of the 
OXPHOS system and also for maintaining and replicating mtDNA as well as organelle 
network proliferation and destruction (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
         Figure 7 – Interaction between nDNA and mtDNA (figure adapted from Chinnery and Hudson, 2013). 
 
 
i) mtDNA maintenance 
Mitochondria in eukaryotic cells have lost much of their original independent function, with 
the nucleus performing the role of mtDNA maintenance, including replication and integrity. 
When the “dialogue” between the two genomes becomes incomprehensible, the resulting 
diseases are characterized by multiple mtDNA deletions and mtDNA depletion. 
Impairment of mtDNA maintenance can be attributable to defects in the replication 
machinery or in the intramitochondrial pool of deoxynucleoside triphosphates (dNTPs), the 
DNA building blocks (DiMauro et al., 2013). 
 
mtDNA replication 
Unlike nDNA, which replicates with each cell division, mtDNA replicates 
continuously and independently of cell division (El-Hattab and Scaglia 2013). 
MtDNA replication and integrity maintenance is handled entirely by the nDNA. In 
eukaryotes, mtDNA is replicated in a ‘replisome’ (a DNA/protein complex making 
up the replication machinery) by a trimeric protein complex composed of a catalytic 
subunit: polymerase gamma (POLG), a 140 kDa DNA polymerase encoded by 
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POLG and two 55 kDa accessory subunits, encoded by POLG2 (Copeland et al., 
2012). This enzyme complex performs three activities, DNA polymerase activity, 
3’-5’ exonuclease/proofreading activity and a 5’ dRP lyase activity (required for 
enzymatic DNA repair). In addition, the replisome also includes the mitochondrial 
single stranded binding protein (encoded by mtSSB), which is involved in 
stabilizing single-stranded regions of mtDNA at replication forks, enhancing POLG 
activity. Twinkle is a 5’-3’ DNA helicase, which unwinds double-stranded mtDNA, 
facilitating mtDNA synthesis, as well as acting as a mtDNA primase (an enzyme 
required to prime nucleotide synthesis) (Figure 8A) (Copeland et al., 2012). Finally, 
the synergy between mitochondrial transcription factor A (encoded by TFAM) and 
mtDNA copy number suggests that TFAM may act as an mtDNA chaperone (a 
protein that assists the function of another protein) protecting it against oxidative 
damage. 
 
Mitochondrial Nucleotide Pool 
MtDNA replication occurs throughout the whole cell cycle, depending on specific 
intramitochondrial dNTP pools. Because mtDNA turns over in post mitotic cells, it 
is clear that mtDNA is able to replicate in the absence of normal cell cycling, but it 
may not be completely autonomous (Rotig et al., 2009). A constant supply of dNTP 
is therefore required for mtDNA replication. dNTPs can be synthesized via either 
the de novo pathway, which is cell cycle-regulated, thereby operative only in S-
phase cells or the salvage pathway in which dNTPs are produced by utilizing 
preexisting deoxynucleosides to synthesize DNA precursors. 
As mtDNA synthesis is continuous throughout the cell cycle, the salvage pathway 
becomes essential for mtDNA maintenance. TK2, DGUOK, SUCLA2, SUCLG1, 
RRM2B, and TYMP genes encode proteins that maintain the mitochondrial dNTP 
pool mainly through salvage pathways; therefore, mutations in any of these genes 
result in depleting the mitochondria of DNA building blocks with subsequent 
mtDNA depletion (El-Hattab and Scaglia 2013). 
 
ii) mtDNA transcription and translation 
Transcription of mtDNA is ‘prokaryotic-like’ and was thought of a two component system 
involving a protein complex containing the mitochondrial RNA polymerase (POLRMT) and 
two transcription factors (TFB1M and 2M) (McCulloch et al., 2002; McCulloch et al., 2003). 
However, recent research indicates that TFB1M does not modulate mtDNA transcription 
in the presence of TFB2M, rather it acts as a dimethyltransferase which stabilizes the 
small subunit of the mitochondrial ribosome. RNA transcription is regulated by TFAM 
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(Metodiev et al., 2009). Briefly, each strand is transcribed as a polycistronic precursor 
mRNA molecule (i.e. the mRNA contains all of the genes in one molecule). L-strand 
transcription is initiated from the light-strand promoter; however, H-strand transcription 
initiates from two H-strand promoters: HSP1 and HSP2 (Gaspari et al., 2004). Transcript 
elongation is performed by POLRMT, enhanced by both ‘transcription elongation factor 
mitochondrial’ (TEFM) and termination of mature transcripts is carried out by 
mitochondrial termination factor 1 (mTERF1) (Gaspari et al., 2004) (Figure 8B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – The human mitochondrial genome and factors involved in mtDNA replication and 
transcription. A) The core mtDNA replication machinery in mammals includes DNA polymerase POLG, 
Twinkle helicase, and mtSSB. Replication also involves RNA priming by POLRMT, mtDNA topology alteration 
by topoisomerases, and possibly RNA incorporation into the lagging strand during leading strand synthesis. B) 
Mammalian mtDNA transcription initiates from three promoters, one for the light strand (LSP) and two for the 
heavy strand (HSP1, HSP2). The core mtDNA transcription machinery includes RNA polymerase POLRMT 
and its accessory subunit TEFM, transcription factor TFB2M, and transcription activator TFAM. RNA synthesis 
beginning from HSP2 is terminated by mTERF1 within the tRNALeu(UUR) gene while transcription started at 
HSP1 results in near genome-length polycistronic transcripts. The building blocks of nucleic acid are dNTPs 
(figure adapted from Pearce et al., 2013). 
 
 
Translation of the 13 mtDNA protein coding genes occurs in the mitochondria. The 
mitoribosomes are partly coded by mtDNA (MTRNR1 and MTRNR2), but require a further 
81 nDNA proteins. Translation is initiated by two mitochondrial initiation factors: mtIF1 and 
mtIF3 (Ma et al., 1995; Koc et al., 2002). mtIF3 begins initiation by dissociating the 
‘mitoribosome’ (the mitochondrial ribosomes) allowing assembly of the initiation complex 
(Christian et al., 2009). The mRNA is then bound to the small subunit, aligning the start 
codon to the peptidyl site of the mitoribosome. Peptide elongation is controlled by a 
 
 
 
 
 
 
A. REPLICATION 
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number of nuclear-encoded genes, including mitochondrial elongation factor Tu (mtEFTu) 
(Hammarsund et al., 2001; Ling et al., 1997), which binds the tRNA to the mitoribosome 
and mitochondrial elongation factor G1 (mtEFG1), required to move the newly added 
amino acid along one position and allowing amino acid inclusion (Smits et al., 2010). 
Translation termination is carried out solely by mitochondrial release factor 1a (mtRF1a) 
(Zhang et al., 1998), which recognizes the stop codons (UAA and UAG) (Soleimanpour-
Lichaei et al., 2007) and triggers hydrolysis of the bond between the terminal tRNA and 
the nascent peptide. 
 
iii) mtDNA arrangement 
MtDNA is also packaged in protein–DNA complexes, known as nucleoids (Bogenhagen et 
al., 2012). Nucleoids of mtDNA are associated with the IMM, spaced evenly along the 
cristae. In addition to a single mtDNA molecule (Kukat et al., 2011), mtDNA nucleoids 
contain a number of proteins (Bogenhagen et al., 2012). These nucleoids contain the 
protein machinery required for DNA replication, transcription, repair and packaging, 
including the mtDNA polymerase POLG, its accessory subunit POLG2, the activator of 
mtDNA transcription (encoded by TFAM) as well as mtDNA helicases and binding 
proteins (Twinkle and mtSSB, respectively) (Bogenhagen et al., 2012). In addition, mtDNA 
nucleoids contain chaperone proteins (HSP90-β and HSP70) required for mtDNA stability 
(Chinnert and Hudson, 2013).  
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1.2. The genetics of mitochondrial disease 
 
Mitochondrial disorders most often refer to the dysfunction of OXPHOS system leading to 
deficiency in the ATP production (Ghezzi et al., 2012).. They are a group of genetically 
and phenotypically heterogeneous disorders with an incidence estimated to be between 
1:5,000 and 1:10,000 live births (Schaefer et al., 2004). 
The clinical spectrum of mitochondrial disease is diverse (Figure 9), however, tissues 
where there is a high metabolic demand, such as the central nervous system (CNS), 
muscle or heart, are typically affected. 
Due to the complex interaction between the two cellular genomes, mitochondrial disease 
can arise through either (i) a primary mtDNA defect (sporadic or maternally inherited) or (ii) 
a defect in a nuclear-encoded mitochondrial protein (autosomal inheritance) (Chinnery 
and Hudson, 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 -  Clinical spectrum of mitochondrial diseases. Schematic diagram showing the most common 
clinical manifestations of mitochondrial disorders (figure adapted from Vafai and Mootha, 2012). 
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1.2.1. Diseases due to mtDNA defects  
Since 1988, the birthdate of mitochondrial molecular pathology (Holt et al., 1988; Wallace 
et al., 1988), the mtDNA circle has become crowded with pathogenic mutations (Figure 
10), and the principles of mitochondrial genetics should, therefore, be familiar to the 
practicing physician. 
Diseases due to defects of mtDNA can be divided into two major categories: i) single 
large-scale rearrangements of mtDNA (e.g. large scale deletions/duplications) and ii) 
mtDNA point mutations (e.g. tRNA, rRNA or protein-coding genes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 -  Morbidity map of the human mitochondrial genome. Schematic map of the 16,569-bp mtDNA, 
in which coloured sections represent protein-coding genes: seven subunits of complex I (ND; pink sections); 
one subunit of complex III (cyt b; light blue section); three subunits of cytochrome c oxidase (CO; purple 
sections); two subunits of ATP synthase (A6 and A8; yellow sections): 12S and 16S ribosomal RNA (green 
sections); and 22 transfer RNAs identified by three-letter codes for the corresponding amino acids (blue 
sections). Diseases due to mutations in genes that impair protein synthesis are indicated as blue circles. 
Mutated genes that encode respiratory chain proteins are indicated as pink circles. Numbers in circles 
represent number of mutations reported at the given site. The two black arrows indicate the 5 Kb deletion. 
Abbreviations: Cyt b, cytochrome b; FBSN, familial bilateral striatal necrosis; LHON, Leber hereditary optic 
neuropathy; LS, Leigh syndrome; MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes; MERRF, myoclonus epilepsy with ragged-red fibres; MILS, maternally inherited Leigh syndrome; 
NARP, neuropathy, ataxia and retinitis pigmentosa; ND, NADH-dehydrogenase (complex I); PEO, progressive 
external ophthalmoplegia; KSS, Kearns–Sayre syndrome; PS – Pearson syndrome (figure adapted from 
DiMauro and Schon 2013). 
 5Kb deletion  
PEO/KSS/PS  
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1.2.1.1. mtDNA rearrangements 
Pathogenic rearrangements of mtDNA are typically single large-scale deletions sporadic 
and not inheritable, and to date over 120 different pathogenic mtDNA deletions have been 
identified (MITOMAP – http://www.mitomap.org). The ratio of deleted versus ‘wild-type’ 
molecules is critical to disease etiology, with mtDNA deletions manifesting disease at a 
lower heteroplasmic threshold (~50–60%) (Rossignol et al., 2003), The exact mechanism 
of deletion formation is under debate and current research indicates two likely models of 
deletion formation: replication error and mtDNA repair inefficiency (Schon, et al., 1989; 
Krishnan et al., 2008). Single deletions of mtDNA have been associated with three 
sporadic conditions: (i) Pearson syndrome (PS), a rapidly fatal disorder of infancy 
characterized by sideroblastic anemia and exocrine pancreas dysfunction (Rotig et al., 
1990); (ii) Kearns–Sayre syndrome (KSS) (Zeviani et al., 1988), a multisystem disorder 
with onset before age 20 of impaired eye movements (sporadic progressive external 
ophthalmoplegia, PEO), pigmentary retinopathy, and heart block; frequent additional signs 
include ataxia, dementia, endocrine problems (diabetes mellitus, short stature, 
hypoparathyroidism), lactic acidosis, elevated cerebrospinal fluid (CSF) protein (over 100 
mg/dl), and ragged red fibres (RRFs) in the muscle biopsy are typical laboratory 
abnormalities. (iii) PEO with or without proximal limb weakness, often compatible with a 
normal life span (Moraes et al., 1989). Deletions vary in size and location, but a 
‘‘common’’ deletion of 5 kb is frequently seen in patients and in aged individuals (Figure 
10). Duplication of mtDNA can occur in isolation or together with single deletions and have 
been seen in patients with KSS or with diabetes mellitus and deafness. Duplications and 
duplications/deletions (as well as the associated phenotypes) are rare and usually 
transmitted by maternal inheritance (DiMauro et al., 2004). 
 
 
1.2.1.2. mtDNA point mutations  
MtDNA point mutations are usually maternally inherited and they may occur within protein, 
tRNA, or rRNA genes. However, more than half of disease-related point mutations 
reported are located within mitochondrial tRNA (mt-tRNA) genes. Phenotypically, point 
mutations in mitochondrial protein-coding genes specifically affect the function of the MRC 
complex to which the corresponding protein belongs, whereas mt-tRNA mutations may 
impair overall mitochondrial translation by reducing the availability of functional mt-tRNAs. 
Point mutations are mostly heteroplasmic and display considerable clinical heterogeneity. 
For common point mutations, a typical threshold of 80-90% mutant is required to manifest 
as disease at the cellular level. There is emerging evidence that mutation levels can 
change over time, increasing in post-mitotic tissues, such as brain and muscle and 
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decreasing in mitotic tissues including blood (Chinnery and Hudson, 2013). However, an 
increasing number of pathogenic homoplasmic mutations, often affecting just a single 
tissue and characterised by incomplete penetrance, are being recognised (Tuppen et al., 
2010; DiMauro et al., 2013). Given the high mutational rate of the mitochondrial genome 
and the presence of numerous family or population-specific polymorphisms, the distinction 
between neutral mtDNA variant and disease-causing mutation can often be difficult. Below 
some illustrations will be given: 
Leber hereditary optic neuropathy (LHON) is a common cause of inherited blindness that 
typically presents with bilateral, painless, sub-acute visual failure in young adult males. 
LHON was the first maternally inherited disease to be associated with an mtDNA point 
mutation (Wallace et al., 1988). Today, clinical diagnosis is usually confirmed by 
molecular genetic analysis for one of three ‘common’ mtDNA mutations, that affect genes 
coding for complex I subunits of the MRC: m.3460G>A, m.11778G>A and m14484T>C 
(Carelli et al., 1997). Mitochondrial dysfunction causes a specific loss of retinal ganglion 
cells (Carelli et al., 2009), whilst preserving the remaining retinal layers. The optic nerve 
also shows characteristic degeneration and an accumulation of mitochondria suggesting 
an impairment of axoplasmic transport. LHON mutations are typically homoplasmic; 
however, not all patients harbouring a pathogenic LHON mtDNA mutation develop visual 
failure. Studies of LHON have identified common mtDNA variants that may modulate 
LHON expression (Hudson et al., 2005; Achilli et al., 2012); additionally environmental 
factors, such as cigarette smoke (Kirkman et al., 2009) and oestrogen levels may play a 
role (Hudson et al., 2007). However, the majority of research has focused on the 
identification of a nuclear-encoded susceptibility allele (Hudson et al., 2005; Carvalho et 
al., 1992; Phasukkijwatana et al., 2010). 
Non-syndromic and aminoglycoside-induced sensorineuronal hearing loss is associated 
with m.1555A>G, a homoplasmic point mutation in the 12sRNA gene (Prezant et al., 
1993). The replacement involves a highly conserved region of 12sRNA, mutating the 
molecule to more closely resemble its bacterial homologue. In vitro experiments on 
m.1555A>G mutant cell lines demonstrated that exposure to aminoglycoside would impair 
growth; however, not all symptomatic individuals have been exposed to aminoglycoside 
(Prezant et al., 1993). Surprisingly, given that they make up only 5% of mtDNA, the vast 
majority of pathogenic mtDNA point mutations occur in the tRNA genes (Zifa et al., 2007; 
McFarland et al., 2004). In addition, pathogenic tRNA mutations are typically 
heteroplasmic. Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes 
(MELAS) is typically a childhood, multisystem disorder. Patients commonly manifest with 
generalized tonic-clonic seizures, recurrent headaches, anorexia with recurrent vomiting 
and postlingual hearing loss (Pavlakis et al., 1984; Hirano et al., 1992; Manwaring et al., 
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2007), but can manifest with impaired: motor ability, vision and mental acuity due to the 
cumulative effect of multiple stroke-like episodes. MELAS is commonly caused by a A>G 
transition at m.3243 in MT-TL1 (80% of cases) (Goto et al., 1990), but is also associated 
with variants in MT-ND5 (Santorelli et al., 1997). Biochemically, MELAS manifests as 
defects of complex I and IV activity; however, care must be taken when interpreting the 
findings as biochemical results can often appear normal. Myoclonus epilepsy with ragged 
red fibres (MERRF) is a neuromuscular disorder primarily caused by m.8344A>G in MT-
TK (Shoffner et al., 1990). Clinically, patients with m.8344A>G present with myoclonus, 
epilepsy, muscle weakness, cerebellar ataxia and dementia, although neurological 
symptoms can develop with age (Shoffner et al., 1990). Clinical severity is correlated with 
patient heteroplasmy with high levels of mutant mtDNA often causing, severe complex I or 
IV deficiency and occasionally a combined complex I and IV deficiency. Much like 
MELAS, the genotype–phenotype correlation of m.8344A>G can be extended beyond 
MERRF. The m.8344A>G mutation has been associated with diverse mitochondrial 
phenotypes such as Leigh’s syndrome. The mutation m.7472insC, affecting MT-TS, was 
first identified in a large Italian family presenting with hearing loss, ataxia and myoclonus 
(Mancuso et al, 2013). This mutation was later found in several unrelated families, all 
showing a wide clinical spectrum, including isolated hearing loss, ataxia and MERRF. This 
mutation has been found at increasing frequencies in families presenting with maternally 
inherited hearing loss (Chinnery and Hudson, 2013). 
 
 
1.2.2. Diseases due to nDNA mutations 
Nuclear–mitochondrial diseases have been described generally as manifesting in the 
neonatal period or early infancy, although occasional late-onset patients have been 
identified. These group of diseases can be classified into four distinct groups: i) disorders 
resulting from mutations in nuclear-encoded components or assembly factors of the 
OXPHOS system; ii) disorders resulting from mutations affecting mitochondrial translation 
and protein synthesis; iii) disorders of the IMM lipid milieu; iv) disorders due to defects in 
genes controlling mitochondrial network dynamics and v) disorders resulting from a 
reduction in mtDNA stability. 
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1.2.2.1. Disorders resulting from mutations in nuclear-encoded components or 
assembly factors of the OXPHOS system 
Isolated complex I deficiency is by far the commonest biochemical defect found in 
mitochondrial disorders; however, it has the most complex etiology and clinical spectrum 
(Haack et al., 2012). Complex I deficiency is associated with a broad range of clinical 
phenotypes ranging from lethal neonatal disease to adult onset neurodegenerative 
disorders (Loeffen et al., 2000; Lebre et al., 2011). A high level of genetic heterogeneity, 
coupled with weak genotype–phenotype correlations, makes difficult to predict the genetic 
basis on pure clinical grounds (Haack et al., 2012). This is important because of the 
different inheritance patterns and different natural histories of the different genetic causes. 
However, some patterns are starting to emerge. There are at least 46 nuclear-encoded 
subunits of complex I (compared with 7 mtDNA encoded subunits) and so it is 
unsurprising that nDNA mutations have been identified in 14 of the structural subunits. 
Pathogenic mutations in NDUFS1 (Benit et al., 2001), NDUFS3 (Haack et al., 2012; Benit 
et al., 2004), NDUFS4 (van den Heuvel et al., 1998), NDUFS7 (Smeitink et al., 1999), 
NDUFS8 (Loeffen et al., 1998), NDUFV1 (Benit et al., 2001; Schuelke et al., 1999;) 
NDUFA10 (Hoefs et al., 2011), NDUFB3 (Haack et al., 2012) and NDUFA2 (Hoefs et al., 
2008) typically manifest as Leigh or Leigh-like syndromes (MITOMAP – 
http://www.mitomap.org; Shoubridge et al., 2001). Conversely, mutations in NDUFS2 
(Loeffen et al., 2001), NDUFS6 (Kirby et al., 2004), NDUFV2 (Benit et al., 2003), NDUFA1, 
NDUFA11 (Berger et al., 2008) and ACAD9 (Haack et al., 2010) are typically associated 
with hypertrophic cardiomyopathy and encephalopathy. In addition, mutations in complex I 
assembly proteins can manifest as disease: Leigh syndrome (NDUFAF2 and NDUFAF5) 
(Calvo et al., 2010; Gerards et al., 2010), encephalopathy (NDUFAF4) (Saada et al., 
2008) and cardioencephalomyopathy (NDUFAF1) (Dunningr et al., 2007).  
Complex II is encoded only by nDNA and is composed of four polypeptide subunits: SDH-
A, B, C and D. Mutations in SDHA are rare, but are associated with Leigh’s syndrome. 
Surprisingly, mutations in SDHB, SDHC and SDHD appear to be a common cause of 
inherited paragangliomas  and phaeochromocytomas (Baysal et al., 2002).  
Complex III deficiency typically causes a severe multisystem early onset disorder, which is 
recessively inherited and rare (Petruzzella et al., 1998; de Lonlay et al., 2001). Identified 
mutations in BCS1L, a complex III assembly protein, presenting with neonatal proximal 
tubulopathy, hepatic involvement and encephalopathy. Subsequently, a deletion in human 
ubiquinone–cytochrome c reductase binding protein of complex III (UQCRB) was 
identified in a consanguineous family presenting with hypoglycaemia and lactic acidosis 
(Haut et al., 2003); and a missense mutation was identified in UQCRC, a ubiquinone-
binding protein, in a large consanguineous Israeli-Bedoiun kindred (Barel et al., 2008). 
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More recently, a mutation in TTC19 (a complex III structural subunit gene) was identified 
in individuals with a progressive neurodegenerative disorder in late infancy (Ghezzi et al., 
2011), expanding the phenotype of complex mutations beyond early infant disorders. 
Mutations in complex IV result in severe, typically fatal, infantile disease and to date 
mutations in four complex IV structural subunits have been identified. A homozygous 
mutation in COX6BI, identified in brothers from a consanguineous Saudi Arabian family, 
presented with gait instabilities visual disturbances, progressive neurological deterioration 
and leukodystrophic brain changes (Massa et al., 2008). Mutations in COX10, a 
homologue of yeast haem A: farnesyltransferase, are associated with Leigh syndrome 
(Antonicka et al., 2003; Coenen et al., 2004a) and a multisystem disorder (Antonicka et 
al., 2003). Atypically, mutations in COX7B (Indrieri et al., 2012) are associated with facial 
dysmorphisms and congenital abnormalities (Zvulunov et al., 1998), and a single mutation 
in the structural subunit gene, COX4I2, was identified in adult Arab Muslim patients with 
exocrine pancreatic insufficiency, dyserythropoietic anaemia and calvarial hyperostosis 
(Shteyer et al., 2009). In contrast, a number of mutations have been identified in complex 
IV assembly factors. Complex IV assembly gene disorders include SURF1 (Surfeit locus 
protein 1), associated with Leigh Syndrome (Zhu et al., 1998; Tiranti et al., 1999); 
C12ORF62 (chromosome 12 open reading frame 62), associated with fatal, neonatal, 
mitochondrial IV deficiency (Weraarpachai et al., 2012); COA5 (cytochrome c oxidase 
assembly factor 5), associated with neonatal hypertrophic cardiomyopathy (Huigsloot et 
al., 2011) and FASTKD2, associated with cytochrome c oxidase defective 
encephalomyopathy (Ghezzi et al., 2008).  
Mutations in nDNA-encoded complex V subunit genes also appear very rare. A mutation 
in ATP5E (ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon subunit) was 
identified in an Austrian woman with complex V deficiency (Mayr et al., 2010), and a 
single gene defect has been identified in the complex V assembly factor gene ATPAF2, 
resulting in impaired complex V activity (De Meirleir et al., 2004). 
 
 
1.2.2.2. Disorders resulting from mutations affecting mitochondrial protein 
synthesis 
Human disorders associated with protein synthesis deficiency can arise either from 
mutation in the mitochondrial genome itself (maternal inheritance) or from mutation in the 
nuclear gene products required for the translation of messenger ribonucleic acids 
(mRNAs) encoded in the mtDNA (Mendelian inheritance). 
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In the tRNA maturation process, a subset of the nucleotide bases within a nascent tRNA 
molecule undergoes specific modifications, which are critical for folding and codon 
recognition. One of the best understood modifications is pseudouridylation, common to 
both nuclear and mitochondrial tRNAs. It is proposed that pseudouridylation facilitates 
base-pairing and base-stacking within the tRNA secondary structure, increasing the 
overall stability and functional conformation of tRNAs (Patton et al., 2005). Pseudouridine 
synthase I (PUS1) has been implicated in this process in both cellular compartments. 
Mutations in PUS1 gene are causative of mitochondrial myopathy and sideroblastic 
anemia (MLASA) [OMIM #600462], a rare autosomal recessive disorder characterized by 
defects in OXPHOS and iron metabolism, with symptoms specific to skeletal muscle and 
bone marrow (Bykhovskaya et al., 2004). The disease is clinically heterogeneous, which 
has in part been attributed to the dual function that PUS1 has in nuclear and mitochondrial 
tRNA maturation, and so perturbation of PUS1 function can impact differentially on the 
two translation systems (Fernandez-Vizarra et al., 2007). 
Defects in tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase (TRMU), a 
mitochondria-specific enzyme that is required for the 2-thiolation on the wobble position of 
the tRNA anticodon, result in reduced steady-state levels of  three tRNAs (tRNALys, 
tRNAGln and tRNAGlu) and consequently impaired mitochondrial protein synthesis (Jacobs 
et al., 2005; Zeharia et al., 2009). Recently, mutations in TRMU, were detected in patients 
with acute liver failure in infancy (Zeharia et al., 2009). All patients harboring mutations in 
this gene showed combined OXPHOS deficiencies, with (near) normal complex II activity, 
and a clear defect in mitochondrial translation. Interestingly, it has been hypothesized that 
human TRMU may modulate the phenotypic manifestations of deafness-associated 
mtDNA mutations (Guan et al., 2006). Impaired tRNA modification is also predicted to 
underlie the hypertrophic cardiomyopathy and lactic acidosis associated with mutations in 
human MTO1 [OMIM #614702] (Ghezzi et al., 2012).  
Mutations in methionyl-tRNA formyltransferase (MTFMT) are another cause of defective 
mitochondrial translation (Tucker et al., 2011). Tucker and colleagues described two 
patients presenting with Leigh syndrome and combined OXPHOS deficiency, whose 
fibroblasts lacked detectable formylate - fMet-tRNAMet. Thus, some residual mitochondrial 
translation must occur in its absence, as there would be no OXPHOS activity without the 
protein products of mtDNA. 
An early essential step of protein translation involves covalently attaching an amino acid 
to its cognate transfer RNA. This process, often referred to as tRNA charging, is 
performed by a highly specialized group of enzymes, the aminoacyl-tRNA synthetases 
(ARSs). Reflecting their fundamental importance, ARSs are ubiquitously expressed 
enzymes that are found in all domains of life. Thirty-six ARSs are sufficient to 
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aminoacylate all tRNAs in humans: 16 act exclusively in the cytoplasm, 17 act exclusively 
in the mitochondria, and three are bi-compartmental. Although few mutations have been 
reported in the cytosolic ARSs, an increasing number of mitochondrial ARS mutations 
have been linked to highly tissue-specific diseases in both humans and mice.  
An intriguing observation is that mutations of genes encoding mitochondrial ARSs are 
usually associated with specific clinical syndromes. For instance, leukoencephalopathy 
with brainstem and spinal cord involvement and high lactate (LBSL) is caused by DARS2 
mutations (440 published cases) [OMIM #611105] (Scheper et al., 2007), pathogenic 
mutations in mitochondrial arginyl tRNA synthetase (RARS2) cause pontocerebellar 
hypoplasia type 6 (PCHD-6) (seven published cases) [OMIM #611523] (Edvardson et al., 
2007), and leukoencephalopathy with thalamus and brainstem involvement and high 
lactate (LTBL) is associated with EARS2 mutations (Steenweg et al., 2012). Furthermore, 
complex rearrangements in MARS2 were recently shown to cause autosomal recessive 
spastic ataxia with leukoencephalopathy (ARSAL) in 54 individuals (Bayat et al., 2012). In 
that report, complex I activity, MARS2 protein levels and mitochondrial protein synthesis 
were reduced in both patients and Drosophila mutants. However, in patient-derived 
fibroblasts steady-state levels of the cognate tRNA were similar to controls. Interestingly, 
the patients and the flies displayed increased production of ROS. The resulting 
progressive neurodegeneration and myopathy in the flies was partially suppressed by 
antioxidant treatment, implying a potential therapeutic avenue for ARSAL patients, and 
possibly other ARSs deficiencies. 
Although currently fewer in number, patients with mutations in YARS2, HARS2, AARS2, 
SARS2 and FARS2 also display distinct phenotype–genotype relationships. YARS2 was 
identified as the affected gene in two families with myopathy, lactic acidosis, and 
sideroblastic anemia (MLASA) [OMIM #613561] (Riley et al., 2010). HARS2 has been 
found mutated in one family with Perrault syndrome [OMIM #614129], a sex-influenced 
disorder characterized by sensorineural deafness in both males and females, and ovarian 
dysgenesis in females (Pierce et al., 2011). Two mutations in AARS2 have been reported 
to cause fatal perinatal or infantile hypertrophic cardiomyopathy [OMIM #614096] (Götz et 
al., 2011). A recessive SARS2 mutation was associated with a infantile multisystem 
mitochondrial cytopathy defined by hyperuricemia, pulmonary hypertension, renal failure 
in infancy, and alkalosis - HUPRA syndrome [OMIM #613845] (Belostotsky et al., 2011). 
Finally, mutations in FARS2 have been recently associated with mitochondrial 
encephalopathy Alpers type, thus expanding the genetic cause of Alpers Huttenlocher 
syndrome (AHS) (previously only associated with mutations in POLG or TWINKLE) (Elo et 
al., 2012; Shamseldin et al., 2012). Despite our increasing awareness of pathological ARS 
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mutations, the mechanisms underpinning the specific clinical–genetic associations are 
unknown. 
Proper assembly of mitochondrial ribosomal protein (MRP) into ribosomes is critical for 
efficient translation. MRPS16 and MRPS22 are components of the mitoribosome. 
Mutations in these genes are known to cause severe, infantile, lactic acidosis, 
developmental defects in the brain, and facial dysmorphisms (MRPS16) and fatal 
neonatal hypertrophic cardiomyopathy and kidney tubulopathy (MRPS22) (Saada et al., 
2007). 
Recently, a mutation in MRPL3 was identified in a patient with hypertrophic 
cardiomyopathy and psychomotor retardation. The mutation altered the stability of MRPL3 
and resulted in defective assembly of the large ribosomal subunit with a severe decrease 
of mitochondrial translation [OMIM #614582] (Galmiche et al., 2011). 
Mutations in genes encoding components of the mitochondrial translation elongation 
machinery are yet another established cause of encephalopathy and other organ failures. 
These include elongation factors EF-Tumt (TUFM) (Valente et al., 2007), EF-Tsmt (TSFM) 
(Smeitink et al., 2006), and EFG1 (GFM1) (Antonicka et al., 2006; Coenen et al., 2004b; 
Smits et al., 2011; Valente et al., 2007). Patients typically present in infancy and die in 
childhood or infancy. They often have profound OXPHOS deficiencies, which are 
invariably associated with decreased mitochondrial translation. Nevertheless, clinical 
symptoms vary greatly between patients, even between those with mutations in the same 
gene. Mutations in EFG1 result in encephalopathy presenting either with or without liver 
involvement [OMIM #609060] (Antonicka et al., 2006). Remarkably, in one patient 
mitochondrial protein synthesis was impaired in fibroblasts but not in muscle. The 
phenotypic differences might result from mutation-specific effects on the stability of the 
protein in different tissues, or variation in the abundance of other elongation factors 
(Antonicka et al., 2006). 
Indeed, two studies have shown that the relative abundance of elongation factors is 
important in determining mitochondrial translation efficiency (Antonicka et al., 2006; 
Smeitink et al., 2006). A fatal mutation in TUFM was identified in a patient who presented 
with lactic acidosis, a diffuse cystic leukoencephalopathy, and polymicrogyria [OMIM 
#610678] (Valente et al., 2007). The mutation, located in the tRNA binding region of EF-
Tumt, impairs the formation of a ternary complex with GTP and aminoacyl-tRNA, leading 
to a severe defect in protein synthesis (Valente et al., 2009). Three unrelated pediatric 
cases share the same mutation in TSFM, encoding EF-Tsmt, yet the clinical features were 
quite different, being associated with either mitochondrial encephalomyopathy or 
hypertrophic cardiomyopathy, or a combination of both [OMIM #610505] (Smeitink et al., 
2006). 
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Two mammalian proteins have been proposed to act as translation activators. 
Translational activator of COX I (TACO1) is necessary for the efficient translation of COXI, 
and mutations in the corresponding gene are associated with late-onset Leigh syndrome 
and COX deficiency [OMIM #612958] (Weraarpachai et al., 2009). The second potential 
translation activator is leucine-rich pentatricopeptide repeat containing protein (LRPPRC), 
which is a loose homolog of Pet309, the yeast mitochondrial translation activator of COXI 
and COXIII. Mutations in LRPPRC have been identified as the cause of French–Canadian 
variant of Leigh syndrome (LSFC) [OMIM #220111] (Mootha et al., 2003; Xu et al., 2004). 
A recent study outlines the effects of a cardiac muscle-specific knockout mouse model of 
LRPPRC (Ruzzenente et al., 2012). Results indicated that the lack of LRPPRC activity 
leads to reduced steady-state levels of most mitochondrial mRNAs and suggested that 
LRPPRC functions to maintain the stability of pools of untranslated mRNAs. 
 
 
1.2.2.3. Disorders of the inner mitochondrial membrane lipid milieu 
Cardiolipin deficiency was first documented in the early 2000s in cultured fibroblasts from 
patients with Barth syndrome (BTHS) is an X-linked mitochondrial myopathy and 
cardiopathy, with neutropenia and growth retardation (Vreken et al., 2000; Schlame et al., 
2003). The tafazzin (TAZ) gene responsible for this disorder encodes a family of proteins 
(‘‘tafazzins’’) that are homologous to phospholipid acyltransferases (Bione et al., 1996). 
Analysis of phospholipids in target tissues from patients with BTHS and TAZ mutations, 
patients with BTHS-like syndromes without TAZ mutations, and both normal and disease 
controls showed decreased cardiolipin in all tissues from genetically proven BTHS 
patients only (Schlame et al., 2002). Cardiolipin was affected selectively and other 
phospholipids were normal, and the molecular composition of cardiolipin was altered in all 
tissues from BTHS patients. 
Since then, four new disease entities characterized by deficiencies in different 
phospholipids have been identified in rapid succession. These entities are: Sengers 
syndrome, Megaconial encephalomyopathy, 3-methylglutaconic aciduria, deafness, and 
Leigh syndrome-like encephalopathy (MEGDEL) and childhood myoglobinuria, which are 
due to mutations in AGK, CHKB, SERAC1 and LPIN1 genes, repectively. 
Similar to BTHS, Sengers syndrome primarily affects heart and muscle, with the 
distinctive additional clinical feature of congenital cataracts, presenting mutations in the 
acylglycerol kinase (AGK) gene (Mayr et al., 2012). Acylglycerol kinase catalyses the 
phosphorylation of diacylglycerol and monoacylglycerol to form phosphatidic acid or 
lysophosphatidic acid. Notably, as phosphatidic acid is a precursor of cardiolipin, it 
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thereby provides a point of convergence in Sengers syndrome and BTHS, which could 
explain some of the clinical similarities between the two disorders.  
In 1998, a new condition characterized by congenital myopathy and mental retardation 
was reported (Nishino et al., 1998). The unusual muscle morphology, which included giant 
mitochondria that were displaced to the periphery of the fibres, was later observed in 
spontaneously mutant dystrophic mice that harboured changes in the gene encoding 
choline kinase-β (CHKB) (Nishino et al., 1998). Sequencing of CHKB in 15 patients with 
the disorder revealed 11 pathogenic mutations (Mitsuhashi et al., 2011). CHKB catalyses 
the first step in the biosynthesis of phosphatidylcholine, a phospholipid that is formed 
through a biosynthetic pathway within the MAM. The relationship between phospholipid 
abnormality and mitochondrial dysfunction could, therefore, be mediated through the MAM. 
Several proteins involved in mitochondrial dynamics are also integral parts of the MAM 
(Schon et al., 2012), raising the possibility that MAM dysfunction might explain both the 
increased size and the intracellular displacement of mitochondria in patients with CHKB 
mutations (Gutierrez-Rios et al., 2012). 
The role of the MAM in the etiology of mitochondrial diseases that are caused by altered 
IMM phospholipid composition was confirmed in another disorder, termed MEGDEL 
(Wortmann et al., 2009; Wortmann et al., 2010). In this case, whole-exome sequencing 
revealed mutations in SERAC1. The SERAC1 protein is localized in the contact sites 
between the endoplasmic reticulum and mitochondria and catalyzes the remodelling of 
phosphatidylglycerol (Wortmann et al., 2012). Analysis of fibroblasts from patients with 
MEGDEL revealed alteration in the distribution of phosphatidylglycerol species and in the 
composition of cardiolipin subspecies. Quantitative or qualitative alterations in cardiolipin 
could, therefore, be a common denominator in the pathogenesis of disorders other than 
BTHS (DiMauro et al., 2013). 
 
 
1.2.2.4. Disorders due to defects in genes controlling mitochondrial network 
dynamics 
Mutations in OPA1 are primarily a cause of optic atrophy (Carelli et al., 2009), but 
additional phenotypes, such as deafness and neuromuscular disease, have also been 
seen. Interestingly, mutations in OPA1 also appear to cause the formation of mtDNA 
deletions, indicating that OPA1 is also important to mtDNA maintenance. Much like OPA1, 
defects in MFN2 cause a disturbance of mtDNA maintenance through impairment of 
mitochondrial network dynamics (Carelli et al., 2009). Mutations in MFN2 are typically 
associated with Charcot-Marie-Tooth disease (CMT2A) and hereditary motor and sensory 
neuropathy (Carelli et al., 2009). DNM1L (dynamin 1-like), another GTPase, is required for 
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fission of mitochondria (Smirnova et al., 1998). To date, only a single DNM1L mutation 
has been identified in an infant presenting with both defective mitochondrial and 
peroxisomal fission (Waterham et al., 2007). The patient presented in the first days of life 
with severe microcephaly, abnormal brain development, optic atrophy with hyperplasia 
and lactic academia (Waterham et al., 2007). 
 
 
1.2.2.5. Disorders resulting from a reduction in mtDNA stability 
The nuclear-mitochondrial intergenomic communication is crucial for the cellular 
regulation of mtDNA integrity and copy number and correct mitochondrial protein 
production. As all the factors responsible for mtDNA replication and repair are encoded in 
the nucleus, it is not surprising that mutations in nuclear genes can disrupt mtDNA 
integrity causing qualitative (multiple deletions) or quantitative (depletion) molecular 
abnormalities. The “mitonuclear” cross-talk has gained increased relevance in the past 
years and since then many genes have been identified as being involved in this group of 
mitochondrial diseases. This topic will be further detailed in section 1.3.  
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1.3. Intergenomic-communication disorders 
The cross-talk between the two genomes is crucial for the cellular regulation of mtDNA 
integrity and copy number and correct mitochondrial protein production therefore 
mutations in genes involved in mitochondrial replication and maintenance can disrupt the 
integrity of the mitochondrial genome, causing intergenomic-communication disorders. 
Multiple deletions, depletion of mtDNA or a combination of both phenomena 
(qualitative/quantitative lesions) in critical tissues, are the hallmarks of these disorders.  
 
 
1.3.1 Clinical manifestations and molecular etiologies of disorders affecting 
mtDNA integrity 
Maintenance of mtDNA is controlled by an intricate homeostatic network, whose effectors 
are the various components of the mitochondrial replicosome and the many enzymes and 
carrier proteins that provide the mitochondrion with a balance supply of 
deoxyribonucleotides (Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 - Schematic overview of the mitochondrion and the mitochondrial disease genes affecting 
mtDNA integrity. Zooming on the mitochondrion allows to appreciate genes (namely, POLG1 and TWINKLE) 
thought to be involved in replication of mtDNA, those assumed to affect the metabolism of the mitochondrial 
dNTP pool (via progressive phosphorylations of dNTPs), and those belonging to the tricarboxylic acid cycle 
(TCA) and affecting the OXPHOS complexes. Moreover, the supposed role of genes involved in the complex 
machinery of mitochondrial protein synthesis (including the aminoacyl-tRNA synthetases). 
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As all of the factors are nDNA encoded, it is not surprising that mutations in genes 
involved in mitochondrial replication and maintenance can disrupt the integrity of the ‘‘tiny’’ 
mitochondrial genome (Hirano et al., 2001) leading to multiple deletions or depletion 
(Spinazzola et al., 2005). The mitonuclear cross-talk has gained increased relevance in 
the past years and since then many genes have been identified as being involved in these 
diseases. 
In the following section we will briefly review the main clinical manifestations and 
molecular etiologies associated with mtDNA multiple deletions and mtDNA depletion 
syndromes. An overview of the main phenotypes and associated mutations is illustrated in 
Table 1. 
 
Table 1 - Major phenotypes of the disorders affecting mtDNA integrity and the associated genes with 
the number of described mutations (source HGMD Professional, Database www.hgmd.cf.ac.uk/). 
 
 
Major Phenotypes Genes Number of Mutations 
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Progressive External Ophthalmoplegia – PEO 
POLG 65 
POLG2 1 
C10orf2 39 
SLC25A4 5 
MGME1* 2 
TK2* 2 
RRM2B 11 
DGUOK 2 
Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis – SANDO POLG 14 SLC25A4 1 
SpinoCerebellar Ataxia – Epilepsy syndrome – SCAE  POLG 1 C10orf2 4 
Mitochondrial NeuroGastroIntestinal Encephalomyopathy –  MNGIE 
Tymp* 81 
RRM2B 2 
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n
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POLG* 1 
Hepatocerebral – Mitochondrial Depletion Syndrome  
POLG 8 
C10orf2 3 
DGUOK 51 
MPV17 28 
TK2 1 
Myopathic – Mitochondrial Depletion Syndrome  
TK2 34 
POLG 1 
RRM2B 3 
DGUOK 1 
Encephalomyopathic – Mitochondrial Depletion Syndrome 
RRM2B 14 
SUCLA2 8 
SUCLG1 13 
TK2 1 
C10orf2 1 
Alpers-Huttenlocher Syndrome – AHS POLG 54 
*Presence of multiple deletions and mtDNA depletion.  
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1.3.1.1. Mitochondrial DNA multiple deletion syndrome 
Mitochondrial diseases associated with the presence of multiple deletions of mtDNA are 
mostly autosomal dominant, occurring most often in adulthood. The size and terminals 
deletions are variable from one individual to another within the same family.  
The main clinical manifestations associated with multiple deletions will be described along 
with molecular etiologies. 
 
PEO (Autosomal Dominant or Recessive Progressive External Ophthalmoplegia) 
The most common clinical features include adult-onset of weakness of the external eye 
muscles, bilateral ptosis, proximal muscle weakness wasting and exercise intolerance. 
Additional symptoms are variable, and may include cataracts, hearing loss, sensory 
axonal neuropathy, ataxia, depression, hypogonadism, and Parkinsonism. Less common 
features include mitral valve prolapse, cardiomyopathy, and gastrointestinal dysmotility. 
Both autosomal dominant and autosomal recessive inheritance can occur; autosomal 
recessive inheritance is usually more severe (Filosto et al., 2003; Luoma et al., 2004). The 
multiple deletions associated with PEO are exclusively found in muscle tissues of patients. 
Mutations in the POLG, POLG2, C10orf2, SLC25A4, MGME1, TK2, RRM2B and DGUOK 
genes have been linked with PEO. Below a small description of the most important genes 
involved in the molecular etiologies of PEO can be found. 
 
i) POLG 
Human mitochondria contain a single DNA polymerase, POLG, nuclear encoded 
and solely responsible for mtDNA replication and repair in mitochondria. POLG is 
composed of a catalytic subunit, POLGA, which possesses both polymerase and 
proofreading exonuclease activities and an accessory subunit, POLGB, which 
increases enzyme processivity (Lee et al., 2009). The POLG holoenzyme functions 
in conjunction with the mtDNA helicase and the mitochondrial single-stranded 
DNA- binding protein to form the minimal replication apparatus (Korhonen et al., 
2004). It was generally accepted that mutations within the mtDNA were the major 
cause of mitochondrial diseases; however this view is changing as several of these 
have been linked to ineffective mtDNA replication by POLG Mutations affecting the 
catalytic subunit POLGA, encoded by the nuclear gene POLG are a major cause 
of mitochondrial disease, being highly heterogeneous: PEO, Parkinsonism, AHS, 
MNGIE, SANDO and SCAE, and usually is associated with multiple mtDNA 
deletions (Horvath et al., 2006). POLG mutations have been shown to be 
associated with all types of inheritance. The unique features of mitochondrial 
physiology are in part responsible for this variability but POLG structure and 
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function add to the riddle of how one gene product can demonstrate autosomal 
recessive and autosomal dominant transmission. POLGA is a key player in mtDNA 
maintenance that is absolutely necessary for mtDNA replication from an early 
stage in embryogenesis (Hance et al., 2005).  
In autosomal dominant PEO (adPEO) due to POLG mutations (most frequent), 
prominent features are severe dysphagia and dysphonia, and, occasionally, a 
movement disorder including Parkinsonism, cerebellar dysfunction, and chorea. 
Recessive mutations of POLG are responsible for sporadic and autosomal 
recessive PEO (arPEO), as well as the syndromes referred above. Mutations in 
this gene can be also associated to the hepatocerebral form of MDS, namely AHS 
(Horvath et al., 2006). 
The POLG gene is located at chromosome 15, comprises 23 exons spanning 
18.55 Kb. The gene was identified in 1996 (Ropp et al., 1996) but only in 2001 the 
first pathogenic mutation was described. Since then more than 150 mutations have 
been reported and POLG gene is considered a hot-spot for mutations in 
mitochondrial diseases (Chinnery et al., 2008). So far, 65 mutations have been 
described as being associated with PEO. 
 
ii) POLG2  
MtDNA is replicated by POLG, which is composed of a 140-kD catalytic subunit 
(encoded by POLG) and a 55-kD accessory subunit (POLG2). The accessory 
subunit increases enzyme processivity therefore it is not surprising that failure in 
this processivity leads to the accumulation of mtDNA deletions. 
The POLG2 gene is located at chromosome 17, comprises 8 exons spanning 
19.28 Kb. In 2006 the first pathogenic mutation was described as being a cause of 
adPEO (Longley et al., 2006). Since then, 12 mutations in POLG2 have been 
reported associated with unspecific mitochondrial phenotype. 
 
iii) C10orf2 (TWINKLE) 
The mitochondrial helicase/primase encoded by C10orf2 gene is also responsible 
for the adPEO (Spelbrink et al., 2001). Mutations in C10orf2 may be of variable 
severity, being associated with clinical presentations ranging from late-onset 
‘‘pure’’ PEO, to PEO complicated by proximal limb and facial muscle weakness, 
dysphagia and dysphonia, mild ataxia, and peripheral neuropathy. Recessive 
C10orf2 mutations were also described in patients with hepatocerebral form of 
depletion (Hakonen et al., 2007).  
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The C10orf2 gene is located at chromosome 10; it comprises 5 exons spanning 
6.38 kb. The first pathogenic mutation was reported in 2001 (Spelbrink et al., 2001) 
to be associated with PEO and since then 39 pathogenic mutations have been 
reported to be associated with this phenotype. 
 
iv) SLC25A4 
This gene, coding for the muscle-heart-specific mitochondrial ANT, is a member of 
the mitochondrial carrier subfamily of solute carrier protein genes (Kaukonen et al., 
2000). ANT is the most abundant mitochondrial protein and in its functional state, it 
is a homodimer of 30-kD subunits embedded asymmetrically in the IMM. The 
dimer forms a gated pore through which ADP is moved from the matrix into the 
cytoplasm. There are three recognized isoforms of this protein. 
Mutations in this gene have been shown to be responsible for the adPEO and 
have been also associated with a relatively mild, slow progressive myopathy, with 
little or no extra-muscular symptoms. 
The SLC25A4 gene was identified in 2000 (Kaukonen et al., 2000), it is located at 
chromosome 4, comprises 4 exons spanning 4.04 Kb. The first pathogenic 
mutations were described in 2000 and since then only eight mutations have been 
reported (five of them associated with PEO). 
 
v) MGME1 (C20orf72) 
The mitochondrial genome maintenance exonuclease 1 gene has recently been 
described (Kornblum et al., 2013). It is located at chromosome 20, comprises 4 
exons and encodes a mitochondrial RecB-type exonuclease belonging to the PD–
(D/E)XK nuclease superfamily and it is essential for effective mtDNA synthesis and 
may have a redundant role in mtDNA repair. It is the first identified mitochondrial 
exonuclease shown to be involved in mtDNA replication, likely through the 
processing of displaced DNA or RNA-DNA flap-like structures during mtDNA 
synthesis (Kornblum et al., 2013).  
Only two mutations affecting this mitochondrial exonuclease have been described 
in a single report in three unrelated families with a mitochondrial syndrome 
characterized by PEO, emaciation and respiratory failure. These mutations affect 
proper mtDNA maintenance and are a clinically relevant cause of mtDNA disorders. 
Muscle biopsies of the identified patients showed mtDNA depletion and multiple 
mtDNA deletions.  
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SANDO (Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis) 
SANDO is an autosomal recessive systemic disorder characterized mainly by adult onset 
of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis. The phenotype varies 
widely, even within the same family, and can include myopathy, seizures, and hearing 
loss, but the common clinical feature appears to be sensory ataxia (Milone and Massie, 
2010). Mutations in the POLG and SLC25A4 genes have been linked with SANDO. 
  
SCAE (SpinoCerebellar Ataxia – Epilepsy syndrome)  
SCAE is a disorder similar to SANDO but with a higher frequency of migraine headaches 
and seizures (Winterthun et al., 2005). Mutations in the POLG and C10orf2 genes have 
been linked with SCAE. 
 
MNGIE (Mitochondrial NeuroGastroIntestinal Encephalomyopathy) 
MNGIE is an autosomal recessive disorder clinically characterized by onset between the 
second and fifth decades of life, PEO, gastrointestinal dysmotility (often 
pseudoobstruction), cachexia, diffuse leukoencephalopathy, peripheral neuropathy and 
early death. Abnormalities of mtDNA can include depletion, multiple deletions, and point 
mutations (Hirano et al., 1994). Mutations in the TYMP, RRM2B and POLG genes have 
been linked with this phenotype. A brief description of the TYMP gene is given below. 
 
i) TYMP (ECGF1)  
The TYMP gene, responsible for MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), encodes the enzyme thymidine phosphorylase (TP), which 
is involved in pyrimidines catabolism. Defects of TP result in systemic 
accumulation of thymidine and deoxyuridine, which leads to deoxynucleotide pool 
imbalance and mtDNA instability, resulting in the presence of multiple deletions 
and partial depletion of muscle mtDNA (Nishino et al., 1999).  
The TYMP gene is located at chromosome 22, comprises 10 exons and spans 4.3 
kb. The first pathogenic mutations were described in 1999 (Nishino et al., 1999) 
and since then 80 mutations have been described as being associated with 
MNGIE. 
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1.3.1.2. Mitochondrial DNA depletion syndrome 
Quantitative alterations are characterized by depletion of mtDNA. The mtDNA depletion 
syndrome (MDS) comprises a heterogeneous group of autosomal recessive disorders, all 
having the same molecular end result, low mtDNA amount in specific tissues. MDS are a 
group of rare and devastating diseases that manifest typically, although not exclusively, 
soon after birth, determining early death usually in infancy or early childhood. MDS differs 
from other MRC disorders, as most often it may manifest solely in a specific organ (most 
commonly muscle or liver) (Suomalainen et al., 2010). However, it may occur that multiple 
organs, including heart, brain, and kidney are affected (Spinazzola et al., 2007).  
Three major clinical categories can be recognized however, the clinical phenotypes are 
heterogeneous, overlapping and ever expanding (Rötig and Poulton 2009; Suomalainen 
et al., 2010). 
 
Hepatocerebral MDS  
Hepatocerebral MDS is most probably the most common variant of MDS. Onset of 
symptoms is between birth and 6 months; death usually occurs within one year of age. 
The most common symptoms and signs include persistent vomiting, failure to thrive, 
hypotonia and hypoglycemia associated with progressive neurological symptoms. 
Histological changes on liver biopsy include fatty degeneration, bile duct proliferation, 
fibrosis, and collapse of lobular architecture. Reduced COX histochemistry and combined 
deficiency of mtDNA encoded MRC complexes were found in the liver of a few patients.  
A peculiar form of hepatocerebral MDS is AHS, an early onset, fatal disease, 
characterized by hepatic failure, intractable seizures, evolving into epilepsia partialis 
continua, and global neurological deterioration. The liver dysfunction is usually 
progressive as well, evolving from microvesicular steatosis with bile duct proliferation into 
cirrhosis and chronic liver failure. Mutations in POLG gene are a frequent cause of AHS 
and to date 55 mutations have been reported. 
Mutations in the POLG, C10orf2, DGUOK, MPV17 and TK2 genes have been identified as 
being associated with hepatocerebral MDS. 
 
i) DGUOK 
Deoxyguanosine kinase is a 2-deoxyribonucleoside enzyme that catalyzes the first 
step of the mitochondrial deoxypurine salvage pathway, the phosphorylation of 
purine deoxyribonucleosides into the corresponding nucleotides deoxyguanosine 
and deoxyadenosine necessary for the maintenance of mitochondrial dNTPs pools 
(Copeland 2008; Spinazzola et al., 2007). The typical phenotype of mutations in 
the DGUOK gene, on chromosome 2p13, is characterized by neonatal onset of 
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progressive liver disease and feeding difficulties, usually with neurological 
dysfunction (hypotonia, nystagmus, and psychomotor retardation), by the age of 3 
months. Peripheral neuropathy and renal tubulopathy have occasionally been 
reported (Rahman and Poulton, 2009). Depletion of mtDNA has been documented 
only in the liver and results in combined MRC deficiencies in the liver, whereas the 
amount of mtDNA is usually normal in muscle and fibroblasts. Histological 
analyses of the liver biopsy show variable findings, typically microvacuolar 
steatosis, cholestasis, fibrosis, and cirrhosis. In most cases, there is a rapidly 
progressive liver disease and neurological deterioration, with death occurring by 
the age of 12 months or shortly thereafter (Ji et al., 2010). The first pathogenic 
mutations was reported in 2001 (Mandel et al., 2001), since then more than 80 
affected patients from approximately 50 families have been reported, and over 50 
different DGUOK mutations have been identified (El-Hattab and Scaglia 2013). 
The infantile hepatocerebral form of MDS is the almost invariable clinical 
presentation. Genotype-phenotype correlation studies show that patients who 
harbor null mutations usually have early onset liver failure and significant 
neurological disease, including hypotonia, nystagmus, and psychomotor 
retardation, and death before two years of age. Patients carrying missense 
mutations usually have isolated liver disease, a better prognosis, and longer 
survival. 
 
ii) MPV17 
The MPV17 gene is located on chromosome 2p23-p21 and encodes a IMM protein 
of unknown function but recently recognized as responsible for mtDNA depletion. 
The clinical presentation is that of severe liver failure, hypoglycemia, growth 
retardation, neurological symptoms, and multiple brain lesions during the first year 
of life (Wong et al., 2007). Marked mtDNA depletion in the liver is the molecular 
hallmark associated with multiple defects of MRC complexes. Normal or mildly 
reduced levels of both mtDNA content and MRC enzyme activities were also found 
in muscle (Alberio et al., 2007). Histological analyses of the liver have revealed 
swollen granular hepatocytes, microvesicular steatosis, and focal pericellular and 
periportal fibrosis. Since the first mutation was described in 2006 (Spinazzola et al., 
2006), 27 different mutations have been reported in infantile-onset hepatocerebral 
syndrome and in Navajo neurohepatopathy, which is an autosomal recessive 
multisystem disorder found in the Navajo of the southwestern United States 
(Copeland et al., 2008). Three main subtypes are to be considered: infantile-onset 
(before 6 months) and childhood-onset (before 5 years) forms with hypoglycemic 
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episodes and severe progressive liver dysfunction requiring liver transplant, and a 
“classic” form with moderate hepatopathy and progressive sensorimotor axonal 
neuropathy. The three forms are also associated with variable degrees of 
demyelination in both the central and the peripheral nervous system. 
 
Myopathic MDS  
Myopathic MDS onset of symptoms usually occur in the first year of life with feeding 
difficulty, failure to thrive, hypotonia, muscle weakness and occasionally PEO. Death is 
usually due to pulmonary insufficiency and infections, but some patients survive into their 
teens (Moraes et al., 1991; Tritschler et al., 1992). Muscle biopsy may show proliferation 
of mitochondria, which can increase with age, and patchy or diffuse COX deficiency. 
Biochemical defects of all mtDNA-related MRC complexes are always present in muscle 
mitochondria. Serum CK levels may be variably elevated (Spinazzola et al., 2005).  
Mutations in the TK2 gene are the most frequently cause of myopathic MDS with 34 
mutations reported however mutations in POLG, RRM2B and DGUOK genes have also 
been identified in myopathic MDS. 
 
i) TK2 
Thymidine kinase (TK2) is an intramitochondrial pyrimidine nucleoside kinase that 
phosphorylates dNTPs, such as: deoxythymidine, deoxycytidine, and deoxyuridine, 
thereby participating in the salvage pathway of deoxynucleotide synthesis in the 
mitochondria (Oskoui et al., 2006). Mitochondrial dNTPs pools arise either through 
active transport of cytosolic dNTP or through salvage pathways. Both pathways 
are essential for the replication of mtDNA, since the mitochondrion is unable to 
synthesize dNTPs de novo. Mutations in the TK2 gene on chromosome 16q22 
affect primarily muscle tissue, with little or no effect on the liver, brain, heart, or 
skin. The typical manifestation of TK2 mutations is a severe, rapidly progressing 
myopathy of infantile or childhood onset. The disease course is rapidly progressive, 
leading to respiratory failure and death in months or years, but milder phenotypes 
with slower progression and longer survival have been reported (Suomalainen et 
al., 2010). Since the first mutation was described in 2001 (Saada et al., 2001), 
approximately 38 different pathogenic mutations in TK2 have been published so 
far, either as recessive homozygous or compound heterozygous mutations, and 
phenotypes may be explained by variable degrees of residual activity of the mutant 
enzymes.  
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Encephalomyopathic MDS 
Encephalomyopathic MDS is characterized by infantile onset of hypotonia with severe 
psychomotor retardation, high lactate in blood, progressive neurologic deterioration, a 
hyperkinetic-dystonic movement disorder, external ophthalmoplegia, deafness, 
generalized seizures and variable renal tubular dysfunction. Brain MRI was suggestive of 
Leigh syndrome (Spinazzola et al., 2007). 
Mutations in the RRM2B, SUCLA2, SUCLG1, TK2 and C10orf2 genes have been 
identified as being associated with encephalomyopathic MDS. 
 
i) RRM2B 
The RRM2B gene on chromosome 8q23 encodes the small subunit of p53-
inducible ribonucleotide reductase, a heterotetrameric enzyme responsible for the 
de novo conversion of ribonucleoside diphosphates into the corresponding 
deoxyribonucleoside diphosphates that are crucial for DNA synthesis (Bourdon et 
al., 2007). The enzyme is the main regulator of nucleotide pools in the cytoplasm, 
and its small subunit is expressed in postmitotic cells, where it probably has a key 
function in maintaining the mitochondrial dNTPs pools for mtDNA synthesis. 
Mutations in RRM2B usually result in hypotonia, lactic acidosis, failure to thrive, 
and tubulopathy in the first months of life. The disease has a rapid progression and 
leads to death in few months. The associated complex phenotype suggests that 
the consequences of a defective mitochondrial dNTPs pools can vary dramatically 
depending on the residual amount of the functional enzyme. Recently, it has been 
shown that inactivating mutations in RRM2B also cause severe neonatal or 
infantile forms of mtDNA depletion, with profound reduction of mtDNA copy 
numbers in skeletal muscle (Bourdon et al., 2007). The first pathogenic mutation 
was reported in 2007 (Bourdon et al., 2007) and since then 29 mutations have 
been described from which 14 are associated with encephalomyopathic MDS, 11 
with PEO, two with MNGIE and three with myopathic MDS. 
 
ii) SUCLA2 and SUCLG1 
Succinyl-CoA synthase is a mitochondrial matrix enzyme that catalyzes the 
reversible synthesis of succinate and ATP or GTP from succinyl-CoA and ADP in 
the TCA cycle. This enzyme is made up of two subunits, α and β, encoded by 
SUCLG1 on chromosome 2p11 and SUCLA2 on 13q12, respectively. Mutations in 
SUCLA2 and SUCLG1 cause an encephalomyopathic form of infantile mtDNA 
depletion syndrome, but SUCLG1 can also cause a very severe disorder with 
antenatal dysmorphisms, neonatal metabolic crisis, and early death, probably 
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depending on the residual amount of the protein (Morava et al., 2009; Rouzier et 
al., 2010). An useful diagnostic clue in succinyl-CoA synthase disorders of 
succinyl-CoA synthase is a ‘‘mildly’’ elevated urinary methylmalonic acid (MMA), 
which is detected in all patients, and the presence of TCA intermediates 
(methylcitrate, lactate, carnitine esters, 3-hydroxyisovaleric acid) in most cases. 
Some patients die early (sudden infant death syndrome), but some of them have a 
longer survival. The clinical features of patients with mutations in these genes 
include early childhood hypotonia, developmental delay, and almost invariably, 
progressive dystonia and sensorineural deafness. SUCLA2 and SUCLG1 
mutations seem to disrupt an association between succinyl-CoA synthase and 
mitochondrial nucleoside diphosphate kinase, resulting in an unbalanced 
mitochondrial dNTP pool and eventually, mtDNA depletion in muscle. The first 
pathogenic mutations were reported in 2005 (Elpeleg et al., 2005) and 2007 
(Ostergaard et al., 2007) in SUCLA2 and SUCLG1, respectively, and since then 
seven and twelve mutations have been reported as associated with 
encephalomyopathic MDS.  
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1.4. Treatment of mitochondrial disorders 
There is no effective treatment for mitochondrial disorders, and current clinical 
management is focused on treating complications or alleviating symptoms. Therapy is 
inadequate and mostly palliative, but promising new approaches are being identified.  
Treatments used to modify the underlying disease process fall into three major categories: 
i) symptomatic therapy (palliative therapy is dictated by good medical practice and 
includes anticonvulsant medication, control of endocrine dysfunction, surgical procedures, 
etc.), ii) pharmacological therapy (aimed to remove toxic metabolites, supplementation 
with vitamins and cofactors to “strengthen” the MRC, scavenging excessive ROS, etc.) 
and iii) gene therapy. 
  
 
1.4.1. Symptomatic therapy 
Lack of a cure for mitochondrial disorders does not exclude treatment and symptomatic 
therapy can be very effective in these patients.  
Seizures usually respond to conventional anticonvulsants. However, valproic acid should 
be used with caution and in association with L-carnitine, because it inhibits carnitine 
uptake (Tein et al., 1993). Valproic acid is especially dangerous in children with AHS, a 
hepatocerebral disorder with mtDNA depletion due to mutations in the gene encoding 
POLG. Seizures are often difficult to manage in AHS and valproic acid can trigger acute 
hepatic failure (Bicknese et al., 1992). 
In patients with PEO, severe ptosis can be ameliorated by selective surgery, at least 
transiently. Congenital cataracts are also treated surgically.  
Diabetes mellitus, whether insulin-dependent or not, responds to dietary or 
pharmacological therapy. The use of growth hormone in children with growth retardation is 
controversial because the increased metabolic demands may be ill tolerated by an already 
metabolically challenged patient. In children with impaired growth due to feeding 
problems, recurrent vomiting, or severe gastroesophageal reflux, useful surgical 
procedures include percutaneous endoscopic gastrostomy or fundoplication.  
Timely placement of a pacemaker can be life-saving in patients with KSS and blocks of 
cardiac conduction. Heart transplantation is controversial in patients with cardiomyopathy 
and multisystemic disorders. However, when cardiac involvement is the predominant or 
exclusive problem, cardiac transplantation is justified (Tranchant et al., 1993; Bohlega et 
al., 1996; Santorelli et al., 2002). 
Neurosensory hearing loss can be alleviated by cochlear implants (Sue et al., 1998).  
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Liver failure, often associated with the mtDNA depletion syndrome, may benefit from liver 
transplantation, especially if other organs seem to be spared (Dubern et al., 2011; Salvati 
et al., 2002).  
Recurrent myoglobinuria is seen in patients with primary CoQ10 deficiency  or with 
mutations in mtDNA protein-coding gene (Ogasahara et al., 1989; Sobreira et al., 1997; Di 
Giovanni et al., 2001). Patients with CoQ10 deficiency benefit from CoQ10 
supplementation. During acute episodes, all patients should be rehydrated and subjected 
to renal dialysis when myoglobinuria is complicated by renal failure.  
Psychotropic drugs are effective in patients with psychiatric symptoms (especially 
depression), which are not infrequent, and sometimes isolated, in mitochondrial patients 
(DiMauro et al., 2013). 
Physical, occupational, respiratory, and speech therapy are of great value in accelerating 
recovery from stroke in patients with MELAS and in aiding patients with other CNS 
problems (ataxia, dysarthria, dysphagia, spasticity, paralysis) (Millhouse-Flourie et al., 
2004).  
Exercise and physical therapy had to be considered in patients with mitochondrial 
diseases due to the fact that these disorders are frequently associated with mitochondrial 
proliferation and that sustained exercise also is associated with increased of mitochondrial 
content in muscle. Inactivity in patients with mitochondrial diseases and exercise 
intolerance is often excused for fear of causing muscle damage, but it only increases 
deconditioning. Instead, aerobic training in these patients has remarkable effects, 
increasing work and oxidation capacity.  
In baseline studies of a larger number of subjects with mitochondrial myopathy and 
normal controls, it was found that the percentage of mutant mtDNA correlates indirectly 
with exercise tolerance. Further independent studies have confirmed these benefits in 
subjects with mtDNA deletions or point mutations, including MELAS. One of these studies 
showed that total mtDNA increases after exercise in subjects with mtDNA mutations (but 
not normal subjects) without significantly altering the ratio of normal/mutant mtDNA (Kerr 
et al., 2010). 
 
 
1.4.2 Pharmacological therapy  
 
Elimination of noxious compounds 
One of the therapeutic approaches to mitochondrial disease is to eliminate the 
noxious compounds that accumulate in these disorders. To decrease brain lactate in 
patients with MELAS, dichloroacetate was used, which keept pyruvate 
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dehydrogenase in the active form and favours lactate oxidation. However, this agent 
had unacceptable neurotoxicity, leading to treatment discontinuation (Kaufmann et 
al., 2006). A more promising ‘detoxifying therapy’ seems to be allogeneic 
haematopoetic stem-cell transplantation (AHSCT) aimed at restoring sufficient 
thymidine phosphorylase activity in patients with MNGIE to normalize circulating, toxic 
levels of thymidine and deoxyuridine (Hirano et al., 2012). A safety study of AHSCT in 
patients with MNGIE is under way. 
 
Administration of Electron Acceptors 
CoQ10 is both a component of the electron-transport chain and an effective oxygen 
radical scavenger. Its dual function, in addition to its safety, make CoQ10 one of the 
most widely used supplements in mitochondrial diseases (DiMauro et al., 2006a). 
There are several reports of the beneficial effect of CoQ10 in mitochondrial diseases, 
usually as a component of a ‘‘cocktail’’ that also includes L-carnitine, vitamin B 
complex, vitamin C and vitamin K1 (Marriage et al., 2004). CoQ10 supplementation is 
mandatory and at times even life-saving in the primary CoQ10 deficiency syndromes. 
Although the response to CoQ10 administration seems to vary in different patients, 
probably depending on the mutant biosynthetic gene, supplementation with high 
CoQ10 doses should be tried in all patients (Schon et al., 2010). 
Two synthetic analogues of CoQ10, idebenone and parabenzoquinone, seem more 
promising. Idebenone, a short-chain benzoquinone, has shown positive results in two 
studies of patients with LHON (Carelli et al., 2011; Klopstock et al., 2011). The 
second compound, a parabenzoquinone named EPI-743, has so far been tested only 
in open-label studies. This compound reversed vision loss in four of five patients with 
LHON (Sadun et al., 2012), produced clinical improvement in 12 children with various 
mitochondrial disorders (Enns et al., 2012), and arrested or reversed disease 
progression in 13 children with genetically proven Leigh syndrome (Martinelli et al., 
2012).  
 
Administration of Vitamin and Cofactors 
Various “cocktails” of vitamins and cofactors have been used–and are still used in 
patients with mitochondrial encephalomyopathies, including riboflavin (vitamin B2), 
thiamine (vitamin B1), folic acid, CoQ10, L-carnitine, and creatine. All of these are 
natural compounds and presumably harmless at the doses used. Some, such as 
riboflavin (an important co-factor for the function of numerous dehydrogenases) are 
components of the MRC, but there is no evidence that they are decreased in primary 
mitochondrial diseases (DiMauro et al., 2006a). Others appear to be decreased in 
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certain conditions; for example, folic acid was lower than normal in the blood and CSF 
of patients with KSS. Still others are decreased secondarily; free carnitine tends to be 
lower than normal in the blood of patients with MRC defects, whereas esterified 
carnitine tends to be increased. This shift may reflect a partial impairment of β-
oxidation, whose reducing equivalents enter the MRC at the level of CoQ10 through 
the action of the electron transfer flavoprotein.  
Creatine monohydrate supplementation has been used with the goal of improving 
ATP synthesis and mean power output, but two randomized studies in patients with 
mitochondrial diseases came to different conclusions: a smaller cohort of severely 
affected patients improved, whereas a larger cohort of less severely affected patients 
did not (DiMauro et al., 2006a). 
Koga and coworkers found that plasma concentrations of both citrulline and arginine 
were decreased in MELAS patients during and between stroke-like episodes (Koga et 
al., 2005). They also found that intravenous administration of l-arginine (0.5 g/kg) 
during the acute phase improved all stroke-like symptoms, whereas interictal oral 
administration (0,15–0,30g/kg daily) diminished both frequency and severity of 
strokes. 
In vitro studies have revealed a potentially useful therapeutic approach to a fatal 
infantile form of encephalocardiomyopathy associated with COX deficiency and due 
to mutations in the SCO2 gene, which encodes a COX-assembly protein needed for 
the insertion of copper into the holoenzyme. When copper was added to the medium 
of cultured COX-deficient myoblasts harboring SCO2 mutations, COX activity was 
restored (DiMauro et al., 2006a). 
Finally, mtDNA depletion could be prevented by the addition of defective products 
[deoxyguanosine monophosphate (dGMP) and deoxyadenosine monophosphate 
(dAMP)] of the enzyme, deoxyguanosine kinase, in fibroblasts from a patient with 
hepatocerebral syndrome and a homozygous nonsense mutation in the DGUOK gene 
(Taanman et al., 2003). As the investigators pointed out, further studies in animal 
models of deoxyguanosine kinase deficiency are needed to establish the uptake, 
therapeutic value, and possible side effects of deoxynucleotide administration.  
The rationale for using these compounds is two fold: some of them are actually 
decreased in patients, either primarily or secondarily, whereas others are considered 
“neuroprotective” in that they may favor ATP production and counteract excitotoxicity, 
calcium-activated proteolysis, free radical generation, or apoptosis (DiMauro et al., 
2013). 
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Administration of Oxygen Radical Scavengers 
Defects of the MRC have detrimental effects that go beyond impairing ATP 
production and include altered intracellular calcium buffering, excessive production of 
ROS, and promoting apoptosis (Hays et al., 2006).  
ROS are normal toxic secondary products of the MRC. They derive from the direct 
reaction of electrons in the MRC with O2 to generate superoxide anion (O2-), which 
can be detoxified by mitochondrial manganese superoxide dismutase (MnSOD) with 
liberation of hydrogen peroxide (H2O2). In the presence of transition metals, H2O2 can 
be reduced to a very toxic hydroxyl radical (.OH). However, H2O2 can also be 
detoxified either through reduction to water by glutathione peroxidase or through 
conversion to O2 and H2O by catalase.  
Defects of the MRC increase the production of ROS, which, in turn, damage cell 
membranes through lipid peroxidation and accelerate the already high mutation rate 
of mtDNA, creating a vicious cycle.  
The concept of “oxidative stress” has taken center stage in the pathogenesis not only 
of “primary” mitochondrial disorders (i.e., defects of the MRC) but also of late-onset 
neurodegenerative diseases. In an attempt to quench the effects of ROS, several 
oxygen radical scavengers have been utilized, including vitamin E, CoQ10, 
idebenone, glutathione, and dihydrolipoate. Although no formal large-scale clinical 
trial has yet been conducted, glutathione administration appears promising because 
glutathione concentration was markedly decreased in muscle specimens from 
patients with isolated or combined respiratory-chain defects. 
CoQ10 is widely used in primary mitochondrial diseases, and the plethora of 
generally positive anecdotal data together with the lack of negative side effects has 
contributed to its popularity. CoQ10 and its analog, idebenone, have also been used 
widely in the treatment of neurodegenerative disorders (DiMauro et al., 2006b). 
 
Enhance of mitochondrial biogenesis 
The enhancement of overall mitochondrial biogenesis has emerged as an exciting 
therapeutic prospect in the last years, through activation of the transcriptional co-
activator PGC-1α. The advantage over disease-induced mitochondrial proliferation, 
which favours mutated mtDNAs, is that pharmacological upregulation of mitochondrial 
biosynthesis increases numbers of all mtDNA molecules, allowing wild-type genomes 
to compensate for mutated ones. Encouraging results have been obtained in four 
mouse models with COX deficiency (DiMauro et al., 2013). 
Recently, a large number of compounds with therapeutic potential have been 
described. These include polyphenolic phytochemicals such as resveratrol, grape 
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seed extract, green tea extract and genistein. Resveratrol is a natural phytoalexin 
found in a wide variety of plant species, including grapes. Among its numerous 
properties, resveratrol has been reported to have anti-oxidant activities and to activate 
the genetic expression of key genes in energy metabolism such as PGC-1α. 
Resveratrol and grape seed extract (a proanthocyanidin) were demonstrated to have 
beneficial effects on mitochondrial function in several experimental models (Lagouge 
et al., 2006). Green tea polyphenols attenuated mitochondrial dysfunction in glucose 
deprived glial cell cultures. Genistein is a soy derived isoflavone which has been 
evaluated in substrate reduction therapy for mucopolysaccharidoses and was also 
reported to induce mitochondrial biogenesis (Kloska et al., 2011; Rasbach et al., 
2008).  
In addition to polyphenols, other substances such as compounds enhancing energy 
metabolism, antioxidants and chemical chaperones are potentially beneficial. 
Representative of this type are AICAR, oltipraz, bezafibrate and sodium 
phenylbutyrate (Golubitzky et al., 2011).  
AICAR is a pharmacological activator of AMP activated protein kinase (AMPK). This 
heterotrimeric protein complex plays a key role in the regulation of energy 
homeostasis. The kinase is activated by an elevated AMP/ATP ratio caused by cellular 
and environmental stress, such as heat shock, hypoxia and ischemia. AMPK regulates 
energy expenditure by modulating NADH+ dependent-type III deacetylase SIRT1, 
resulting in the deacetylation of downstream targets including PGC-1α forkhead box 
O1 and 3 transcription factors (Canto et al., 2009).  
Oltipraz is a 1,2-dithiole-3-thione compound with antioxidant properties. Oltipraz has 
also been demonstrated to reduce apoptosis in cells with chemically inhibited CI by 
exerting its cytoprotective effect though AMPK (Golubitzky et al., 2011).  
Bezafibrate is an agonist of PPARs stimulating oxidative metabolism and has a 
documented positive effect on mitochondria. On the other hand, fenofibrate was 
reported to have a negative effect on CI (Wenz et al., 2010).  
Sodium phenyl butyrate is a histone deacetylase (HDAC) inhibitor, affecting protein 
phosphorylation and relief of endoplasmic reticulum stress. Although the mechanism 
of action of this compound is poorly defined, it has been found to be beneficial in a 
number of diseases including cancer, neurodegenerative diseases and metabolic 
diseases (Cudkowicz et al., 2009).  
Finally, Bendavia (MTP-131) is a novel therapeutic agent that preserves mitochondrial 
integrity and ATP synthesis, while reducing ROS production. This compound acts via 
a unique mechanism, selectively targeting the IMM by interacting with cardiolipin to 
facilitate flux through the electron transport  chain, providing more efficient electron 
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flow. Importantly, Bendavia does not seem to scavenge ROS and does not require a 
transmembrane potential to be efficient, which differentiate it from other therapeutic 
approaches that target mitochondria (Chen et al., 2011).   
All of the aforementioned compounds have been documented to exert positive effects 
in OXPHOS deficient patient’s cells. 
 
 
1.4.3. Gene therapy 
For nDNA-related mitochondrial disorders, ‘classic’ gene therapy is an option, but well-
known issues are associated with this approach, including choice of appropriate viral or 
nonviral vectors, delivery to the affected tissues, and potential immunological reactions. 
Nonetheless, adeno-associated virus-mediated gene transfer has proven successful in 
two animal models: the Ant1 mutant mouse (Flierl et al., 2005) and a mouse model of 
ethylmalonic encephalomyopathy (Di Meo et al., 2012). 
For mitochondrial diseases due to mutations in mtDNA, the problems are more complex 
because of polyplasmy and heteroplasmy and because no investigators have so far been 
able to transfect DNA into mitochondria in a heritable manner (DiMauro et al., 2006a). 
 
 
Shifting of heteroplasmy 
For mtDNA-related disorders, an obvious but challenging goal is to shift heteroplasmy to 
lower the mutation load to subthreshold levels. Several strategies have been attempted in 
cybrid cell lines, often with good results. When deprived of glucose and exposed to 
ketogenic media, cybrids harbouring single mtDNA deletions shifted their heteroplasmy 
level and recovered mitochondrial function, probably through selective mitochondrial 
autophagy (mitophagy) (Gilkerson et al., 2012). Suomalainen’s group recently used a 
ketogenic diet to rescue metabolic function in a mouse model of late-onset mitochondrial 
myopathy due to deletions of mtDNA but, interestingly, the metabolic improvement was 
not accompanied by any obvious reduction in mutation load (Ahola-Erkkila et al., 2010). 
This discrepancy might be explained, however, by the possibility that instead of reducing 
mutation load, the ketogenic stress ‘‘normalized’’ the distribution of the mutation so that 
cells contained more mitochondria below the threshold for dysfunction (Schon et al., 
2010). 
A genetic approach to heteroplasmic shifting involves use of restriction endonucleases to 
eliminate specific pathogenic mutations. Dormant stem cells in skeletal muscle (satellite 
cells) have fewer mtDNA mutations than do adult muscle fibres, and muscle regeneration 
after induced myonecrosis was used to shift heteroplasmy in a patient with strabismus. For 
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example, the T to G mutation at nt-8993 in the MT-ATP6 gene that causes MILS  and/or 
NARP  creates a novel and unique SmaI site in human mtDNA. Because WT mtDNA has 
no SmaI sites, if functioning SmaI could be targeted to mitochondria in cells from 
heteroplasmic NARP/MILS patients, it would be possible to selectively cleave (and 
thereby destroy) the mutated mtDNAs while leaving the WT mtDNAs intact (Figure 12).  
In 2002, Tanaka and colleagues demonstrated 
that such approach is possible. Although this 
strategy would only work for a mutation that 
generates a unique restriction site absent in wt 
mtDNA, the precedent for the importation of a 
nuclease into mitochondria has been set. 
 
 
Figure 12 - Mitochondrial importation of a restriction 
endonuclease to cleave mutated mtDNAs selectively. 
The example shown is of the importation of SmaI (pink 
rectangle) to eliminate the T→G mutation at mtDNA 
position 8993 (p.L156R mutation in ATP6) associated 
with NARP/MILS. Following the transfection of the 
construct into the cell (blue), mitochondrially targeted 
SmaI expressed from the nucleus (yellow) is targeted to 
the organelle (gray) via an N-terminal mitochondrial 
targeting sequence (MTS; green rectangle) that is 
cleaved from the precursor polypeptide following import. 
Only mutated mtDNAs are cleaved and then degraded, 
leaving the normal mtDNAs intact (figure adapted from 
Schon et al., 2010). 
 
 
 
Fighting against ROS Accumulation 
A genetic approach to scavenging ROS proved successful in transgenic mice. First, it was 
documented that the complex I deficiency brought about by expression of an anti-
NDUFA1 ribozyme (NDUFA1 is a catalytic subunit of complex I) induced lesions of the 
retina and optic nerve similar to those of LHON in humans. Second, it was shown that 
downregulation of MnSOD by expression of anti-SOD2 ribozyme in mice also induced 
LHON-like lesions. These data established that excessive production of ROS damaged 
the retina and the optic nerve. When the investigators coexpressed anti-NDUFA1 
rybozyme (the poison) and SOD2 (the antidote) in the same mice, the lesions were not 
produced, thus documenting the powerful therapeutic action of SOD scavenging (DiMauro 
et al., 2006b). 
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Stem Cell Therapy 
Promise for stem cell therapy in mtDNA-related diseases is offered by a study 
documenting that mitochondria can migrate from cell to adjacent cell. Coculturing human 
rho0 cells with normal osteoblastoma cells or fibroblasts resulted in rescue of the 
mitochondrial function of rho0 cells due to transfer of normal mitochondria, which occurred 
in the absence of cell fusion (Spees et al., 2006). 
 
 
Cytoplasmic transfer 
For mtDNA-related diseases, many of which are devastating and undiagnosable before 
birth, the ultimate goal is to prevent their occurrence altogether via cytoplasmic transfer. In 
this approach, the nucleus of an in vitro-fertilized oocyte from a carrier is transferred to an 
enucleated oocyte from a normal donor: the embryo will have the nDNA of the biological 
parents but the mtDNA of a normal mitochondrial donor (Figure 13). This approach would 
result in a mitochondrially normal child carrying the nuclear traits of both parents. The 
feasibility of cytoplasmic transfer has now been demonstrated by the Newcastle group in 
the UK (Craven et al., 2010), and a variant of this approach was recently used in the US 
to produce two ‘‘transmitochondrial’’ rhesus monkeys (Tachibana et al., 2009). Of course, 
the ethics of cytoplasmic transfer would need to be addressed before this type of germline 
gene therapy could be undertaken (Rubenstein et al., 2005). 
 
 
 
 
 
 
Figure 13 - Cytoplasmic 
transfer. Following in vitro 
fertilization, the haploid parental 
pronuclei (i.e. the normal 
pronucleus from the ooplasm of a 
woman carrying a mtDNA 
mutation [pink] and the normal 
pronucleus from the father [light 
green]) are transferred to an 
enucleated donor oocyte 
containing normal mtDNAs (blue); 
following fusion of the pronuclei, 
the embryo now contains a 
normal diploid nucleus from the 
parents (green) and normal 
mtDNA from the cytoplasmic 
donor, and can be implanted into 
the mother’s uterus figure 
adapted from Schon et al., 2010). 
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1.5. Genetic counseling  
Prenatal diagnosis for tRNA point mutations, including the common ones associated with 
MELAS and MERRF, is practically impossible because of two concerns. First, the 
mutation load in amniocytes or chorionic villi does not necessarily correspond to that of 
other fetal tissues. Second, mutation load measured in prenatal samples may shift in utero 
or after birth due to mitotic segregation.  
At the other end of the spectrum, large-scale deletions of mtDNA as a rule are neither 
inherited nor transmitted. They probably arise de novo in oogenesis or in early 
embryogenesis, or, when they are present in a fertilized oocyte, are unlikely to slip 
through the bottleneck between ovum and embryo that allows only a small minority of 
maternal mtDNAs to populate the fetus. However, in counseling a woman who harbors a 
large-scale mtDNA deletion, the possibility of transmission should not be excluded 
completely. There is good evidence that mutations in ATPase 6 associated with 
NARP/MILS do not show tissue- or age-related variations, thus making prenatal diagnosis 
feasible for parents who have lost a child to maternally inherited Leigh’s syndrome. 
However, once medium-low levels of mutated genomes are found in chorion villi, it is not 
practicable to assure parents on the future safety of their offspring. 
The rapid progress in our molecular knowledge of nDNA-related defects of the MRC is 
improving genetic counseling and making prenatal diagnosis an option for families with 
fatal infantile conditions, such as Leigh’s syndrome or mtDNA depletion syndromes 
(DiMauro et al., 2004). 
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AIMS 
 
The mitochondrial and nuclear genomes exert a dual genetic control on the OXPHOS and 
associated systems. Diseases caused by nuclear genes, that affect mtDNA stability are 
an interesting group of mitochondrial disorders, involving both cellular genomes. In these 
pathologies, a primary nuclear gene defect causes either qualitative (mtDNA multiple 
deletions) or quantitative (mtDNA depletion) molecular abnormalities, which leads to 
tissue dysfunction. 
 
The overall aim of this project was to study patients with nuclear-mitochondrial 
intergenomic communication using the following approach: 
 
i) to identify patients with mtDNA multiple deletions and/or mtDNA depletion by 
real-time qPCR.  
ii) to perform mutation screening of nuclear genes associated with disorders of 
cross-talk in the previous identified patients. 
iii) to expand the number of identified mutations in these genes. 
iv) to set up a number of functional assays to appreciate the efficacy/toxicity of 
standard and new therapeutic agents in cross-talk disorders. 
 
The current project should improve the study of these patients in our country, by providing 
a complete molecular diagnosis approach to find the causative nuclear gene mutations 
and by contributing to the development of novel therapeutic strategies against these 
disorders. 
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PATIENTS AND METHODS 
 
3.1. Patients 
The Laboratory of Mitochondrial Pathology at the Genetic and Metabolism Unit of the 
Genetic Department from the Portuguese National Institute of Health (INSA, IP) is a 
reference center for mitochondrial disorders of oxidative metabolism in Portugal since 
1993.  
In the past 20 years, the laboratory has received more than 2000 samples (muscle, liver, 
fibroblasts, and blood) to study a possible defect causing mitochondrial disease. Patients 
had been referred from hospitals from all over the Country and overseas (Italy, Brazil and 
The Netherlands).  
For this study a total of 90 samples (52 muscle, 10 liver, 5 fibroblasts and 23 blood 
samples) were selected to investigate a possible defect of intergenomic communication 
(multiple deletions or mtDNA depletion). According to standard clinical and biochemical 
criteria, patients for this study (84 paediatric and 6 adults) were divided into three major 
groups (Figure 14):  
 
i) The first group consisted of 26 individuals with a hepatocerebral presentation. The major 
clinical criteria to be included in this group were liver diseases (cholestasis, 
hepatomegaly, altered hepatic enzymes or liver failure) with lactic acidaemia and 
neurological dysfunction (including hypotonia, developmental delay or cerebral atrophy). 
Muscle or liver samples were available from 4 and 10 patients, respectively. Eligible 
patients showed either altered activities of the MRC complexes except for complex II, or 
generalized deficiencies of OXPHOS complexes, or normal activities in muscle in spite of 
a severe liver pathology. Solid tissues from 12 patients were not available, but were 
included in the genetic study due to a clinical history highly suggestive of the 
hepatocerebral form of MDS. Total DNA was obtained in these cases from blood. 
 
ii) The second group was made of 22 individuals with an encephalomyopathic 
presentation. The major criterion to be included in this group was occurrence of “mild” 
methylmalonic aciduria with normal homocistinuria and the presence of neurological 
symptoms such as hypotonia, developmental delay, sensoneuronal deafness and clinical 
features suggestive of Leigh, or Leigh-like, syndrome. In addition, some patients showed 
lactic acidaemia and increased succinylcarnitine (C4-dicarboxylic carnitine - C4DC) in 
serum. Muscle tissue was available only from 9 patients, and DNA of the remaining 13 
cases was studied from blood in 10 patients, or cultured skin fibroblasts in three cases. 
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iii) The third group was made of 42 individuals showing a purely myopathic presentation of 
a mitochondrial disorder. Feeding difficulties, failure to thrive, hypotonia, muscle 
weakness or wasting and occasionally ptosis and PEO were the major clinical criteria to 
be included in this group. Muscle tissue from 39 patients and fibroblasts from two were 
available, whereas in the remaining patient blood DNA was analyzed.  
 
Figure 14 – Schematic clustering of the samples selected to investigate a possible defect of 
intergenomic communication. A group of patients (N=90) was distributed in three different categories of 
clinical presentation. 
 
 
 
Before considering these patients to start molecular investigations it is important to obtain 
the appropriate biochemical and/or clinical information. Suspicion of intergenomic 
communication disorders arising from clinical presentation may range from well defined 
syndromes to unspecific multisystemic phenotype, where neurological involvement is 
usually present. Biochemical data, such as lactate, pyruvate, alanine, organic acid profiles 
as well as neuroimaging findings are also important clues for the diagnosis of these 
disorders. Establishing a specific diagnosis in a patient with suspected Mendelian disease 
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is challenging and requires integration of clinical assessments, family history, biochemical 
testing and histopathological examination.  
 
Thus, to select patients eligible for this study, among a total of 90 cases, the relative 
mtDNA/nDNA ratio by real-time qPCR was analyzed in samples from solid tissues in order 
to identify patients with mtDNA depletion or multiple deletions. Regarding patients with 
mtDNA depletion, we defined “primary” or a “secondary” mtDNA depletion when a 
significantly low level of mtDNA (that is, <30% range of control samples) or a moderate 
reduction (that is, 40-60% of the control range) was detected, respectively.  
From the 90 initial cases, 47 were considered eligible for further investigations using an 
algorithm that favors prioritization in molecular diagnosis (Figure 15).  
A molecular study was performed in 27 patients with mtDNA quantitative/qualitative 
alterations, and in 20 patients in whom DNA could be obtained only from blood, taking into 
account their clinical and biochemical features. Table 2 summarizes the clinical and 
biochemical data of these 47 eligible patients. 
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Figure 15 - Diagnostic algorithm for investigate suspicious patients of intergenomic communication 
disorders.  
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Table 2 – Clinical and biochemical data of the 47 eligible patients for this study. 
Patient Sex Diagnostic 
age  Country Specimen Clinical and Biochemical data 
Hepatocerebral form 
1† M 29 Days Pt Mus Severe acidosis; Cholestasis; Mutiorganic/ Liver failure; Cardio-respiratory arrest 
2† F 1 Mo Pt Bld Coagulopathy; Hepatopathy; Anemia. 
3 
 
M 2 Mo Pt Bld 
Hepatopathy with hepatic fibrosis; Ascite; 
Cardiac Ventricular Hypertrophy; Severe 
malnutrition; Neonatal Cholestasis; 
Hypertrophic Cardiomyopathy; Muscle 
atrophy. 
4 
 
M 10 Mo Pt Bld 
Hepatic cytolysis; Insulin-dependent 
diabetes; Liver alterations; Relevant family 
history (consanguinity and brother with a 
similar picture). 
5† F 5 yrs Br Bld 
Myoclonus; Seizures with left hemiparesis; 
Hypotonia; Difficulty in walking and in the 
balance maintaining; Developmental delay; 
Metabolic acidosis; Liver failure; Involuntary 
eye movements. 
6 M 1 Mo Pt Bld Cholestasis; Myoclonies. 
7 
 
M 1 yrs Pt Bld 
Unexplained cholestasis in the first months 
of life; Changes in brain imaging; 
Macrocephaly; Cardiac and pulmonary 
alterations (pulmonary valve stenosis). 
8 F 15 Mo Pt Liv Liver failure. 
9† M 9 Mo It Liv 
Hypotonia; status epilepticus; MRI with 
basal ganglia changes and atrophy; 
Abnormal liver function suggesting AHS; 
Liver failure.  
10 M 1 Mo Pt Bld Liver failure. 
11 M 1 Mo Pt Bld 
Neonatal hemochromatosis; Liver failure, 
Hypotonia; Feeeding difficulties; 
Hyperlactacidemia; Brother (P11a) 
deceased during neonatal period. 
12 M 1,5 Mo Pt Bld Liver failure. 
13 M 3 Mo Pt Bld Liver failure. 
14† M 2 Mo Pt Liv Acute liver failure; Elevated levels of transaminases; thrombocytopenia. 
15† M 1 Mo Br Liv 
Neonatal hypoglycemia; Digestive bleeding; 
Sepsis; Elevated levels of total and free 
serum bilirubin and transaminases. 
Hyperlactacidemia; Failure to thrive; 
Hypotonia; Nystagmus; Cirrhotic ascites; 
Sister (P15a) deceased with hepatic 
insufficiency. 
16† M 4 yrs Nth Liv Seizures; hypoglycemia; Liver Failure; Steatosis; Hyperlactacidemia. 
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17 M 11 yrs Pt Bld Hypotonia; Failure to thrive; Liver failure 
18 M 13 yrs Nth Liv 
Myoclonic epilepsy; Headache and bilateral 
high signal lesions of the occipital horns of 
the ventricles. Liver failure after treatment 
with valproate; Liver transplantation; Multi-
organ involvement. 
Encephalomyopathic form 
19 F 15 Days Pt Bld Lactic acidaemia; Hypotonia; Developmental delay. 
20 M 4 yrs It Fibr 
Rapidly progressive cerebral and ponto-
cerebellar atrophy with intractable epilepsy; 
Hyperlactacidemia; Neonatal Hypotonia; 
Intractable seizures; Frequent myoclonic 
jerks in upper limbs.  
21 F 1 Mo Pt Bld “Mild” methylmalonic aciduria with normal homocistinuria; Increased C4DC. 
22 M 3,5 yrs Pt Bld Developmental delay; Hyperlactacidemia; increased blood C4DC. 
23 M 3 Mo Pt Bld 
Hypotonia; Frequent vomiting; Sepsis; 
“Mild” methylmalonic aciduria with normal 
homocistinuria. 
24 M 4 Mo Pt Bld Hypotonia; “Mild” methylmalonic aciduria 
with normal homocistinuria; Dysmorphism. 
25 M 1 yrs Pt Bld Hypotonia; “Mild” methylmalonic aciduria 
with normal homocistinuria. 
26 M 9 Mo Pt Bld Hypotonia; Irritability; “Mild” methylmalonic 
aciduria with normal homocistinuria. 
27 M 17 Mo Pt Fibr 
Hypotonia; Failure to thrive; developmental 
delay; Weight loss during a gastroenteritis 
crisis; dysmorphisms; Muscular atrophy; 
Deafness; Hyperlactacidemia; moderate 
urinary excretion of MMA and elevated 
C4DC. 
28 F 1 Mo Pt Bld Failure to thrive; developmental delay; 
elevated C4DC. 
29 M 3 yrs Pt Mus 
Failure to thrive; Hypotonia; moderate 
urinary excretion of MMA with normal 
homocistinuria. 
30 M 4 Mo Pt Bld 
Hypotonia;Dysmorphisms; hyperlactacidemia; 
moderate urinary excretion of MMA with 
normal homocistinuria. 
31 F 1 Mo Pt Mus Hyperlactacidemia; Failure to thrive; Hypotonia. 
32 M 2 yrs Pt Mus 
Developmental delay; Hyperlactacidemia; 
Progressive neurologic findings including, 
Strabismus; Ataxia. 
33 M 49 yrs Pt Mus 
Progressive back pain; Gait difficulties; 
Psychiatric manifestations; Neurological 
examination at age 37 revealed difficulties 
in tandem gait, loss of balance segmental 
ataxia; Dysarthric speech; Dysphagia; 
Severe muscle atrophy; Unable to walk or 
stand; Respiratory insufficiency. Three 
additional sibs (P33a,b,c) showed an ataxic 
syndrome and psychiatric manifestations. 
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Myopatic Form 
34 F 5 yrs Pt Mus Failure to thrive; Hypotonia; Similar twin-
sister.  
35 F 4 yrs Pt Mus 
Feeding difficulties; Ventricular hypertrophy; 
Retin alterations; Low weight increasing; 
Loss of consciousness.   
36 M 50 yrs Pt Mus 
Intermittent postprandial vomiting; 
gastrointestinal dysmotility, episodes of 
diarrhe; constipation; Severe cachexia and 
numbness distally in the four limbs. Mild 
generalized weakness; Diffuse muscle 
atrophy. 
37 F 5 yrs Pt Mus Developmental delay; Hypotonia; Unable to 
walk and talk.   
38 M 9 Mo Pt Mus 
BTHS: Hyperlactacidemia;  cardiomyopathy, 
skeletal myopathy, growth delay, 
neutropenia, and urinary excretion of 3-
MGCA. 
39 M 2 yrs Nth Fibr Generalized epilepsy; ATP syntesis and fresh muscle oxidation rate decreased. 
40† F 1 Days Pt Mus 
Cardiac failure; Congenital anemia; 
Cardiomegaly; Miocardic hypertrophy; 
Metabolic acidosis; Perinatal asphyxia; Died 
with 5h of life. 
41 M 38 yrs Nth Fibr 
Chronic fatigue; Generalized muscle 
weakness. 
 
42† F 10 Mo Pt Mus 
Psychomotor delay; Hypotonia; Spasticity; 
Neurosensorial deafness; Epilepsy; Urinary 
excretion of 3-MGCA; Hyperlactacidemia; 
Nephew (P42a) deceased in the neonatal 
period with hypotonia, nystagmus,  feeding 
difficulties and urinary excretion of 3-MGCA; 
Niece (P42b) with a similar clinical 
phenotype. 
43 F 7 yrs Pt Mus Hypotonia; Failure to thrive; Cardiomyopathy; Lipidic myopathy. 
44 F 2 Mo Pt Mus 
Hypotonia; Feeding difficulties; Weight loss; 
Brother deceased with a similar clinical 
phenotype. 
45† F 4 Days Pt Mus Respiratory insufficiency; Metabolic 
acidosis; Multiple organ failure. 
46 M 1 Mo Pt Mus Hypotonia; Failure to thrive; Hypertelorism. 
47 M 3 yrs Pt Mus Feeding difficulties; Hypotonia; Failure to thrive.  
 
Legend: M - Male; F - Female; Mo - Months ; yrs - Years; Pt - Portugal; Br - Brazil; It - Italy; Nth - The 
Netherlands; Mus - Muscle; Liv - Liver ; Bld - Blood ; 3-MGCA - 3-methylglutaconic acid; C4DC - 
succinylcarnitine; BTHS – Barth syndrome; MMA - methylmalonic acid. 
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3.2. Methods 
 
3.2.1. DNA / RNA extraction and quantification 
i) Total genomic DNA was extracted from different tissues, using commercial kits: the EZ1 
DNA Blood 350 µl Kit (QIAGEN®) was used for blood samples, and Puregene Tissue kit 
(Gentra), for muscle and liver biopsies.  
ii) Total RNA was extracted from different tissues, using commercial kits: PAXgene blood 
RNA kit (PreAnalitiX) was used for blood samples, and RNeasy Mini Kit (QIAGEN®), for 
skin biopsies.  
 
NanoDrop® ND-1000 UV-Vis Spectrophotometer was used for nucleic acids quantification 
and purity. 
 
 
3.2.2. Real-time qPCR 
The comparison of techniques such as Southern-blot and real-time quantitative 
polymerase chain reaction (qPCR) allowed to conclude that qPCR is a more sensitive, 
faster and specific technique, and thus more appropriate for a better and accurate 
diagnosis of mtDNA depletion and multiple deletions (Chabi et al., 2003; Bai and Wong 
2005). 
Calibration curves were prepared in triplicate for two mitochondrial genes (ND1 and ND4) 
and one nuclear gene (rRNA18S), using serial dilutions of the PCR product of the target 
gene. The primers used for this assay are described in supplementary material.  
MtDNA copy number (mtDNA depletion) was calculated from the standard curve and 
threshold cycle number using the ratios ND1/18SrRNA or ND4/18SRNA, and the 
ND4/ND1 ratio was used to determine the presence of mtDNA deletions. 
For qPCR reaction was used 1.25 µl of 1x GoTaq (Promega), 1.5 µl of each primer – 
forward and reverse (5 mM) (Supplementary material), 3 µl of MgCl2 25mM (Promega), 2 
µl of dNTPs 2.5 mM (Promega), 1.25 µl of Eva Green (Biotium), 5 ng of DNA (sample or 
calibrator) and water in a final volume of 25 µl. The qPCR amplification conditions were 2 
min at 50°C and 10 min at 95°C, followed by 40 cycles of 15s of denaturation at 95°C and 
60s of annealing/extension at 60°C. At the end of the amplification process, melting 
curves were analyzed between 60-95ºC (temperature transition of 0.1 ºC/s), with 
continuous fluorescence monitoring to control for the absence of nonspecific products. 
The fluorescent signal intensity of PCR products was recorded and analyzed in a Rotor-
Gene 6000 (Corbett, Life Sciences). 
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The cycle threshold (Ct) value within the linear exponential phase was used to construct 
the standard curve. Using the comparative Ct method, outlined in reference (Livak and 
Schmittgen, 2001), the starting copy number of the unknown samples was determined in 
comparison with the known copy number of the calibrator sample, using the following 
formula: ∆∆Ct = [∆Ct 18S rRNA (calibrator sample) – ∆Ct mtDNA (calibrator sample)] – 
[∆Ct 18S rRNA (unknown sample) – ∆Ct mtDNA (unknown sample)]. The relative gene 
copy number was calculated by the expression 2–(∆∆Ct). Values in patients were compared 
to results obtained in five normal individuals.  
 
 
3.2.3. Mutational screening of genes associated with cross-talk disorders  
Molecular screening for mutations in the genes associated with cross-talk disorders, such 
as POLG, C10orf2 (TWINKLE), DGUOK, MPV17, TK2, RRM2B, SUCLA2, SUCLG1 and 
TYMP was performed by PCR, followed by direct sequencing. Additionally, some other 
nuclear genes, recently described in the literature and associated with these diseases, 
were also screened: RARS, TRMU, TSFM, TUFM, GFM1, TAZ and TTC19. 
 
PCR amplification 
For PCR reactions a commercial mix was used: ImmoMix Red (Bioline) containing 
IMMOLASETM DNA polymerase, (NH4)2SO4, Tween 20, MgCl2, dNTPs and Tris-HCl buffer.  
Primers were designed using the program Primer 3.0 (http://frodo.wi.mit.edu/primer3/) in 
order to flank the coding sequences and exon-intron junctions of the genes described 
above (see supplementary material). All primers (Forward and Reverse) were tagged with 
M13 universal sequences and used at a 50 pmol/µl. 
The program Fast PCR Professional 5.1 was also used to predict the formation of dimers 
and to evaluate the quality of the design primers (Kalendar et al., 2009).  
For each fragment the PCR conditions were optimized using annealing temperature 
gradients. The optimal annealing temperatures for each fragment are indicated in 
supplementary material. The hot start PCR protocol included an initial denaturation step at 
95 ºC for 10min, followed by 35 cycles of amplification, which consists on a step of 
denaturation at 95 ºC – 1min; annealing at variable temperature, depending on the 
fragment – 1min and extension at 72 ºC – 1min.  A final extension step was done at 72 ºC, 
lasting between 5min and 10min, depending on the size of the fragment amplified. 
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The PCR amplification product was analyzed in an 2 % Agarose (Lonza-Seakem® LE 
Agarose) with SYBR Green (Roche) in Tris-acetate-EDTA (TAE) buffer and visualized in a 
Gel Doc System (Bio-Rad). 
 
Sequencing analysis 
PCR amplified fragments were purified with ExoSAP (GE Healthcare) and sequenced with 
BigDye® Terminator v1.1 Cycle Sequencing Kits (Applied Biosystems) in an ABI 3130xl 
Genetic Analyzer (Applied Biosystems). 
For amplicons purification 1 µl of Exo-SAP and 2 µl of PCR product were incubated at 
37ºC for 30 min followed by a step at 80ºC for 15 min for enzyme inactivation. 
For sequencing the following program was used: initial denaturation step at 94ºC for 4min, 
followed by 25 cycles consisting in 94ºC for 10sec, 50ºC for 6sec and 72ºC for 4min; and 
a final step of elongation at 72ºC for 5min. The DyeEx 96 Kit (QIAGEN) was used to 
remove the unincorporated dye terminators, following the instructions of the manufacturer.  
Mutations were confirmed by resequencing a second amplicon with both sense and 
antisense primers. Segregation of the mutations in available family members and 
frequency of novel mutations in a panel of 200 ethnically-matched healthy chromosomes 
was performed by direct sequencing. 
 
Bioinformatic analysis tools 
The sequences obtained were compared to the reference of the respective gene using the 
Ensemble Genome Browser (http://www.ensemble.org), and the variants found were 
searched for in HGMD® Professional database (https://portal.biobase-
international.com/hgmd/pro/start.php?). 
For novel variants Clustal W program (http://www.ebi.ac.uk/Tools/msa/clustalw2/), 
multialignments were done to determine the degree of evolutionary conservation of the 
amino acid residue involved (Thompson  et al., 1994). Furthermore, the amino acid 
substitution was analysed by PolyPhen (PolyPhen: Prediction of functional effect of 
human nsSNPs. http://genetics.bwh.harvard.edu/pph/), to predict if an amino acid change 
is likely to be deleterious to protein function. Profile scores of >2.0 indicate that the 
polymorphism is probably damaging to protein function whereas scores of 1.5–2.0 are 
possibly damaging, and scores of <1.5 are indicative of a benign variant. To confirm 
results from PolyPhen, we also used (i) the MutPred Server (http://mutpred.mutdb.org/), 
which generates a probability for a given mutation to be deleterious to protein function 
(scores that range from 0 to 1), and the likelihood of it being pathogenic (scores over 0.5) 
and (ii) SIFT (http://sift.jcvi.org/), which yields a score of ≤0.05 if the amino acid 
substitution is predicted to be damaging and >0.05 if it is predicted to be tolerated. 
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3.2.4. BN-PAGE 
For BN-PAGE, mitochondria-enriched fractions were isolated from cultured fibroblasts 
(Nijtmans et al., 2002).  
The harvested cells were treated with digitonin, which selectively dissolves membranes 
containing cholesterol, saving the IMM. The undissolved IMM fraction was then collected 
by centrifugation and the membrane proteins were solubilized with dodecyl-β-D-maltoside. 
Briefly, the phosphate-buffered saline (PBS) washed cells were resuspended in 
approximately 100 µl of PBS. The same volume (100 µl) of cold digitonin was added (C=8 
mg/ml in PBS) to the cell suspension. This mixture was maintained in ice for 10min, after 
which 1 ml of cold PBS was added. It was then centrifuged for 5min, at 10000g, at 4ºC. 
The supernatant was discarded and the pellet washed once more in 1 ml of cold PBS. 
The pellet obtained can be frozen or immediately dissolved. 
In order to isolate mitochondria, the cell pellet was washed twice in the homogenization 
buffer (0.25 M sucrose, 1 mM EGTA, 10 mM HEPES/NaOH, 0.5% bovine serum albumin, 
(pH 7.4), being centrifuged at 1500g for 5min. The pellet was resuspended in 
approximately 5 mL of the homogenization buffer and kept in ice. It was added 10 µl of 
Protease (100 µg/ml), allowing the disruption of the membrane and after 7min, a mixture 
containing  5 ml of homogenization buffer with 5 µl of pepstatin (1 mg/ml), 5 µl of leupeptin 
(1 mg/ml), and 10 µl of PMSF (1 M) was added. This suspension was homogenized with 
12 up and down strokes in a rotating glass Teflon homogenizer and then centrifuged at 
1500g for 8min at 4°C. The supernatant was transferred to another tube and was kept in 
ice. The pellet was dissolved, homogenized and centrifuged as above. The supernatant 
obtained was added to the first one, and a crude mitochondrial pellet was collected by 
centrifugation at 14600g for 12min at 4°C. This pellet was resuspended in 140-200 µl of 
washing buffer (10 mM Tris/HCl, 1 mM EDTA, 0.25 M sucrose, pH 7.5), which was frozen 
or immediately suspended (Garcia et al., 2000). 
After measuring the protein, using the bicinchoninic acid (BCA) protein assay, at λ=562 
nm, lysis of mitochondria-enriched fractions for BN-PAGE, from fibroblasts was obtained. 
Once solubilized, the pellets (150-250 µg of protein) were vigorously pipetted in 100 µl 
buffer containing 1.5 M aminocaproic acid, 50 mM Bis–Tris/HCl, pH 7.0 with 1% (v/v) of 
lauryl maltoside (Sigma Aldrich), and incubated on ice for 30min. They were centrifuged at 
20000g for 30min at 4ºC. The supernatant was transferred to a new Eppendorf tube, after 
which a new protein determination was done. The amount of protein needed was 
transferred to a new eppendorf tube and 10% of sample buffer (750 mM aminocaproic 
acid, 50 mM Bis–Tris/HCl, pH 7.0, 0.5 mM EDTA, and 5% Serva Blue G) was added. This 
sample is ready to load on a gel, or stored for at least a month at -80 ºC.  
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The assembly and level of expression of complex III in the patient fibroblasts was 
analyzed using BN-PAGE and second-dimension (2D) SDS-PAGE (Schagger and von 
Jagow 1991). Detergent-solubilized IMM enzyme complexes (30-60 µg proteins) were 
separated by BN-PAGE in a linear 5-13% acrylamide gradient gel (Nijtmans et al., 2002; 
Calvaruso et al., 2008).  
The gradient gel was polymerized in a gel caster, using 1.5 mm thick spacers. Two 
mixtures were prepared, one corresponding to the 5% gel and other to the 13% gel (see 
supplementary material), and were added to the gradient maker. After polymerization of 
the previous gel,  the stacking gel was also casted. 
The electrophoresis apparatus is set up, with the cathode buffer A (50 mM Tricine, 15 mM 
Bis-Tris, 0.02% Serva Blue G, pH 7.0) in the inner compartment and the anode buffer (50 
mM Bis-Tris pH 7.0) in the outer compartment. The samples were loaded and  
electrophoresed at 4ºC, until they have entered the stacking gel, at 30 V for 30min, after 
which the voltage was increased to 80 V. When the front has reached the middle of the 
separating gel, the cathode buffer A was replaced for the cathode buffer B (50 mM Tricine, 
15 mM Bis-Tris, pH 7.0). Electrophoresis continued at 80 V until the blue dye front 
reached the end of the gel. 
After that, proteins were either subjected to western-blot or the lanes were cut off and the 
enzyme complexes were separated into subunits by 2D SDS-PAGE. 
 
 
3.2.5. 2D-SDS-PAGE 
For further separation in a second-dimension SDS-PAGE, the lanes from first-dimension 
BN-PAGE were cut out. Gel strips were equilibrated for 1h in a dissociating solution (1% 
SDS and 1% β-mercapthoethanol) and excess of solution was drained with filter paper. 
The gel strip was placed into the top of the glass plate and a second-dimension SDS-
PAGE of the same thickness was done. A separating gel of 12% was poured and overlaid 
with water. After polymerization, we added the 5% stacking gel , including strips around 
the gel. The electrophoresis apparatus was prepared with the cathode buffer (0.1 M Tris, 
0.1 M Tricine, 0.1% SDS, pH 8.2) and the anode buffer (0.2 M Tris-HCl, pH 8.9), and 
started at 30 V for 30min and continued at 80 V (2-4h) or at 20 V, overnight. 
Immunoblotting were performed according to standard protocols (described above). 
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3.2.6. Western-blot 
Proteins separated either by BN- or SDS-PAGE were transferred to a polyvinylidene 
difluoride (PVDF) membrane (Immobilion-P transfer membrane, Millipore) and subjected 
to Western blotting according to standard protocols (Towbin et al., 1979). First the PVDF 
membranes were cut in the proper size and immersed in methanol for about 30s, which 
was then discarded and substituted by the transfer buffer (25 mM Tris, 192 mM Glycine, 
20% Methanol for SDS-PAGE membranes and 25 mM Tris, 192 mM Glycine, 20% 
Methanol and 0.02% SDS for BN-PAGE membranes). The gel was removed from its cast 
and immersed in the transfer buffer. The sponges, filter papers had been previously 
wetted in the same buffer. The sandwich was assembled in the following order from 
cathode to anode, avoiding air bubbles: sponge – filter paper Whatman 3MM – gel – 
PVDF membrane – filter paper Whatman 3MM – sponge. The sandwich was placed inside 
the transfer apparatus and filled with cold transfer buffer,  which was then set up at 4 ºC 
on a stir plate. The transfer was done at 100 V for 1h. 
When finished, depending if the membranes were from BN-PAGE or SDS-PAGE, they 
were treated in different ways. The membrane from SDS-PAGE was stained with 
Ponceau (Ponceau S 0.3%, TCA 3%) and washed two times with water. Instead, the 
PVDF membrane from BN-PAGE was air dry for at least 1h, after which was washed 
quickly two times with methanol and once with water.  
The membranes were then blocked in milk 5%, prepared in 0.1% Tween 20 – Tris-
Buffered Saline (T-TBS) (20 mM Tris-HCl, 137 mM NaCl, 1% Tween 20, pH 7.6) one hour 
at room temperature or overnight at 4ºC. 
After the blocking, membranes were successively incubated with primary antibodies 
diluted in 2.5% milk/T-TBS (Supplementary material), for 60min at room temp, or 
overnight at 4 ºC. Different monoclonal antibodies against the human OXPHOS subunits 
were used (Table 3), all of which purchased from Mitosciences (Eugene, OR, USA). The 
membranes were then washed three times, for 5min, with T-TBS and incubated with the 
secondary antibody (diluted in 2.5% milk/T-TBS – 1:50000) for 1h at room temperature. 
The Peroxidase-conjugated anti–mouse IgGs (GE Healthcare) was used as the 
secondary antibody. Prior to the signal detection, the membranes were washed two times 
with T-TBS for 5min and one time with TBS (20 mM Tris-HCl, 137 mM NaCl, pH 7.6) for 
10min. The signal was detected using the Immobilon Western Chemiluminescent HRP 
Substrate detection kit (Millipore Corporation) and the fluorescence were quantified using 
the software Quantity One (Bio-Rad). 
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 Table 3 – Monoclonal antibodies against the human OXPHOS subunits used in this study. 
 
Monoclonal Antibody Final Concentration 
CI subunit NDUFA9 1 µg/ml 
CII subunit 70 0,1 µg/ml 
CIII subunit Core 2 1 µg/ml 
CIV subunit COX II 1 µg/ml 
CV subunit alfa 1 µg/ml 
Porin 0,1 µg/ml 
 
 
3.2.7. Multiplex ligation-dependent probe amplification - MLPA 
Multiplex Ligation-dependent Probe Amplification (MLPA®) is designed to detect 
deletions/duplications of one or more sequences in the aforementioned gene(s) in a DNA 
sample. In this work two commercially available probe sets were used: SALSA MLPA KIT 
P089-A1 TK2 and SALSA MLPA probemix P010-A2 POLG (both from MRC-Holland), for 
detecting copy-mumber variation in TK2, DGUOK and C10orf2, and in the POLG gene, 
respectively. 
This is a high-throughput method developed to determine the copy number of up to 50 
genomic DNA sequences in a single multiplex PCR-based reaction. The MLPA reaction 
results in a mixture of amplification fragments between 100 to 500 nt in length which can 
be separated and quantified by capillary electrophoresis. In contrast to a standard 
multiplex PCR, only one pair of PCR primers is used in the MLPA PCR reaction (Figure 
16), resulting in a more robust system. 
 
 
 
 
 
 
 
 
           
       Figure 16 - PCR program for the MLPA reaction. 
 
 
Each MLPA probe consists of two oligonucleotides which have to hybridise to adjacent 
DNA targets in order to be ligated. Since only ligated probes can be amplified 
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exponentially during the subsequent PCR, the amplification of a given probe depends on 
the presence of its target DNA. Moreover, the relative amount of each probe’s 
amplification product is a measure for the relative quantity of that probe’s target sequence 
in the DNA sample. To quantify this relation, two calculations need to be done: (1) 
establishing the relative signal of each probe as compared to that of the other probes 
(intra-sample normalisation); (2) establishing the relative signals in the sample under 
study compared to those of reference samples (inter-sample normalisation). Upon 
normalisation, it is possible to establish whether any deletions or duplications in the target 
DNA have occurred. Heterozygous deletions of recognition sequences should give a 35-
50% reduced relative peak area of the amplification product of that probe. 
 
 
3.2.8. Measuring ROS and ATP production in cultured primary cells  
Human fibroblasts were obtained from skin biopsies and grown in regular Dulbecco's 
modified Eagle's medium (DMEM) medium supplemented with 10% fetal bovine serum, 
4.5 g/L glucose and 50 µg/ml uridine or in glucose-free medium supplemented with 5 mM 
galactose, to induce a stress culture condition. 
The cells were harvested with trypsin and washed two times with PBS. Depending on the 
application, the pellet was immediately used or frozen at -80 ºC.  
 
ROS production 
Fibroblasts cells at a density of 1×104, incubated in a 96-well plate, were analyzed 72h 
post-treatment with the following compounds: 0.5 mM AICAR (Tocris, Bioscience, Bristol, 
UK), 200 µM bezafibrate (Sigma-Aldrich) and 3,5 µM riboflavin (Sigma-Aldrich), for rate of 
ROS. After washing with respiration buffer (142 mM NaCl, 10 mM HEPES, 2 mM KCl, 1.2 
mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4) (Sigma, St. Louis, MO), supplemented with 
1% FBS (ROS buffer), 100 µl of 5 µM 5-(and-6)-chloromethyl-2,7-dichlorodihydro-
flouorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular Probes, Invitrogen, 
Paisley, UK) in ROS buffer were added to each well and incubated 15 min at 37°C.   
After washing with the same buffer, the cells were incubated for 30 min at 37°C with 100 
µl of ROS buffer with or without 100 µl H2O2 (500µM in buffer ROS) (Sigma-Aldrich). Wells 
were subsequently washed with the same buffer and after added another 100 µl of ROS 
buffer fluorescence could be detected. Fluorescence was measured at excitation and 
emission wavelengths of 490 nm and 527 nm, respectively, using a Varian Cary Eclipse 
Fluorescence plate reader (Agilent Technologies).  
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ATP production 
ATP levels were assayed using the Luminescence ATP Detection Assay System 
(PerkinElmer Life Sciences). Briefly, cells were seeded in a 96-well plate (1 x 104 
cells/well) incubated in DMEM for 48 h. After discarding the medium, wells were washed 
with ATP record buffer (156 mM NaCl, 3 mM KCl, 2 mM MgSO4, 1.25 mM KH2PO4, 2 mM 
CaCl2, 20mM HEPES, pH 7.35) and incubated for 2 h in ATP record buffer with the 
following conditions: 10 mM glucose; 10 mM glucose plus 2.5 µg/ml oligomycin (glycolytic 
ATP generation) and 5 mM 2-deoxy-D-glucose plus 5 mM pyruvate (oxidative ATP 
production). Cells were incubated with the luciferin/luciferase reagent and ATP production 
in samples was measured using an Orion L microplate luminometer (Berthold Detection 
Systems GmbH). 
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RESULTS 
 
The population presented in this study was selected from the cases referred to the 
Laboratory of Mitochondrial Pathology and with a clinical or biochemical suspect of 
disorders of intergenomic communication. Eligible patients were recruited if they satisfied 
clinical, biochemical and/or morphological criteria for disorders of intergenomic 
communication. Figure 17 shows a scheme recapitulating the approach used to select 
patients.  
   
 
 
                 
   
   
         
             
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   Figure 17 - Scheme illustrating the patients eligible for this study. 
 
In a total of 90 cases, we analyzed the relative mtDNA/nDNA ratio by real-time qPCR in 
67 samples obtained from solids tissues and identified a significantly low level of mtDNA 
(<30% range of control samples) in 17 patients (defined as “primary” mtDNA depletion). In 
an additional set of 8 patients, we detected a moderate reduction (40-60% of the control 
range) (“secondary” depletion). In one patient we did not detect mtDNA depletion or 
multiple deletions, yet he was considered eligible for this study, based on his suggestive 
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clinical features. A patient with multiple deletions was also identified by real-time qPCR, 
through the ratio ND4/ND1. In addition, 20 of the 23 patients in whom we could obtain 
DNA only from blood were also analyzed in this study based on their suggestive clinical 
features.  
The remaining patients were not included in this study because either they did not show 
defects of intergenomic communication or they had different metabolic diagnosis.  
 
 
 
 
4.1. “Primary” mtDNA depletion 
A primary mtDNA depletion was detected in 17 patients with a severe to moderate mtDNA 
depletion or clinical phenotype suspicious of MDS. A subset of these patients (Figure 18)  
presented mutations in the following genes associated with MDS: MPV17, SUCLA2, 
DGUOK, C10orf2 and POLG, whereas one patient presented mutations in the TAZ  gene. 
In this group we included two patients expected to have “primary” mtDNA depletion, 
however in P18, with a pathogenic POLG mutation commonly associated with AHS no 
mtDNA depletion was found in the studied tissues. Additionaly in P27 with a pathogenic 
SUCLA2 mutation, we expected a more pronounced mtDNA reduction, but the tested 
tissue (fibroblasts) was not adequate to illustrate such mtDNA content reduction, as it 
would be expected in muscle.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – Bar chart showing the relative quantification of mtDNA content by qPCR using the 2-∆∆Ct 
method. The error bar in controls (Ct) indicates three times the standard deviation. Data represents the mean 
± SD of three different determinations; rho0 are cells experimentally deprived of their own mtDNA. L – Liver; 
M- Muscle;  F – Fibroblasts. 
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MPV17 
The hepatocerebral forms of mtDNA depletion syndromes typically manifest soon after 
birth and with premature death in childhood (Suomalainen  et al., 2010). Presentation is 
usually with early liver failure, followed by development delay and muscle weakness 
during the first year of life, as well as lactic acidosis and hypoglycemia (El-Hattab and 
Scaglia 2013). These conditions are associated with mutations in at least five genes 
(Rötig et al., 2009) though further heterogeneity is expected. An ample array of MPV17 
mutations (Figure 19) has been described in about 30 patients from different ethnicities. 
 
 
 
 
 
Figure 19 - Described mutations in the MPV17 gene. ○Missense mutation; ●Nonsensemutation; ∆ Small 
deletion; ▲ Gross deletion; ◊ Small insertion; □ Splicing mutation; ■ c.186+2T>C. 
 
We identified a Brazilian infant (P15), the second child of apparently unrelated healthy 
parents, who presented neonatal hypoglycemia, digestive bleeding and sepsis in the first 
week of life was included in this study. Laboratory tests also showed elevated levels of 
total and free serum bilirubin and transaminases. Amino acids were normal whereas 
organic acids revealed the presence of lactic acid (3X normal values) and TCA cycle 
intermediates at age 2 months. Shortly after the patient manifested failure to thrive, severe 
hypotonia, nystagmus, poor echoarchitecture at liver ultrasound, and cirrhotic ascites. He 
died at 5-months with hepatic insufficiency associated with bleeding and multiple organ 
failure. The child had a severe mtDNA depletion (residual mtDNA levels were 2% in liver 
and 23% in muscle) and molecular studies detected a homozygous c.186+2T>C 
replacement in MPV17 (Figure 20), a variant already reported with poor prognosis in a 
singleton (El-Hattab et al., 2010). The c.186+2T>C was also detected in the proband’s 
elder sister (P15a) who had presented at birth with neonatal hypoglycemia, failure to 
thrive and hepatic insufficiency, later developed seizures and hypotonia, and died at 10 
months. The mutation was heterozygous in the parents who were from nearby villages in 
south Brazil. This study expands the ethnic 
background of MPV17-mutated patients and 
reinforces the lethal nature of the c.186+2T>C 
probably through skipping of critical protein domains.  
 
Figure 20 - Electropherogram of the MPV17 gene flanking the 
homozygous splice site mutation (c.186+2T>C). The mutated 
base identified in the patient (Pt) is underlined. Wild-type 
sequence in a control (Ct) is also shown. 
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DGUOK 
Deoxyguanosine kinase (dGK) deficiency  is a frequent cause of the hepatocerebral form 
of MDS, Approximately 100 individuals have been reported with this form which can 
present  as a multi-organ failure in neonates and as isolated hepatic disease later in 
infancy or childhood (El-Hattab and Scaglia 2013). More recently, DGUOK mutations have 
been reported in one patient with clinical and autopsy findings consistent with neonatal 
hemochromatosis and mtDNA depletion, and in individuals with adult-onset mitochondrial 
myopathy and mtDNA multiple deletions in skeletal muscle (El-Hattab and Scaglia 2013). 
Hepatic dysfunction is progressive in most individuals regardless of the presentation and 
is the most common cause of death.  
Neonatal hemochromatosis was suspected initially in one of the studied patients (P11). 
He was the third child of consanguineous parents, with a brother deceased (P11a) during 
neonatal period with the diagnosis of haemochromatosis. Since the first day of life, he 
presented with generalised hypotonia, feeding difficulties with poor suction reflexes and 
hypoglycaemia. Wide anterior fontanel, hypotelorism and macroglossia were noticed. At 
third day of life, acute liver failure emerged. Neonatal haemochromatosis was considered 
and he was transferred to a center hospital for liver transplantation. He had 
hyperlactacidemia, high lactate/pyruvate ratio, high ferritin level, elevated α-fetoprotein 
level and elevated tyrosine plasma concentration, with absence of succinylacetone in 
urine. After a period of stabilisation, cholestatic liver dysfunction with frequent 
hypoglycaemia episodes and neurologic dysfunction with rotary nystagmus manifested at 
3 months of age. A severe reduction of mtDNA content was expected to occur in liver 
biopsy (not available). We detected a DGUOK homozygous missense mutation (p.L250S; 
c.749T>C) already described by Villarroya and collaborators in 2009. The mutation, was 
identified in blood DNA from this patient (Figure 21). This mutation was also presented in 
his brother who had died earlier with a possible diagnosis of hemocromatosis. The index 
case was submitted to liver transplantation at 5 
months of age. Liver morphology showed 
cholestasis and cirrhosis. One year later, graft 
function was normal (with minimal 
immunosuppression), however nystagmus 
persisted and he has visual impairment, severe 
psychomotor retardation and failure to thrive.  
 
Figure 21 - Electropherogram of the DGUOK gene flanking the homozygous mutation p.L250S 
(c.749T>C). The mutated base identified in the patient (Pt) is underlined. Wild-type sequence in a control (Ct) 
is also shown. 
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SUCLA2 
Succinyl-CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible 
synthesis of succinate and ATP from succinyl-CoA and ADP in the TCA. This enzyme is 
made up of two subunits, α and β, encoded by SUCLG1 and SUCLA2, respectively.  
We identified a 17-month-old-boy (P27), the first child born to unrelated parents, who 
presented since birth severe muscular hypotonia and frequent vomiting. Growth 
retardation and developmental delay were noticed since the age of 3 months. Initial 
investigations disclosed a male karyotype with normal thyroid, renal and hepatic functions, 
as well as normal blood lactate levels. Plasma amino acids and urinary organic acid 
profiles showed unspecific abnormalities. A brain MRI disclosed slight cerebral atrophy 
and normal myelin pattern (Figure 22); a cardiac ultrasound was normal.  
 
 
Figure 22 - Brain MRI scan of the patient. Imaging disclosed mild cerebral atrophy and a slight 
hyopointensity of basal ganglia. Coronal (a), sagittal (b) and axial (c) scans are shown. 
 
 
The baby boy was referred to a Central Hospital at age 16.5 months because of a 
possible inherited disorder of metabolism. At that age, his physical examination was 
significant for developmental delay, failure-to-thrive, microcephaly, muscular atrophy with 
dystonic posturing, recurrent vomiting and high ammonia level (115 µM, normal: 25-44 µM) 
in blood. During hospitalization, metabolic workup revealed a compensated metabolic 
acidosis with persistently high serum lactate (2.2 to 9 mM, normal <1.3), and 
lactate/pyruvate ratio. There were also fluctuating hyperammonemia (up to 75 µM), high 
alanine, proline and glycine levels in plasmatic aminoacid profile, “mildly” elevated MMA 
and significantly high urinary levels of TCA cycle intermediates (methylcitrate, lactate, 
carnitine esters and 3-hydroxyisovaleric acid). Acylcarnitines profile showed an elevated 
succinylcarnitine. Brainstem auditory evoked potentials showed a pattern suggestive of 
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moderate sensorineural hearing loss. Based on laboratory findings, the patient was put on 
a protein restricted diet, with nasogastric tube feeding and vitamins and coenzyme 
supplementation. At the age of 18 months, the child manifested axial hypotonia (no head 
control), severe generalized dystonia, muscle wasting and constipation. All anthropometric 
parameters were below the 5th centile (weight 7.1 kg, height 76.8 cm, head circumference 
45.2 cm) in spite of adequate caloric intake. At age 24 months, his global developmental 
quotient (DQ) was below 50 (< 1 percentile), with a mental age of 6 months, using the 
Griffths scale (Griffiths, 1984). Brain MRI scans showed mild atrophy and abnormal 
signals in deep brain at that age. Since parents refused to grant permission for a 
diagnostic muscle biopsy, the child underwent a punch skin biopsy with written parental 
consent. 
Direct sequencing of SUCLA2 in this patient revealed a homozygous mutation, p.M329V 
(c.985A>G), in exon 8 (Figure 23A). The parents presented a cognitive impairment and 
were heterozygous carriers of the mutation. The missense change was novel and not 
detected in a large set of in-house ethnically-matched control chromosomes and in 
dbSNP (www.ncbi.nlm.nih.gov/projects/SNP/) and Exome Variant database 
(evs.gs.washington.edu/EVS/).  
The mutation seems predictably deleterious after assessments in silico with Polyphen2 
(genetics.bwh.harvard.edu/pph2/index.shtml), ClustalW (http://www.ebi.ac.uk/Tools/msa/ 
clustalw2/) and SIFT (sift.jcvi.org/), and affects an amino acid that is highly conserved in 
different species through evolution (Figure 23B; 23C; 23D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 - Molecular analyses of a patient harboring a novel mutation in SUCLA2. A) 
Electropherograms of the SUCLA2 gene flanking the homozygous p.M329V (c.985A>G) in the index case (Pt). 
The wild-type sequence in a control (Ct) is also shown. The mutated base is underlined;  B) PolyPhen-2 
prediction of functional effects of human variations; C) ClustalW aligments; D) Sift predictions. 
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A moderate reduction of mtDNA copy number (residual mtDNA levels were 69% of normal 
age matched controls) was observed in cultured skin fibroblasts after replacing galactose 
for glucose in the cell medium. Western blotting showed a ∼30% decrease of SUCLA2 
protein in patient’s fibroblasts (Figure 24) with normally expressed components of the 
MRC complexes.  
 
Figure 24 - Representative 
immunoblot analysis in fibroblasts 
homogenates from a control (Ct) 
and patient (Pt). Specific antibodies 
against SUCLA2 and subunits of 
complex III (Core 2) and complex I 
(ND39) were used. VDAC/porin was 
used to control for equal loading. The 
histogram shows the residual activity 
in the patient as compared to controls 
(n= 5). Data represents the mean ± 
SD of three different determinations. 
 
 
 
Total and mitochondrial ATP production in skin fibroblasts were 22% and 50% (p<0.03), 
respectively when compared to normal control values (Figure 25A). We also observed a 
statistically significant increase of ROS production in basal condition and after short-term 
H2O2 treatment (Figure 25B, p<0.05). ROS production was then restored to basal levels 
upon treatment with 0.5 mM AICAR, a compound known to enhance cellular oxidative 
metabolism (Golubitzky et al., 2011). Bezabibrate and riboflavin were also tested, 
however no improvements were observed (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 25 - Biochemical analyses in cells harboring the new c.985A>G/p.M329V in SUCLA2. A) 
Luminometric measurement of ATP expressed as relative luminescence units (RLU), in skin fibroblasts from 
controls (Ct) and patient (Pt) cultured in regular medium (RM) for 48 h. Cells were incubated 2 h in ATP record 
buffer supplemented with 10mM glucose (Glu), 2.5 µg/ml oligomycin (Oligo) and 5 mM 2-deoxy-Dglucose plus 
5 mM pyruvate (2GD+Pyr). Data represents the mean ± SD of three different determinations. B) Reactive 
oxygen species (ROS) production measured by CM-H2DCFDA and expressed as % of relative fluorescent 
units (RFU) in skin fibroblasts from controls (Ct) and the patient (Pt). Cells were cultured in medium 
supplemented with galactose (GAL) or  Gal+AICAR 0.5mM, and incubated with or without 0.5mM H2O2 for 30 
min. Data are mean ± SD of three different determinations. Significance (*) was set at p<0.05. 
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C10orf2 
Although the spectrum of diseases attributable to C10orf2 gene defects involves different 
clinical presentations, including infantile-onset spinocerebellar ataxia (IOSCA), adPEO 
and hepatocerebral MDS, the signs in IOSCA demonstrate a fairly distinct pattern. Among 
these, peripheral neuropathy seems to be the most common presenting feature in C10orf2 
defects, especially in infantile onset spinocerebellar ataxia and hepatocerebral syndrome 
but rarely seen in adPEO forms (Dundar et al., 2012).  
Detailed clinical and laboratory evaluations in one of the studied patients (P32), born to 
unrelated healthy parents, showed hypotonia and Pierre-Robin sequence (OMIM 
#311895) with mandibular retrognathism, partial syndactyly of 2nd-3rd fingers, bilateral 
strabismus, and eyelid asymmetry. The child manifested severe intellectual and 
developmental disability and nystagmus in the following months. Brain MRI revealed brain 
atrophy and a thin corpus callosum (Figure 26).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 - Brain MRI (coronal and axial images). There was decreased intensity in the posterior 
periventricular white matter and a thinner corpus callosum. No pathological signal changes were seen in the 
striatum, brainstem and dentate nuclei. F-frontal; P-posterior. 
 
 
Serum lactate levels were increased, OXPHOS activities in a skeletal muscle biopsy were 
in the low normal range and there was a severe mtDNA depletion in muscle (residual 
mtDNA levels were 20% of normal age matched controls). 
In the patient we identified two “in cis” homozygous splice site mutations in C10orf2 
([c.1593-3T>C + c.1593-5C>T]; Figure 27) predicted in silico to activate a new cryptic 
acceptor site and lead to missplicing. The novel mutations were observed in 
heterozygosity in the mother and in the healthy brother whereas the father was a non-
carrier.  
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Figure 27 - Electropherograms of the C10orf2 gene flanking the homozygous splice site mutations 
([c.1593-3T>C + c.1593-5C>T]. The mutated bases identified in the patient (Pt) are underlined. Wild-type 
sequence in a control (Ct) is also shown. 
 
 
Once we had ruled out false paternity and a multi-exon deletion on the paternal allele by 
MLPA (Figure 28), we genotyped three microsatellite markers and 12 SNPs flanking 
C10orf2 on chromosome 10q24. Whilst a number of markers were uninformative, SNP 
genotyping was also consistent with segmental uniparental dissomy (UPD) of the 
maternal chromosome 10 (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 - MLPA analyses of C10orf2 gene (SALSA MLPA probemix P010-A2 POLG (both from MRC-
Holland). Coffalyser Sample Plate Generator (S.P.G.) was used to automatically create sample plate files for 
MLPA analysis. A) Patient 32; B) Normal control. 
A B 
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Figure 29 - Segregation analysis of polymorphic microsatellite markers and single nucleotide 
polymorphisms flanking the C10orf2 gene suggested maternal UDP. Family tree: square, men; circle, 
women; filled symbol is the affected patient (arrow). M, C10orf2 mutated sequences; Wt, wild-type sequence. 
 
 
 
A similar condition has already been reported for TYMP and DGUOK (Douglas et al., 
2011; Haudry et al., 2012) two other genes associated with relatively common forms of 
MDS. 
Description of UDP in a patient presenting mutations in TWINKLE corroborates the need 
of a full molecular examination of apparently homozygous changes in MDS to define more 
precisely the risk of recurrence in subsequent pregnancies. 
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POLG 
Diseases resulting from mutations in POLG are associated with an extremely 
heterogeneous spectrum of clinical presentations, ranging from adPEO and arPEO forms, 
to SCAE and AHS. Severe heterozygous mutations of POLG, often affecting the spacer 
(DNA-binding) and the catalytic polymerase domains of the enzyme, cause mtDNA 
depletion, and manifest in infancy or early childhood with severe liver and brain disease.  
We identified four patients with POLG mutations: 
P9, a boy with a mild global developmental delay at age 9 months, developed muscular 
hypotonia was noticed at age 15 months before the sudden onset of status epilepticus. In 
the 2 weeks prior to the admission he had had evidence of an eye deviation and he had 
been admitted to hospital a week before with a “viral” infection, when he had appeared 
floppy and had been vomiting. CSF oligoclonal bands and other routine tests were normal 
on that admission. The first seizure at the age of 18 months was followed by persistent 
seizures after which he remained markedly encephalopathic, having multiple seizures that 
were refractory to all antiepileptic drugs including sodium valproate. The preliminary brain 
MRI was normal, but then basal ganglia changes and some atrophy were found. A further 
scan 3 months later showed a new lesion in the right parietal cortex. Brain MRI 
spectroscopy showed an increased choline peak in the right frontal cortex and increased 
lactate peak in the posterior fossa. The patient then developed mildly abnormal liver 
function suggesting AHS but assessment of OXPHOS complex activities was not possible 
in a liver biopsy. Subsequent EEG recordings revealed a very disordered background with 
epileptiformic discharges. The patient died due to intractable epilepsy and liver failure at 
age 2 years. The parents refused a post mortem examination. Determination of 
mtDNA/nDNA ratio in liver DNA showed a profound reduction  of mtDNA copy number 
(residual mtDNA levels were 5% of normal control levels). Analysis of the POLG gene 
sequences in blood DNA detected the p.R309H (c.926G>A) mutation in compound 
heterozygosity with the p.A889T (c.2665G>A) change (Figure 30). 
 
 
 
 
 
 
 
 
Figure 30 - Electropherograms of the POLG gene flanking the heterozygous mutations: A) p.R309H 
(c.926G>A) and B) p.A889T (c.2665G>A). The mutated bases identified in the patient (Pt) are underlined. 
Wild-type sequence in a control (Ct) is also shown. 
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P18, a 13-year-old boy, presented with myoclonic epilepsy, headache and bilateral high 
signal lesions of the occipital horns of the ventricles. Liver failure after treatment with 
valproate was documented, and he underwent liver transplantation. Multi-organ 
involvement and progressive course of the disease later manifested. The patient harbored 
a described homozygous p.A467T (c.1399G>A) mutation in POLG (Van Goethem et al., 
2001) (Figure 31). The mutation found in this patient represents the most common in the 
POLG gene, usually found in AHS disease with valproate induced hepatic failure. No 
mtDNA depletion or multiple deletions was found in muscle and liver in this patient. The 
parents of the index patient are both carriers of the same mutation confirming the 
Mendelian inheritance. 
 
 
 
 
Figure 31 - Electropherogram of the POLG gene 
flanking the homozygous mutation p.A467T 
(c.1399G>A). The mutated base identified in the 
patient (Pt) is underlined. Wild-type sequence in a 
control (Ct) is also shown. 
 
 
 
 
 
 
P35, a 4-year-old daughter of non consanguineous parents, presenting feeding difficulties, 
ventricular hypertrophy, retine alterations, low weight increasing and loss of 
consciousness. Low mtDNA levels were found in this patient (residual mtDNA levels were 
15% of normal controls levels in muscle) and the molecular analysis of POLG gene 
revealed a reported mutation p.G268A (c.803G>C) in heterozigozity (Figure 32). No 
additional mutations, gross deletions or insertions were found by MLPA analysis, in the 
other allele of this patient. Thus other MDS genes are being investigated. 
 
 
 
 
Figure 32 - Electropherogram of the POLG gene 
flanking the heterozygous mutation p.G268A 
(c.803G>C). The mutated base identified in the 
patient (Pt) is underlined. Wild-type sequence in a 
control (Ct) is also shown. 
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P42 is the youngest daughter born from healthy consanguineous parents (Figure 33A). 
Her older siblings (two sisters and one brother) are normal. The patient presented at age 
4 months with psychomotor delay, hypotonia which evolved to spasticity, neurosensorial 
deafness and epilepsy. Urinary organic acids (GC/MS) showed the presence of 3-
methylglutaric, 3-methylglutaconic, 3-hydroxysebacic, malic and fumaric acids and 3-
hydroxyadipic acid lactone. There were increased levels of serum and CSF lactate and 
pyruvate whereas acylcarnitines were in the normal range. At age 5 months, 
spectrophotometric determination of MRC enzymes in a muscle biopsy showed a reduced 
activity of complex I (37% reduction as compared to the average value of age-matched 
controls). Histological studies showed predominance of type I fibers. The child died at age 
10 months of cardiorespiratory arrest. Low mtDNA levels were found in this patient 
(residual mtDNA levels were 25% of normal age matched controls in muscle) and two 
reported mutations in POLG gene: p.G848S (c.2542G>A) in compound heterozygosity 
with the p.Q1236H (c.3708G>T), were found in the patient (Figure 33B and 33C), but not 
in her relatives P42a and P42b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 – A) Pedigree of P42 family; Electropherograms of the POLG gene flanking the heterozygous 
mutations: A) p.G848S (c.2542G>A) and B) p.Q1236H (c.3708G>T). The mutated bases identified in the 
patient (Pt) are underlined. Wild-type sequence in a control (Ct) is also shown. 
 
P42 
P42a P42b 
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P42a is the first son born to the eldest sister of case P42. The baby boy born from a 
consanguineous marriage and presented since the neonatal period with hypotonia, 
nystagmus and feeding difficulties. Urine organic acids showed the presence of 3-
methylglutaconic acid. There was increased lactate in blood and in the CSF. At the age of 
2 months, the patient presented with drug resistant seizures and died shortly after 
because of a cardiac failure, and therefore a muscle biopsy was not performed. 
Consequently mtDNA copy number was not performed, however the molecular study of 
POLG gene was performed in the DNA extracted from blood, but none of the mutations 
identified in his aunt were present. His younger sister, P42b, niece of P42, with 5-month-
old, had since age 1 month a similar clinical picture, as well as a similar pattern of urinary 
3-methylglutaconic acid production. OXPHOS studies in a muscle biopsy showed a 
reduced activity of complex I (38% reduction as compared to the average value of age-
matched controls) and a severe mtDNA depletion was also found in muscle (residual 
mtDNA levels were 18% of normal age matched controls), although no mutations in POLG 
gene were identified. 
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TAZ 
BTHS is an X-linked infantile-onset cardioskeletal disease caused by mutations in the TAZ 
gene. The majority of reported mutations are small insertions or deletions as well as 
missense mutations, although large deletions and truncating mutations have also been 
reported. 
In this study we identified a patient (P38) who presented some of the reported clinical 
features associated with BS, such as: cardiomyopathy, skeletal myopathy, growth delay, 
neutropenia, with no urinary excretion of 3-methylglutaconic acid (3-MGCA), which must 
not be considered mandatory for a definitive diagnosis of  BS.  The patient also presented  
lactic acidosis since birth. MtDNA content was severely reduced in muscle tissue (residual 
mtDNA levels were 30% of normal age matched controls). Molecular analysis of the TAZ 
gene  confirmed the clinical diagnosis by revealing a new missense mutation in 
hemizygosity: p.H176R (c.527A>G). This aminoacid substitution had not been found in 
200 healthy control alleles. ClustalW analysis revealed a high degree of evolutionary 
conservation of histidine at residue 176 (His176) in the tafazzin protein (Figure 34). 
PolyPhen predicted that the mutation is probably damaging. This prediction was 
confirmed by ClustalW and SIFT analyses.  
 
 
 
 
 
 
Figure 34 - Molecular analyses of a patient harboring a novel mutation in TAZ. A) Electropherograms of 
the TAZ gene flanking the heterozygous p.H176R (c.527A>G). The mutated base identified in the patient (Pt) 
is underlined. The wild-type sequence in a control (Ct) is also shown. B) ClustalW aligments; C) Sift 
predictions; D) PolyPhen-2 prediction of functional effects of human variations. 
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4.2. “Secondary” mtDNA depletion 
We detected a mild-to-moderate mtDNA depletion in 11 individuals with neurometabolic 
diseases that secondarily impact on OXPHOS production or mtDNA levels. Few of those 
are worth reporting for their clinical importance, including four individuals in a family where 
we identified a clinical phenotype consistent with severe olivo-ponto-cerebellar atrophy, 
late-onset ataxia and psychosis together with a low complex III activity in muscle and a 
novel mutation in TTC19, and one patient with a deficiency in the mitochondrial arginyl-
tRNA synthetase, caused by a mutation in RARS2. 
 
 
TTC19 
Autosomal recessive cerebellar ataxias are inherited disorders typically manifesting within 
the second decade of life, although metabolic forms of the disease might present at 
younger age. Atrophy of the cerebellum and brainstem are often prominent features, but 
other structures can be affected as well, leading to a broad range of clinical phenotypes. 
CIII catalyzes the transfer of electrons from reduced coenzyme Q to cytochrome c. One of 
the 11 subunits, cytochrome b, is mtDNA-encoded. Mutations in the MT-CYB and BCS1L 
genes account for the vast majority of patients with CIII deficiency detected in skeletal 
muscle. It has recently been suggested that mutations in the human tetratricopeptide 19 
gene (TTC19) may also be involved in the etiology of CIII deficiency, probably through 
impaired assembly of the holocomplex.  
Four siblings in a consanguineous Portuguese family with CIII deficiency were 
investigated. Sequence analysis of genomic DNA was carried out to identify disease-
causing mutations. Studies in muscle homogenate and skin fibroblasts from patients were 
also performed to investigate the functional consequences of the mutation on oxidative 
metabolism. 
The propositus, P33 (II-01), (Figure 35A), was a 49-year-old man who had no clinically 
relevant complaints until the age of 27 years, when he manifested progressive back pain, 
clumsiness, gait difficulties, and a generalized anxiety disorder. Over the following years, 
additional psychiatric manifestations appeared, including major depression and visual 
hallucinations which did not respond to antipsychotic drugs. Neurological examination at 
age 37 revealed difficulties in tandem gait, loss of balance while climbing stairs, 
segmental ataxia, observable as dysmetria in the nose-finger and heel-shin tests, and 
interruptions in fast alternating hand movements. Dysarthric speech, dysphagia, and slow 
saccades were also detected. Subsequently, the patient displayed moderate spastic 
paraparesis with pyramidal tract signs affecting both the upper and the lower limbs. By the 
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age of 42, he presented severe muscle atrophy and, unable to walk or stand, was 
bedridden. His psychosis had worsened as a result of the onset of visual and acoustic 
hallucinations. He died of respiratory insufficiency aged 49 years.  
Three additional sibs P33a (II-04), P33b (II-05), and P33c (II-06) showed an ataxic 
syndrome and psychiatric manifestations. The parents and two additional siblings (in their 
50s), who were all asymptomatic, had no major neuropsychiatric complaints and a normal 
examination.  
Brain imaging in all the patients at different ages showed a pattern of olivo-ponto-
cerebellar atrophy (Figure 35B) and abnormal hypersignal in the caudate, putamen, 
medullary olives, cerebellar dentate nucleus and medial midbrain on T2-weighted MRI 
scans. Cortical brain atrophy (especially in the frontal lobe) appeared at a later age in 
patients P33 and P33a. No white matter changes or structural brain lesions were 
observed. Routine histochemical stains for oxidative metabolism in muscle biopsies were 
unremarkable in the four patients, whereas measurement of RC enzymes revealed a 
marked reduction of CIII activity in all of them (on average, residual activity corresponded 
to 33% of that recorded in age-matched normal controls). 
A novel c.963_966delTGGC mutation in TTC19 was identified (Figure 35C) in the 
propositus. This mutation predicts a frameshift and the synthesis of a truncated protein 
(p.A321Afs*8), lacking about 35% of its carboxy terminus. The new mutation was found to 
be homozygous in the four patients, heterozygous in their parents and in unaffected sibs, 
and absent in 300 ethnically-matched controls. The c.963_966delTGGC was expressed in 
tissues from patients P33 and P33c and the amount of mRNA/TTC19 transcript appeared 
to be semi-quantitatively reduced in muscle from case P33c (data not shown). Using 
BNGE followed by 2D-SDS and anti-Core2 antibody, there were nearly absent spots for 
CIII and CIII2+IV super-complexes in muscle from patient P33c compared to control 
muscle (Figure 35D), suggesting early impairment of assembly of CIII, as already outlined 
elsewhere (DiMauro et al., 2005). By Western blotting, we found no protein using a 
specific anti-TTC19 antibody in muscle and fibroblasts from patients P33 and P33c 
(Figure 35E). We also observed a statistically significant increase (p<0.03) of ROS 
production in basal condition and after short-term H2O2 treatment (Figure 35F). Neither 
cellular ATP level nor ROS production were influenced by treatment with AICAR or 
bezafibrate, drugs known to enhance cellular oxidative metabolism.  
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Figure 35 - Family pedigree, brain MRI and molecular studies in the new Portuguese kindred harboring 
a mutation in TTC19. A) Family tree. Square, men; circle, woman; filled symbols are affected individuals. 
Slash indicates deceased subjects. B) Brain MRI in three different affected patients (II-04, II-05, II-06) in this 
family. Arrows indicate pontine atrophy. C) Electropherograms of the TTC19 gene flanking the homozygous 
c.962_967delTGGC (p.A321Afs*8) variant identified in patient II-06. Wild-type sequence in a control (Ct) is 
also shown. The deleted bases are underlined. D) BNGE followed by 2D-SDS-PAGE in muscle homogenates 
from patient II-06 and a control (Ctrl) using antibodies against the Core2 subunit to detect complex III and 
subunit I of cytochrome c oxidase (CO I) for complex IV. E) A representative immunoblot analysis of muscle 
homogenates from control (Ctrl) and patient II-06 using specific antibodies against subunits of complex II 
(SDHA), complex III (Core2), and TTC19. VDAC/porin was used to control for equal loading. Similar results 
were seen in cultured skin fibroblasts. F) Reactive oxygen species (ROS) production measured by CM-
H2DCFDA and expressed as relative fluorescent units (RFU) in skin fibroblasts from control (Ctrl) and patient 
II-06 incubated with or without with 1mM H2O2 for 30 min. Data are mean ± SD of three different 
determinations. Significance was set at p<0.05. 
B 
P33 P33a P33b P33c 
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Interestingly, we also observed a moderate reduction of mtDNA copy number in muscle 
from P33c (residual mtDNA levels were, on average, 45% those of controls) (Figure 36A). 
The immunodetection pattern of the RC complexes was within normal values in skin 
fibroblasts (Figure 36B). A less profound defect for CIII and CIII2+IV super-complexes 
was seen in skin fibroblasts, by BNGE followed by 2D-SDS and anti-Core2 antibody 
(Figure 36C). ATP production was not reduced in either glucose or galactose medium in 
the patient cells (Figure 36D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36 - Cellular and molecular analyses in a patient harboring a novel mutation in TTC19. A) Bar 
chart showing the relative quantification of mtDNA content by qPCR using the 2-∆∆Ct method. The error bar in 
controls (Ctrl) indicates three times the standard deviation. Data represents the mean ± SD of three different 
determinations; rho0 are cells experimentally deprived of their own mtDNA. B) Bar chart showing the relative 
quantification of immunoblot analysis of skin fibroblasts from patient II-06 using specific antibodies against 
subunits of complex I (NDUFA9), complex II (α-SDHA), complex III (Core2), complex IV (COX II). Values are 
reported as the ratio to the internal control for loading (porin), and are expressed in reference to the average 
control value whose expression was arbitrarily attributed the value 1.0. Data are mean ± SD of three different 
determinations. C) BNGE followed by 2D-SDS-PAGE in patient II-06 and control (Ctrl) fibroblasts using 
antibody against the Core2 subunit to detect complex III (and supercomplexes III2+IV), and an antibody 
against the subunit NDUFS3 of complex I. D) Luminometric measurement of ATP expressed as relative 
luminescence units (RLU), in skin fibroblasts from control (Ctrl) and patient II-06 cultured in either regular 
medium (RM) or medium supplemented for 72 h with galactose (GAL). Data represents the mean ± SD of 
three different determinations. 
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RARS 
To guarantee fidelity in translation, it is important to attach the right amino acid to the 
tRNA, and to ensure that the tRNA recognizes, through its anticodon, the correct codon in 
the ribosomal A-site. Incorporation of an incorrect amino acid into the nascent polypeptide 
could cause misfolding and production of defective or dominant interfering proteins. Amino 
acids are attached to tRNAs by amino-acyl-tRNA synthetases, each of which is specific 
for a single amino acid. However, as there can be several codons and several different 
tRNAs for a single amino acid, an amino-acyl-tRNA synthetase can “charge” several 
different tRNAs. If this function were defective, certain codons would become ambiguous, 
resulting in the synthesis of misfolded proteins, which could aggregate to form inclusions 
and induce further protein misfolding. Misfolding and protein aggregation are thought to 
underlie several neurodegenerative disorders. This holds true for both cytoplasmic and 
mitochondrial protein synsthesis. In particular, mutations in RARS2 are associated with 
severe encephalopathy with pontocerebellar hypoplasia.  
 
In this study we identified a 4-year-old boy (P20) who presented early-onset, rapidly 
progressive cerebral and ponto-cerebellar atrophy with intractable epilepsy. Lactate was 
markedly elevated in blood and urine (three-fold normal values) but not in the CSF. At age 
4 months, brain MRI showed marked cerebellar hypoplasia and atrophy and MR-S 
revealed an elevated lactate peak. At 1 year, head circumference dropped below the 3rd 
percentile. Lactic acidosis was no longer consistently detected in blood and urine. The 
patient continues to suffer from intractable multifocal seizures without improvement. Serial 
MRI scans performed at the ages of 12 months, and 2 years confirmed the progression to 
severe cortical and ponto-cerebellar atrophy (Figure 37).  
 
 
 
 
 
 
 
 
 
Figure 37 - Brain MRI (Sagittal T1 weighted serial images). These images were performed in P20 at age 4 
months (A), 1-year (B) and 2-years (C) showing atrophy of the cerebrum, cerebellum and brainstem. 
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From these findings the disease appears to affect selectively the brain with first symptoms 
appearing in the neonatal period and manifesting with severe hypotonia, intractable 
seizures, and lactic acidosis. The EEG pattern consisted of diffuse slowing and bilateral, 
multifocal epileptiform abnormalities at onset with progressive deterioration. After the first 
year of life, the child showed very frequent myoclonic jerks in upper limbs.  
Molecular investigations of RARS2 disclosed in compound heterozygousity the p.Q12R/ 
p.W241R (c.35A>G/ c.721T>A) mutations (Rankin et al., 2010; Namavar et al., 2011). It 
has already been demonstrated that p.Q12R interferes with a splicing-enhancer element, 
producing abnormal splicing with retention of 221-bp of intron 1, resulting in frameshift 
with an expected protein truncation at residue 25 (p.Q12fsX25). The p.W241R mutation is 
predicted to be probably damaging upon SIFT, Polyphen2, and PMut 
(http://mmb.pcb.ub.es/PMut/PMut.jsp) analyses. None of the mutations identified in this 
study were detected in 200 healthy, ethnically-matched control chromosomes by 
sequencing (Cassandrini et al., 2013). 
Western blotting in skin fibroblasts showed that the level of the protein was reduced to 28 
%, of the control mean value after normalization to the immunodetection of VDAC/porin 
(Figure 38A). A moderate reduction of mtDNA copy number was also observed in cultured 
skin fibroblasts from the patient (residual mtDNA levels were, on average, 43% those of 
controls) (Figure 38B) .  
 
 
 
 
 
 
 
 
Figure 38 - Cellular and molecular analyses in P20, harboring a novel mutation in RARS2. A) A 
representative immunoblot analysis of fibroblasts homogenates from control (Ct) and P20 using specific 
antibodies against RARS2. VDAC/porin was used to control for equal loading. B) Bar chart showing the 
relative quantification of mtDNA content by qPCR using the 2-∆∆Ct method. The error bar in controls (Ct) 
indicates three times the standard deviation. Data represents the mean ± SD of three different determinations; 
rho0 are cells experimentally deprived of their own mtDNA. 
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4.3. Multiple deletions 
One of the patients analyzed in this study, whose clinical syndrome satisfied the criteria 
for MNGIE in association with weight loss and progressive gastrointestinal dysmotility, 
presented multiple mtDNA deletions together with a mutation in TYMP. 
 
 
TYMP 
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare, autosomal 
recessive, multisystem and devastating disease that usually manifests in childhood and 
leads to death around age 35 years. MNGIE is caused by mutations in the TYMP gene 
encoding thymidine phosphorylase (TP). Loss of TP activity determines marked elevation 
in thymidine and deoxyuridine levels in body fluids, nucleotide pool imbalance, 
subsequent instability of mtDNA and impairment of the mitochondrial MRC. Among the 
important consequences of MNGIE syndrome, multiple deletions and/or depletion of 
mtDNA have been observed. 
We studied a 50-year-old patient (P36) who had complained of intermittent postprandial 
vomiting and gastrointestinal dysmotility with episodes of diarrhea and constipation 
leading to progressive weight loss over few years. Neurological examination showed 
severe cachexia and numbness distally in the four limbs, mild generalized weakness and 
diffuse muscle atrophy. Multiple mtDNA deletions were also detected by qPCR.  
Molecular analysis of the TYMP gene in muscle DNA from P36 revealed the p.S160P 
(c.478T>C) mutation in compound heterozygosity with the p.A465T (c.1393G>A) mutation, 
both already described in the literature (Nishino et al., 2000; Kocaefe et al., 2003) (Figure 
39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39 - Electropherograms of the TYMP gene flanking the heterozygous mutations: A) p.S160P 
(c.478T>C) and B) p.A465T (c.1393G>A). The mutated bases identified in the patient (Pt) are underlined. 
Wild-type sequence in a control (Ct) is also shown. 
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Additionally a novel variant p.M74K (c.221T>A), presented in heterozygosity, was also 
identified in this patient (Figure 40A). This variant has not been found in 200 healthy 
control alleles. ClustalW analysis revealed a high degree of evolutionary conservation of 
metionine at residue 74 in the TP protein (Figure 40B). Bioinformatic analysis using Sift 
and Polyphen2 showed that the mutated aminoacid is not tolerated and that the mutation 
is probably damaging. (Figure 40C, 40D). 
 
 
 
Figure 40 - Molecular analyses of a patient harboring a novel mutation in TYMP. A) Electropherograms 
of the TYMP gene flanking the heterozygous p.M74K (c.221T>A). The mutated base identified in the patient 
(Pt) is underlined. The wild-type sequence in a control (Ct) is also shown. B) ClustalW aligments; C)Sift 
predictions; D) PolyPhen-2 prediction of functional effects of human variations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER V 
 
DISCUSSION
  
 
 
Chapter V  Discussion 
103 
 
DISCUSSION 
 
A mitochondrial disease manifesting at birth or soon after is more likely to be associated 
with nDNA than with mtDNA mutations, but until very recently, our lack of knowledge 
regarding the mechanisms underlying mitochondrial gene transcription and translation and 
the complex interaction between the ‘‘two genomes’’ has limited the diagnostic power. 
mtDNA deletion and depletion syndromes, and disturbances in the mitochondrial 
translation machinery have increasingly emerged as a major cause of a wide spectrum of 
infantile and childhood-onset multisystem disorders. Depletion syndromes could result 
from any imbalance of the mitochondrial dNTP pools available for mtDNA replication, as 
well as abnormalities in either the mitochondrial helicase or DNA polymerase. Consistent 
with the different phenotypes, mtDNA depletion may affect specific tissue (most 
commonly, the brain and muscle or liver) or multiple organs, including heart and kidney. 
More than 75% of these patients had onset during the first year of life, and the disease 
was rapidly fatal in most cases (Hirano et al., 2001, Sarzi et al., 2007). Moreover, though 
the components of the complicated mitochondrial protein-synthesis machinery are 
exclusively nuclear encoded, the majority of mutation affects correct translation of mtDNA 
encoded subunits of the OXPHOS and arises from a still undetermined number of genetic 
defects. Indeed, there is still limited information on the many mitoribosomal proteins; the 
several tRNA maturation enzymes; the aminoacyl-tRNA synthetases; the translation 
initiation, elongation, and termination factors; and the predictably larger number of 
unidentified factors needed for ribosome assembly (Jacobs et al., 2005, Smits et al., 
2010). 
Expansion in the number of proteins regulating mitochondrial diseases and associated 
genes are going hand in hand with an increasing genetic and clinical phenotypic 
heterogeneity of this group of disorders. Identifying the causative genes is important not 
only to allow adequate antenatal options, family planning and prenatal diagnosis, but also 
to improve understanding of the disease pathophysiology and, therefore to envisage the 
therapeutic options. The elevated number of genes found to be involved is a driving force 
for the development of high throughput strategies. The recent advances in sequencing 
technology will facilitate the molecular investigations of genes associated with mtDNA 
disorders in general. Reports concerning the use of next generation sequencing (NGS) for 
the diagnosis of mitochondrial disorders are already emerging (Vasta et al., 2009; Calvo 
et al., 2012; Haack et al., 2012). A recent one proved the efficacy, in clinical diagnosis, of 
the use of target NGS for mitochondrial disorders; indeed, a clear molecular etiology was 
found in 55% of the patients studied by some groups (Calvo et al., 2012). Since NGS is 
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becoming a common option in neurogenetic disorders (Shendure et al., 2012), it holds the 
promise to identify a greater number of patients with mitochondrial disorders as well 
(Dündar et al., 2012). This would likely resolve some of the open issues emerging from 
the clinic, including difficult diagnosis, uncertain or unavailable genetic counseling and 
prenatal diagnoses, and unpredictable prognoses. 
 
 
In this work, 47 of 90 cases, suspicious of disorders associated with mtDNA depletion or 
multiple deletions, as well as with biochemical and suggestive clinical features, were 
eligible for this study. In 55% of patients (26/47) we identified mtDNA depletion or multiple 
deletions; 65% of these patients presented “primary” mtDNA depletion, 31% “secondary” 
depletion and 4% mtDNA multiple deletions. The remaining 45% of the patients (21/47) 
were considered eligible for this study based on their suggestive clinical features (Figure 
41). 
 
 
            
            
 
 
~ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41 - Schematic representation of the group of patients investigated in this study.  
 
 
A positive molecular result was obtained in 25% of total eligible patients (12/47): 10 were 
part of the group with mtDNA depletion or multiple deletions (N=26), and only two were 
from the other group of patients (N=21). Most of the patients in this study (35/47) 
remained with an undetermined molecular diagnosis.  
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Identification of a positive molecular etiology varied between groups with mutations found 
in “primary” mtDNA depletion (75%), “secondary” mtDNA depletion (17%) and mtDNA 
multiple deletions (8%) (Figure 42). We also considered two patients from the group of 
MDS suggestive clinical phenotype (N=21) as presenting “primary” mtDNA depletion, due 
to their typical clinical phenotype associated with mutations in DGUOK  and POLG genes 
(Villarroya et al., 2009; Van Goethem et al., 2001). One of these patients, P18, was tested 
for mtDNA depletion and multiple deletions, however did not present any of these 
alterations, in the studied tissues.   
 
 
 
 
 
 
 
 
 
        Figure 42 - Schematic representation of the positive molecular patients.  
 
 
The spectrum of identified mutations found in patients with “primary” mtDNA depletion 
encompasses the following genes: MPV17 (P15), DGUOK (P11), SUCLA2 (P27), C10orf2 
(P32), POLG (P42, P9, P35, P18), and TAZ (P38), while those with “secondary” mtDNA 
depletion include: TTC19 (P33) and RARS2 (P20). Finally, we identified a mutation in 
TYMP in a patient with mtDNA multiple deletions (P35).  
 
 
The group of “primary” mtDNA depletion showed a high positive molecular rate (75%) in 
the most common genes associated with MDS, with the exception of P38 harboring a 
mutation in TAZ gene. The positive cases will be further discussed below. 
 
 
MPV17 
To date a total of 31 patients have been reported with MPV17 mutations, and here we 
describe a new Brazilian patient with fatal hepatocerebral presentation of MDS. MtDNA 
depletion was confirmed by comparing patient’s mtDNA copy number with tissue and age 
matched controls, being 98% and 77% in patient’s liver and muscle, respectively. 
75% 
8% 
17% 
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Molecular studies identified a homozygous c.186+2T>C mutation in MPV17 gene, only 
been described in one previous case in the heterozygous state with a “little” better 
prognosis (El-Hattab et al., 2010). This mutation is located at the invariant splice donor 
site and is predicted to abolish the splicing donor site of exon 3 
(http://www.cbs.dtu.dk/services/NetGene2/ and http://www.fruitfly.org/seq_tools/other. 
html). Although the parents were non-consanguineous, they were from the same Brazilian 
region and the presence of a homozygous mutation suggests that the parents shared a 
common ancestor or that this recessive mutation has high population prevalence in the 
Brazilian population. 
In this study, we identified for the first time a Brazilian (P15) with a MPV17 splicing 
mutation in a homozygous state. Our study contributed to expand the spectrum of patients 
with MPV17 mutations, and will be important for an accurate genetic counseling and a 
prenatal diagnosis to the affected family. 
 
 
DGUOK  
In one case (P11) with suspected hemochromatosis we found a homozygous mutation in 
DGUOK. In principle, an excess of free iron ions may have deleterious toxic influence on 
the liver and subsequent organ damage (Visapää et al. 2002; Ramm and Ruddell 2005).  
An impaired function of the mitochondria associated with dGK deficiency may still 
aggravate the process. Decreased hepatic ATP content and reduced activity of the 
cytochrome c oxidase was observed in an experimental model of iron overload (Bacon et 
al., 1993). In one report describing a child with iron storage disease, a severe depletion of 
mtDNA (9% of the normal value) was identified (Vu et al., 2001). 
A better understanding of the primary or secondary factors influencing liver damage in 
MDS (including hypoglycemia and iron overload) may contribute to the improvement of 
the short- and long-term prognosis in children with the hepatic form of this mitochondrial 
disorder. 
 
 
SUCLA2 
We reported a new case (P27) of “mild” MMA with mutations in SUCLA2. The clinical and 
biochemical phenotype of our patient is strikingly similar to patients harboring mutations in 
SUCLA2 previously reported in larger series (Carrozzo et al., 2007). The mild elevation of 
the urinary levels of methylmalonate and succinylcarnitine raised the suspicion of a 
succinyl-CoA synthetase disease, which was confirmed by the identification of a novel 
Chapter V  Discussion 
107 
 
mutation and the presence of mtDNA depletion, although not in high percentage in the 
fibroblasts, as expected in the muscle tissue. 
Thus, our study shows the first SCS deficiency in the Portuguese population. The novel 
mutation meets several canonical criteria for pathogenicity. An additional interesting 
observation arising from our study relies on the reduction on ROS production upon AICAR 
treatment in cells from a SUCLA2 patient. AICAR has already been found to improve 
growth and ATP content while decreasing ROS production in patients presenting 
mutations in subunits of the respiratory complexes I and IV (Golubitzky et al., 2011) and is 
reported to fight the pathological mechanisms in a mouse model of mitochondrial 
encephalomyopathy (Viscomi et al., 2011) AICAR as a pharmacological activator of AMP 
activated protein kinase (AMPK) might play a key role in the regulation of energy 
homeostasis, increasing mitochondrial biogenesis without altering mitochondrial 
membrane potential (Golubitzky et al., 2011). If induction of mitochondrial biogenesis has 
a “therapeutic” role or influences mechanisms fighting apoptotic cell death (Dam et al., 
2013) will require further investigation. 
 
 
C10orf2 
We also identified a new case (P32) harboring mutations in C10orf2. It is unclear why 
some mutations in the TWINKLE gene cause autosomal recessive diseases (in the form 
of IOSCA syndrome or as a hepatocerebral/hepatocerebrorenal syndrome), whereas 
others result in autosomal dominant transmission of a disorder confined to extraocular 
muscles. However, a similar condition occurs in the syndromes associated with mutations 
in POLG, the DNA polymerase that is closely associated with the Twinkle helicase to 
control mtDNA replication. As similar reports (Dundar et al., 2012), it seems that our study 
suggests to consider IOSCA in the differential diagnosis of neurometabolic disorders even 
outside Finland. 
Our study also expands the background of MDS patients with uniparental dissomy (UPD) 
(Douglas et al., 2011; Haudry et al., 2012) and illustrates the need to consider UPD in 
cases of homozygosity of a rare mutation being responsible for recessive disease in non-
consanguineous families. We report the first UDP of chromosome 10 in a patient 
presenting mutations in C10orf2. 
Because the recurrence risk for UPD is very low, the risk for disease in further offspring 
for this couple is negligible (Haudry et al., 2012). 
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POLG 
We studied a patient (P9) with a severe clinical phenotype who died due to valproate 
induced fatal acute liver failure. Analysis of the mtDNA content revealed a severe 
depletion in liver (approx. 95%) and a heterozygous compound in the POLG was identified 
[p.R309H (c.926G>A); p.A889T (c.2665G>A)]. 
Several inborn errors of metabolism are known to represent a risk factor for severe 
idiosyncratic reactions to valproate, including liver toxicity. Many studies have focused on 
the interaction between valproate and mitochondrial function in general and mitochondrial 
disorders such as AHS in particular, as conditions predisposing to severe valproate 
toxicity. Recent studies gave evidence that POLG mutations can lead to a range of clinical 
phenotypes which predispose to the development of fatal liver failure after exposure to 
valproate. Nevertheless, a single case report suggests that there may be mutations in the 
POLG gene associated with reversible hepatotoxicity (Schaller et al., 2011). 
Another mutation commonly found in POLG and associated with valproate induced 
hepatic failure in AHS patients is the p.A467T (c.1399G>A). This condition was observed 
in P18. However, no mtDNA depletion or multiple deletions was found in muscle and liver 
from this patient. The cellular mtDNA content may be an indicator of the underlying 
molecular mechanism linking genotype to phenotype and explaining the patient’s acute 
liver failure (Schaller et al., 2011). 
We also described in P35 in which a severe reduction od mtDNA copy number, but only 
one POLG mutation, p.G268A (c.803G>C), could be identified in heterozygousity. This 
mutation is located in the 3’->5’ exonuclease region and is associated with the 
proofreading activity of POLG. It seems to act in a recessive way, unless a different 
genetic background may act as a modifier factor. In homozygosity usually causes the 
accumulation of mtDNA deletions (Graziewicz et al., 2006). As no additional mutations, 
gross deletions or insertions were found in the other allele of this patient, other MDS 
genes, such as TK2, RRM2B and C10orf2, are being investigated.  
We also investigated a family where the affected individuals have in common an abnormal 
pattern of urinary organic acids, with the presence of 3-methylglutaconic acid. At age of 4 
months P42 presented psychomotor delay, hypotonia, neurosensorial deafness and 
epilepsy. The spectrophotometric determination of MRC enzymes in a muscle biopsy 
showed a reduced activity of complex I (37% reduction as compared to the average value 
of age-matched controls) and histological studies showed predominance of type I fibers. 
Patient 42a and 42b, her relatives, presented with a similar clinical phenotype, however 
the spectrophotometric determination of MRC enzymes was not performed in P42a 
because skeletal muscle biopsy was not available and P42b also showed a complex I 
deficiency. SDS-PAGE and BN-PAGE showed decreased levels of several subunits of 
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complex I and decreased amount of fully assembled complex I in P42. As POLG is one of 
the essential factors required for mtDNA replication (Ropp and Copeland 1996), it is 
tempting to speculate that variations in this gene might impair mtDNA replication, affecting 
the synthesis of ND subunits. This ultimately could affect the ND subunit pools, that are 
believed to exist, and consequently affect complex I assembly due to its dependence on 
ND subunits to form the membrane arm (Ugalde et al., 2004). 
A significative reduction of mtDNA copy number was also detected in P42 and in P42b. In 
case 42 but not in 42a and 42b, we identified two mutations in POLG: p.G848S 
(c.2542G>A) and p.Q1236H (c.3708G>T). Mutations in this gene could affect the catalytic 
activity, the processivity of the enzyme or the the fidelity of mtDNA replication (Chan and 
Copeland 2009). However, due to the high consanguinity, this family could have two 
different disorders, what explains the fact that the molecular characterization of P42 
relatives remain indeterminated. As these affected individuals have in common an 
abnormal excretion of 3-methylglutaconic acid, and there are different etiologies of 3-
methylglutaconic aciduria syndromes, associated with OXPHOS dysfunction, this should 
be taken into account in further investigations. 
 
 
TAZ 
We identified in P38 a new hemizygous missense mutation, p.H176R (c.527A>G), 
associated with a significant reduction of mtDNA copy number in patient 38, who 
presented a clinical phenotype of BTHS.   
Fewer than 200 living males are known worldwide, but evidence is accumulating that the 
disorder is substantially under-diagnosed (Clarke et al., 2013). Allelic heterogeneity and 
the intrafamilial variability of expression are high. Thus, no genotype-phenotype 
correlation has been observed in any patients (Rigaud et al., 2013).  
The new mutation identified in this study contributed to expand the spectrum of patients 
with TAZ mutations, and will be important for an accurate genetic counseling and a 
prenatal diagnosis to the affected family. 
Management of these patients includes medical therapy of cardiomyopathy, cardiac 
transplantation, antibiotic prophylaxis and granulocyte colony-stimulating factor therapy. 
Multidisciplinary teams/clinics are essential for minimising hospitalizations and allowing 
many more individuals with BTHS to live into adulthood (Clarke et al., 2013). 
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In the group of “secondary” mtDNA depletion the positive rate was 17%, in genes that are 
associated with the assembly of the MRC complexes, in this case assembly of CIII, and 
mitochondrial translation. These cases will be discussed in the following parahraphs.   
 
 
TTC19 
In the course of our study we investigated a kindred with a “secondary” mtDNA depletion 
where four siblings, showed a novel mutation in TTC19. The Portuguese family we 
described is additional evidence that it is difficult to predict the onset (timing and 
symptoms) and progression of a neurodegenerative disease due to defective oxidative 
metabolism even when multiple cases have already occurred. In the family described 
herein, the age at onset and pattern of progression varied significantly, with P33a and 
P33b manifesting symptoms in their teens and showing a rapid downhill course, and P33 
and P33c showing a later onset with a progressive disease course. In P33c, 
neuropsychiatric features appeared in spite of annual monitoring and attempts to treat the 
symptoms. Second, our data add to the relatively limited array of variants in genes related 
to CIII deficiency. Like the previously described TTC19 mutation, the new 
c.963_966delTGGC seems to lead to a significant reduction of CIII holoenzyme, and 
impairment of early assembly steps, or overall stability, of the holoenzyme. However, the 
mechanism by which lack of TTC19 and the ensuing biochemical features affect cortical 
and deep brain neurons and lead to the clinical manifestations seen in our family remains 
at large unexplained.  
It is tempting to hypothesize that the high levels of ROS production seen in cells from 
TTC19 patient are even higher in selective brain structures probably because lack of 
functional components of CIII holoenzyme (for example, RISP) that are usually assembled 
in later stages. Interestingly, severe ROS damage, impaired motor coordination, and 
neurodegeneration in limbic system structures have been observed upon ablation of RISP 
in a brain-specific mouse model of CIII deficiency. 
Summarizing, we described the first family outside Italy with a mutation in TTC19. The 
novel change manifested as a disorder characterized by degeneration of olivary-cerebellar 
neurons and a progressive psychiatric syndrome, findings that should alert clinicians when 
searching for additional cases. 
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RARS2 
Infantile-onset diseases due to mutations in nuclear genes encoding proteins targeted to 
the mitochondria are more common than primary mutations in the mitochondrial genome 
itself and their number increases at a rapid pace (McFarland and Turnbull 2009; 
Chrzanowska-Lightowlers et al., 2011). A mutation in any of these genes has the 
possibility to produce severe biochemical defects of OXPHOS or be harmful for mtDNA 
maintenance, or both. As a consequence, clinical presentations may vary but patients, 
especially infants and children, frequently suffer from severe neurological illness because 
the developing brain has the highest request in oxidative substrates for functioning.   
A similar pattern of early-onset epileptic encephalopathy and progressive cerebello-
cerebral encephalopathy are common to one of the studied patients (P20) and represent 
useful clues for screening RARS2 particularly if associated with early lactic acidosis and 
lactate peak at MR-spectroscopy. Early onset seizures have also been observed in 
previously reported RARS2 patients (Edvardson et al., 2007; Rankin et al., 2010; 
Namavar et al., 2011; Glamuzina et al., 2012) but lactic acidosis may be overlooked as 
disease progresses and its absence should not preclude RARS2 testing.  
At the long-term follow-up, this patient showed progressive microcephaly, spastic 
quadriplegia, and virtual absence of psychomotor development. Gastroesophageal reflux 
was also particularly severe in this case as disease progressed. Considering that the first 
signs of encephalopathy such as diffuse hypotonia and poor eye contact were already 
present in the neonatal period, as well as a relative microcephaly at birth, it seems 
obvious that the genetic condition has a prenatal onset in most patients and affected 
mostly the brain. Follow up MRI revealed ensuing cerebral cortical atrophy together with 
progressive pontocerebellar atrophy and confirmed described aspects of white matter 
“depletion” (Edvardson et al., 2007).  
Given the clinical and characteristic neuroimaging pattern related to mutations in RARS2 
the differential diagnosis with other neurodegenerative conditions starting in early infancy 
such as neuronal ceroid-lipofuscinoses and AHS is not complex.  
Lending further evidence to the heterogeneity of clinical presentation of infants with 
mitochondrial encephalopathies, this work has expanded the array of disease-causing 
variants in RARS2, offering clues to recognize further similar patients. 
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The methodology of qPCR also enabled the detection of mtDNA multiple deletions, which 
was the case of P36, whre we found mutations in the TYMP gene.  
 
TYMP 
In this study we identified a MNGIE patient (P36) with mtDNA multiple deletions. 
Molecular analysis of the TYMP gene revealed the presence of three heterozygous 
mutations two of them already described in the literature [p.S160P (c.478T>C) and 
p.A465T (c.1393G>A)] and a novel variant [p.M74K (c.221T>A)], probably pathogenic. In 
this case a familial investigation should be performed to clarify the segregation of the 
alterations found in this patient.  
The poor quality of life and early death in patients with MNGIE demand urgent treatments, 
but so far, therapy has been largely supportive, including total parenteral nutrition, pain 
relief, and treatment of infections. Abdominal pain is often treated with some success by 
celiac plexus neurolysis. Hemodialysis is another strategy but re-accumulation of the 
nucleosides is too rapid. Recently, allogenic stem cell transplantation and platelet infusion 
have been proposed and though showing promising results  they require longer follow up. 
 
 
DISCUSSION  HIGHLIGHTS  
The group of studied patients suspicious of cross-talk disorders was investigated at a 
molecular level based on their suggestive clinical features and/or the presence of mtDNA 
depletion or multiple deletions. 
In this study, using a classical molecular approach (PCR followed by Sanger sequencing), 
we have successfully characterized 25% (12/47) of the studied patients, a number that is 
in accordance with recent reports using novel sequencing technologies (Calvo et al., 2012; 
Lieber et al., 2013). The majority of mutations was found in genes directly involved in the 
mtDNA maintenance. Furthermore, identification of these novel patients has contributed to 
expand the molecular spectrum of these diseases, as six novel mutations were identified. 
These molecular results will also be important to offer an accurate genetic counseling and 
a prenatal diagnosis to the affected families.  
However, a significant number of eligible patients (35/47) still remain without molecular 
characterization. The use of targeted NGS of mitochondrial proteins has shown the 
efficacy of the new methodology to amplify the rate of molecular diagnosis as well as to 
find new genes related to MDS (Lieber et al., 2013). Furthermore, several lessons can 
already be taken from the incorporation of NGS in the clinic, such as: i) targeted exome 
sequencing is a cost-effective and time-efficient alternative to traditional, sequential 
testing of the mtDNA and individual nuclear genes. For a subset of patients, a firm 
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molecular diagnosis can be established quickly in a minimally invasive manner; ii) there is 
a great phenotypic overlap between mitochondrial disorders and other genetic syndromes 
limiting the rate of detection of confirmed mutations, and, as costs decrease, this argues 
for whole exome or whole genome sequencing, and iii) when possible, familial sequencing 
can be performed to facilitate phasing of haplotype, detection of de novo variants, and 
filtering of candidate variants. These features demonstrate that targeted exome 
sequencing could be an effective alternative to the sequential testing of mtDNA and 
individual nuclear genes as part of the clinical investigation of mitochondrial disease. 
 
The final aim of this study was to address therapeutical options for mitochondrial 
disorders. We have selected some compounds from the literature, such as AICAR, 
bezafibrate and riboflavin, that were tested in other groups of mitochondrial diseases. 
Upon bezafibrate and riboflavin treatment of cells from SUCLA2 and TTC19 patients no 
significant changes were observed in ROS content between treated and untreated cells. 
However, bezafibrate was beneficial for increasing ATP content in both patient cell lines. 
For AICAR treatment, the results obtained showed a reduction in ROS production in the 
same cell lines. AICAR has already been shown to improve growth and ATP content in 
cells from patients harboring mutations in subunits of the MRC complexes I and IV and it 
is said to fight the pathological mechanisms in a mouse model of mitochondrial 
encephalomyopathy (Viscomi et al., 2011). Our data indicate that AICAR has the 
possibility to raise ATP production and counteract ROS production even in cases with 
impaired mtDNA biogenesis. Whether stimulation of mitochondrial biogenesis has a 
“therapeutic” role or influences mechanisms fighting apoptotic cell death will require 
further investigation. Screening of potential therapeutic compounds for mitochondrial 
diseases is a challenge and a hope for the patients carrying these devastating diseases. 
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CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
The investigation carried out in this work, using a combination of clinical, biochemical, 
neuroradiological, pathologic, and molecular information, has further reinforce the need for 
a multidisciplinary methodology to establish the basis of intergenomic communication 
defects.  
From a general point of view, a good approach to study patients suspicious of 
intergenomic communication diseases could pass through: i) a better clinical selection of 
patients, which may range from well-defined syndromes to non-specific multisystem 
phenotypes, in which neurological involvement is usually present; ii) a detailed 
biochemical data, such as lactate, pyruvate, alanine and organic acid profiles, as well as 
neuroimaging and pathological findings, are also important clues for the diagnosis of 
these disorders; iii) determination of MRC complexes enzymatic activity, as mtDNA 
encodes subunits of  CI, CIII, CIV and CV and a mtDNA depletion can be expected to 
cause a combined deficiency of all, but not complex II, as it is not mtDNA-encoded. 
However, this result can be normal, if skeletal muscle is not among the affected tissues, 
e.g., brain or liver; iv) determination by real-time qPCR of mtDNA depletion and multiple 
deletions; and v) identification of the causative genes. All of these features are 
represented in the diagnostic algorithm illustrated in Chapter III, based on our laboratorial 
experience and practice. 
The molecular etiology of the disease in most patients presenting mtDNA copy number 
reduction remains unknown. This suggests that in perspective, a wider use of next 
generation high-throughput strategies, such as Targeted MitoExome Sequencing, Whole 
Exome Sequencing (WES) and/or Whole Genome Sequencing (WGS) are likely to 
provide advantages in terms of screening of individual genes (including the “tiny” mtDNA), 
definition of new etiologies, and benefit for a larger number of patients, as demonstrated 
by the analysis of a representative cohort of 291 unrelated infantile patients with “definite” 
OXPHOS disease from the Murdoch Childrens Research Institute. However, 124 cases 
had previous molecular diagnosis, which suggests that MitoExome sequencing could 
enable diagnosis in roughly 47% of all infantile patients and prioritize candidates in a 
further 20% of cases (Calvo et al., 2012). 
The identification of new disease-related genes open the possibility to study their 
functions and to understand their pathogenetic mechanisms, which will lead to 
fundamental advances in our understanding of mitochondrial biology and hopefully 
provide insights towards novel therapeutic strategies. On the other hand, a larger outlook 
of the MitOME (the set of proteins predicted to be target to mitochondria) expand the 
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possibility of variants of unknown significance (VUS) and require more robust and 
relatively simpler functional methods for validation. WES or WGS might provide on the 
biology of communication between the two genomes and also on the possibility that also 
point mutations in mtDNA (and not only depletion or multiple deletions) might be effect of 
variants in nuclear genes. 
The use of a model organism, such as zebra fish, will be also powerful to analyze disease 
significance and functional consequences of variations detected in genes involved in the 
intergenomic communication disorders. Promoting the use of this system in combination 
with more traditional in vitro experimental models will offer the opportunity not only to 
investigate genes harboring VUS (and attribute their pathogenicity) but also to improve 
our knowledge on the level of functional complementation between two apparently 
different cell systems. 
Moreover we expect to develop and validate a cell-based, high-throughput screening 
assay to search for new therapeutically active molecules, assessing not only ATP 
production but also potential oxidative damage to the cell. The disturbance in the pro-
oxidant-antioxidant balance in favor of the former is defined as oxidative stress, which is 
present in many inborn errors of metabolism, causing the accumulation of toxic 
metabolites or their precursors and leading to an increased free radical production 
(Wajner et al., 2004). Cells can protect against oxidative stress through non-enzymatic 
and enzymatic antioxidants defenses. Thus, testing potencial therapeutical compounds in 
patient's cells could have an impact on patient’s health and advance new opportunities in 
personalized medical treatment of mitochondrial disorders. 
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SUPPLEMENTARY MATERIAL 
 
 
8.1 Real-time qPCR primers  
 
Gene Forward 5’-3’ Reverse 5’-3’ 
MT-ND1 CCCTAAAACCCGCCACATCT GAGCGATGGTGAGAGCTAAGGT 
MT-ND4 CCATTCTCCTCCTATCCCTCAAC CACAATCTGATGTTTTGGTTAAACTATATTT 
18S rRNA GGCGTCCCCCAACTTCTTA GGGCATCACAGACCTGTTATTG 
 
 
8.2 PCR Reactions Mix 
 
A. Reaction Mix for PCR 
Reagents Volume 
ImmoMix Red 6,25 µL 
Primer Forward (10 pmol/µL) 0,25 µL 
Primer Reverse (10 pmol/µL) 0,25 µL 
DNA (0,5-1,5) µL 
H20 qbp 12,5 µL 
Total Volume 12,5 µl 
 
 
B. Reaction Mix for Sequecing PCR 
Reagents Volume 
BigDye 0,5 µL 
Buffer 0,5 µL 
Primer M13F or Primer M13R 
(C = 3,2 pmol/µL) 0,5 µL 
DNA product 3 µL 
H20 5,5 µL 
Total volume 10 µL 
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8.3 Primers used in this study 
 
Oligonucleotide primers (5’-3’) and thermocycling conditions used for Polymerase Chain 
Reaction Amplification of the coding exons of the genes analyzed in this study. Note that 
all primers are tagged with an M13 universal primer, either forward (5’-3’): 
TGTAAAACGACGGCCAGT, or reverse (5’-3’): CAGGAAACAGCTATGACC. Universal 
M13 primers were used for sequencing. 
 
Gene Exon Forward 5’-3’ Reverse 5’-3’ Tm 
POLG1 
2a CTCCACGTCTTCCAGCCAGTAAAA TTCTGCAGGTGCTCGACGCT 
65 
2b GGGCTGCACGAGCAAATCTT AGCCCGTAACAGGACCTCAGAAAA 
3 CAGTGGTTGTTGTGGAGTG CAGCAAAGGCAACAGAGACA 
4 GTCCACACCACCAAGCAGT GTCCCAAGCACTATGCTCC 
5-6 GCAGGAGCATAGTGCTTG AAGCTAAGGTCCCCAACCTG 
7 TCAGGGATTGGGCCAGTCTT GAGCCAGGGGTCTTCTTTGT 
8 GGCCTAGCCTTCGGCTTA AGACAACCCCTACCCTACCC 
9 GGGTGGGAGCAGATCTTATTG TGAGAATGGAGCAAGGGTAGA 
10 GGGACATTGTGAGAGAGAGA ACTCTTTCCACTAGCCTGAG 
11-12 CAGAGTGGGCATCTGGTAAT AAGAGGAAGCCCTTTCCACC 
13 ATGGCCCTTGCTGAATGCAG TGGGCCTTGAGCAGAATGAG 
14 GCAGGTACTCACGTTGGTTC CTGTGGGAATCCAGGGTTAG 
15-16 GGATGTGGGATAGATTCTGCT CCTCAGAGCCCAGTTTCTACA 
17-18 GTAGGAAGAGTCTCATTTGGG CCTGGGTGTTAAAGTGGATG 
19-20 TGAACATTCCTTGCCAAGGC TCTGCCCATGCTCCAAAGGTA 
21 GCTTCTACCCTGGAGTTAAT CAAGGAACGCTCACCCAAAG 
22 GTCATTGCTCCAGGAGTGAT CTGTTCTCCAAGACCCACTT 
23 GCTCCTTTGCTCACTTCTGA CTACTGAAAAATGGCTGGCC 
C10orf2 
1a GGCACCTAAGGCATTTCAAG ATGCAGAGAAAGTGGCCTGT 
60 
1b CACAGCTCAAAGGCCAGACT CCAAGGGAAGACAAGACTGC 
1c GGTTACAGATGACACACTCAAGC CTTCCCAGGACCGAAGGT 
1d CCCTGCCTTACTCCCTTACC ACCCACTTGCTTTTGTCACC 
2 GTCTTGGTTTCAAGGGTAGG GATATGTCTGGGAAAGCAAGG 65 
3+4 GAGTTTTCAGGATGCTAGT GTCACACCTACCCACTC 60 
5 CTTTCTGCTTTGCTCATGTCC CCTTGCAGAGTTTTATGCTCC 65 
TK2 
1 TCCAAGTTATGGGTGCGTTC CGGGAGTAGGTGGGCGCAT 
60 2 TTTTAGGCCAGGGAGTGAGCAT TTCCTTCTCCCTGGAGATCCT 
3 GCCCTTTCCGTAGCCATTAT TTTCTCCGCTTCCTTCAAACC 
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Gene Exon Forward 5’-3’ Reverse 5’-3’ Tm 
TK2 
4 TCACTTTCCCCTCAACACTTA ACCATCATTCTCAGGTGC 
60 
5 TGTCCTTCAGTGCCTTGTGA AAGTTTCCCTTCCTGGCAA 
6 ACATTTCTCAAGGCCTCCTG CTCCATATCTGTCAATCGAATA 
7 TCCAGTATTGCACGGATCAC GGCAGACAGAATTCGGGAC 
8 CTGTGTGCCTGCTTTGCTT AGGTGGTTTCCCAGTTTGTC 
9 CTCTGCTTGACACCCTTGG CCCTCCCCTGTCTGCAAG 
10 CTCCAGCTGTGAAAGGAGGAT AAAATCAAGCTGGCCAGACA 
DGUOK 
1 ATACCTAGGGCGGAAGTGCTCT AGCTCCTTTCCCAGCCTCTGTC 
60 
2 CTTGAGTTTGGGCGTTTGTG AACTGGGCTACTTTACTCACTG 
3 AAACCTGTTTGGGGAGGT GATCAAACAGGCAGCACTGA 
4 CTCGTGCCTTTCATTCCAT GCTCTCTGTGCTGCAGGTAA 
5 CCGAAGACTGCATTGTAGCA GACATTTCCAACCATTTCCAG 
6 TGGCGAGTATGTGAAACTT CCATAGGCCTTGGAGTGTGA 
7 CTCATGGGCTTGGCTGCATAT GCTCTTGAGCGGCAGAGT 
MPV17 
2 AATGTCAGGCGGCTTCTTA AAGCCTCTGGCTTCCAAATC 
65 
3 CCCTGGGGTTCAGAGTAC CCTGCCCCAAGTATCAGAAT 
4+5 TTCCCTTGGACTCTCACAC ACCTGCACTTACCCCCTTTT 
6+7 TGCAGGAATGTGCTCTTTG GTTCCGTTTGGGGGTCTAAG 
8 CTCCTTTGCCATTTCATGCT CTTAAGCTCTGACCGGCAAC 55 
RRM2B 
2 GTAAGGATTCAACCCAGGCA CCTGTAAAACAAGAAGGAACAC 
65 
3 TCCCAAACACTTTGAGAAGAA TTTGCTGGTCAAAGGATAAGC 
4 TTAAGCGATAATGCTGATGTCC TATTATGCTCAGAAACTTCCA 
5 AGATCGTGCCACTGCACTC CCATGCTGTAACTTTGATTCG 
6 TCTTTGCAAACAGTTGTGGTAT GTGACAGAGTGAGATCCTGT 
7 GAACCACTTTATACAATGCTTG CTGGTATTTTTATTGACCTACA 
8 GAAAGTCCTCTTTCTATTTGGA AACCTTGTTCATACAAAAC 
9 CCTGACCTCTGTTTTGGTC GCAAACCCCCAGTCCTTTA 
SUCLA2 
1 GTCTAGCGGCTGCAGTGTT CACACCTCACCCTTTCTCC 65 
2 GCAAGAGTGACTGCCAAATCA TCCCACGTCACTGGCATTAT 60 
3 CTATGTCTGGCATGCTGCTC TCCTCCAGTTGAGAAAAAGCA 65 
4 TGTGGATTTGCTTTTTCTCA CATGCTCATGACATACAAACA 60 
5 CTGTGCTGGAGATGTGAG GACAATTACTTCAGTTGTACGG 65 
6 TGGTAGCTGCTATTTCAGT TGGGTCTAATAGTGTTTTGTT 60 
7 TCCCTAAATGAAAGACCATT TGTATAAGCAACAAACACAGA 60 
8 TCTGTGTTTGTTGCTTATACA TGATACTTCACATCCCTTAT 55 
9 GGGTATTGTGGTTTGGTCTGA CTGAACTCCATGGAAATGTGA 60 
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Gene Exon Forward 5’-3’ Reverse 5’-3’ Tm 
SUCLA2 
10 AACCTGGGCTTTTACAGTG TGCCTTAACATCTTTCAGCAA 65 
11 CCAGATGTTTTAAATGGAA AAATGCAGTCCAAATCCTT 60 
SUCLG1 
1 TTTGTTCAGGCGACTGCT GAAGCCGGAATCCCAAGC 65 
2 TTTTTGTGATCAAGTTGAATT TTTTTCTGCAACAATCATGTG 60 
3 AGATTGCTTTTGCTTCTCTT CCAAAGAATGCTCGCTCTTC 
65 
4+5 TCCTTTTCTTACCCCAAGA GGGTTTAAGGCAAATAAGC 
6 TTAGTCACTCGAAGTGTTTGG TCATCCAATGAAGACACCACA 
7 TTGACCTAAATTCCATGGTTCA GAAGGCCCTGCTCAGAAAG 
8 GCCCAAGCCATTTACCATTT GCTGCACATCAGAAAACC 
9 GTGTTCAAACACCCTCATCC TGTCAGGCACATAGGCTG 
TYMP 
2+3 GGAGCACGTGGCTCAGAC GGTAGGGTCTTGGAGGCTT 
65 
4 AATCCAGCTGCACTCCTA TGACCCTAATGATCCACCAG 
5 GCTGCTAAGTCATTTACCA GAGCCTGTGAACATGCAGA 
6 GCTCCAGGTTCTCCATTGTC GAGGGGTGAAGGGTAGGC 
7+8 GCTGGAGTTCGACCAAGAAC GGGAGAGGGGCTGAGAGG 
9+10 CCCTGTGCTCGGGAA GTCACGTGTTCATCGAG 
RARS2 
1 GCTGCAGGGCAGAGGTTAG CACCCTCCAGCTGACTGAG 62 
2 GGAATGCATTTGGAGCTCATT CAGGAGTAATAGGCTGAGTAT 60 
3 CACCTTCTTCTGGTAAAGGTA CAATGTCAGCTCAAGAGGAG 60 
4 GGGACCATGAAAGATGACTTA GGTGGTACTCTCCAAGTTATG 60 
5 GTGGTGCTGGAGGTAGTGC GATTGATTCACTGTGATTTCAAG 62 
6 GCCCTAATACCAAAGGCCAT GGCAGGAGGCTCATATAAATT 60 
7 CTCCCTTTCCATAACACATGA GTAGGACATACTACTTCATCC 60 
8 GACTTGTGTCAGATTATGGGG GCAACAGAGCGAGACCCTG 62 
9 CACTCTGTAATGTACCCAACT CACAAGCTTAACACGCAACTT 60 
10 CATGAGCCACCACACTCAG GCTGCACATTGCATTCTGTTG 62 
11 GCTTGAATTGGCACTGCTCA TGTCATCAGCTGTGGAATCC 60 
12 CTAAGTGTGGGTGGAATTCC GAAGTTGCCCACTTTAAACATAC 62 
13 CTTAGACACTCTTCTTGTGGC CCTTTCCACACCAGTATCTTG 62 
14 CTCTGCTCTGATGGTTAAAGT GTGACACTTCAATGGAGGGA 60 
15+16 CTCATTCTGAATCTGTTCTTGAT GCCTCTGGTCTTAGAATCAC 62 
17 CCTCCACTGTGTATGGATATT GGCATACCTTTGGGAAAAGTC 
60 
18 TTACAGACGTGAGACACTGC CCAGTCTACAGTGACAGTAC 
19 GGGCCAAGATCTAAAGCTTG GTATGGCTTCAGATAAGGGG 
20 GGCACTTTGACATATTGTTCC CAGCAAGGCATCTCAGAATAG 
TRMU 1 ACAGCGCAGAAGAAGAGCAGT ACTACACAGGTGGAGGGCGA 65 
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Gene Exon Forward 5’-3’ Reverse 5’-3’ Tm 
TRMU 
2 CTCAGGCACCAAGATGGAAAC GAGGCCTCTTGCAGTCTTCAG 60 
3 CGTAGTGGCAGAGAATAACACCA ACAGTTGTGACACCATCTCCAA 60 
4 CAGAGTGCTAGGATTACAGGC GGCAGGGACACTGTTTACTAC 65 
5 GAGTGTTGATGTCTGCCTCTGA CCTCAGCAAACTCCTCCATCT 65 
6+7 TCTAAGGCTCTGGCATCGTGT GGACGACAGGAACTCTGGTCTAG 60 
8 GATGTGCTCAGGTGCTTGGT GACCAGCATACAACTCAGCCTA 65 
9+10 GTGTGCTGGTAGGACAGTTGTT GTGACACCAGAGTGGAAATCC 65 
11 TCTCCTGTTCAGCAGCAGCA ACACAGGTCAGCATCGCAGG 65 
TSFM 
1+2 AGCAGGTGGCACCATACTC TGCCATTATGGTCACTGAAG 65 
3 TGGTAGACTGCCAGTAAATGATAG TCTTCAAGAACAGGCCC 60 
4 TTTCCGTTGAGTCTGTAGCTTG AGCATTTAAGCAGAGATGTGAAG 60 
5 ACGCCTGGCCAATACTTTTC CACACCACTTCTCACGTTGC 65 
6 GACTGTCTTCCAAACTGGGC CTCGGTCTGAAGAGGTTTGG 65 
TUFM 
1+2 AGCTCTAACTTCCGCCGGAA TCCAGGTCCCATCAGTAGATA 60 
3 TGCCTCTAGCACTGGAACTT TCCTGACAAGAGGCAGCTTCT 65 
4+5 GTGAACTGAAGCGCTCGTTG AGACACAAAGCAGAGCTCTG 60 
6+7 CAGAGCTCTGCTTTGTGTCT AGAGGGAAGGCACAAGGGA 65 
8+9 TCCCTTGTGCCTTCCCTCT GGAACTATGAGTGAAGCAAAGG 65 
10 TTAAGGAATGAAGGCACCCTGG TCCTCCCCTATCCTCTCCAAT 65 
GFM1 
1 GCTCTTACAACATTGGCTGC GTGTCACGGCCTTCCATTG 65 
2 GGAGGAATAATGTCCACCATAC TGTCAAAAGTCCGCTGTTACC 65 
3 CTGGTCTCAAACTCTTGGGC GAAGTGCTCTAGGTCCTAAGTTAGTC 60 
4 GCACCTAAGGGTTGGTGAATAG GCCAATTTACTAAAATCAGTGTTCC 
65 5 TGTGACCTGATGGTAACACCC TCTGCGTTTGATGAACTTATCC 
6 CTTGACCTTAAACTTGCCTATTTC GCATCATGTCCCCTCCC 
Gene Exon Forward 5’-3’ Reverse 5’-3’ Tm 
GFM1 
7 AGTAAATCACTTCCCAGCCC AACAAATCATACTTCCAACTCAAAAC 
65 
8 CAGCAGTAATATCCCACACACG GCTTTGGAAATTCTCTACCTGC 
9 GGAGGGAGTTATGAAGCTTTCC CTAGTGGGGCTCAGGATACC 
10 AGCAGAGAGATTCTGCCACG CTTGATGAGTGTCCTACTCAACG 
11 TTATTTTGGGAAGGAGGAACC AAGAAGATCTCAATACCAACAGAGG 
12 TTGGCTGTGTGGTATCCAAG AACCAGAGTGACGCATGAAG 
13 TCAACAATGGTGACGTTTTAGTG GGCCAAATAATCCCAAAGTG 
14 TTAATAGGAGTTATTTTATTTT TGATAGACAACATGATGGAAGA 
15 GAGGGGTGAAATACAGCACAC GCCTAGTGCTCTGGGTGAAG 
16 TTGCCGTTTGTGTTTGTACC AAGCCACAAATTCAGCAAGG 
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GFM1 17+18 AAATGGCTAAAATGCGTCTG GAATTTCTTGTTTCAGCAGCC 65 
TAZ 
1 TCAGGGGCCAGTGTCT CTCGTACAGCACCTCCCT 65 
2 GGAGGTGGGACTTA GGAGGTGGGACTTA 55 
3+4 CACTTTGGGCTGTAGGGAAA CCATAGGTCCCTCCAAAACA 65 
5 AGGCTTGTGGGGTGA AAACTCCTGGGCTTGAGT 60 
6+7 TTTGGAGAGTGTTGAGG CCATCTACCCCCATACAA 65 
8+9 GCTGGCACAGAAGCT TGGCCTCCATAGTGCTGA 65 
10+11 GCTGTGGGCACTCCTA GAGGGCACTTGAGAGGGTCT 65 
TTC19 
1 CGAACAAGAGGTTTAGAGAACCA AGCTCAGGAGCCGGAACAT 
60 
2 GATGTCCTGCTCAGTCGTCA GAGAGAGTAATGCGCAGCAA 
3 GCTGACCTCCCTGTCATCTC GAACATCGTGAAAGTCAGGAAT 
4 TGATTGCTGTCCTGTGCTTC TGCCTATGTCTGTCTGCCTTC 
5+6 TGTTGCATCAGACTGGCACT TCCCAGAGTCAAAGTTTCCTG 
7 CGGAGGTGGAGGTTGCTCT TTCCAAAACTTCTGCTGATACC 
8 AGTGACATGTGGGTCCCATT CCAAGGAGGATCTAGGACCA 
9 TCCCTCATCTTTTGTGGAATG CCCTTGCCCTCCCTACATAC 
10 TGCATTCATGCTCTCTCTTCA TGCATTCATGCTCTCTCTTCA 
Legend: Tm – Temperature of melting in ºC 
 
 
8.4 SDS and BN-PAGE experiments 
 
A. BN-PAGE gel of 5-13% 
 Gradient gel 5% Gradient gel 13% Stacking gel 5% 
Acrylamide 40% 
(29:1) 0,4 ml 1 ml 0,5 ml 
BN-gel buffer 3x 
(1,5M aminocaproic acid; 
150 mM Bis-Tris, pH 7,0) 
1,33 ml 1,33 ml 1,67 ml 
Glycerol 
 0,8 ml  
H2O 2,27 ml 0,87 ml 2,83 
APS 10% 44 µl 12 µl 55 µl 
TEMED 4,4 µl 1,2 µl 5,5 µl 
Total volume 4 ml 4 ml 5 ml 
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B. SDS-PAGE gel of 12% 
 Resolving gel 12% Stacking gel 4% 
Acrylamide 30% 4 ml 1,33 ml 
Tris 1,5M, pH 8,8 2,5 ml - 
Tris 0,5M, pH 6,8 - 2,5 ml 
H2O 3,35 ml 6 ml 
SDS10% 100 µl 100 µl 
APS 10% 50 µl 60 µl 
TEMED 5 µl 7 µl 
Total volume 10 ml 10 ml 
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Letter to the Editor
MPV17: Fatal hepatocerebral presentation in a Brazilian infant
The hepatocerebral forms of mtDNA depletion syndromes typically
manifest soon after birth and cause premature death in childhood [1].
Presentation is usuallywith early liver failure, followed by development
delay and muscle weakness during the ﬁrst year of life, as well as lactic
acidosis and hypoglycemia [2]. These conditions are associatedwithmu-
tations in at leastﬁve genes [3] though further heterogeneity is expected.
An ample array ofMPV17mutations (Fig. 1) has been described in about
30 patients from different ethnicities.
We describe a Brazilian infant, the second child of apparently
unrelated healthy parents, who presented neonatal hypoglycemia,
digestive bleeding and sepsis in the ﬁrst week of life. Laboratory tests
also showed elevated levels of total and free serum bilirubin and trans-
aminases. Amino acids were normal whereas organic acids revealed
the presence of lactic acid (3× normal values) and Krebs cycle interme-
diates at age 2 months. Shortly after the patient manifested failure to
thrive, severe hypotonia, nystagmus, poor echoarchitecture at liver ul-
trasound, and cirrhotic ascites. He died at 5-months-oldwith hepatic in-
sufﬁciency associated with bleeding and multiple organ failure. He had
severe mtDNA depletion (residual mtDNA levels were 2% in liver and
23% inmuscle) andmolecular studies detected a homozygousmutation
c.186+2T>C inMPV17, a variant already reportedwith poor prognosis
in a singleton [4]. The c.186+2T>C was also detected in the proband's
elder sister who had presented at birth with neonatal hypoglycemia,
failure to thrive and hepatic insufﬁciency, later developed seizures
and hypotonia, and died at 10 months. Themutationwas heterozygous
in the parents who were from nearby villages in south Brazil.
Our study expands the ethnic background of MPV17-mutated pa-
tients and will be important for an accurate genetic counseling and
a prenatal diagnosis to the affected family. MtDNA depletion should
be looked for in neonates with progressive cholestasis and neurolog-
ical deterioration.
References
[1] A. Suomalainen, P. Isohanni, Mitochondrial DNA depletion syndromes—many
genes, common mechanisms, Neuromuscul. Disord. 20 (2010) 429–437.
[2] A.W. El-Hattab, F. Scaglia, W.J. Craigen, L.C. Wong, MPV17-related hepatocerebral
mitochondrial DNA depletion syndrome, in: R.A. Pagon, T.D. Bird, C.R. Dolan, K.
Stephens, M.P. Adam (Eds.), GeneReviews™, Seattle, 2012.
[3] A. Rötig, J. Poulton, Genetic causes of mitochondrial DNA depletion in humans,
Biochim. Biophys. Acta 1792 (2009) 1103–1108.
[4] A.W. El-Hattab, F.Y. Li, E. Schmitt, S. Zhang,W.J. Craigen, L.C.Wong,MPV17-associated
hepatocerebral mitochondrial DNA depletion syndrome: new patients and novel
mutations, Mol. Genet. Metab. 99 (2010) 300–308.
Célia Nogueira
Genetics Department, National Institute of Health, INSA, Porto, Portugal
Corresponding author at: Rua Alexandre Herculano, 321, 4000-055
Porto, Portugal. Fax: +351 223401109.
E-mail address: celia.nogueira@insa.min-saude.pt.
Carolina F.M. de Souza
Antonette Husny
Medical Genetic Service, Hospital de Clinicas de Porto Alegre, Brazil
Terry G.J. Derks
Division of Metabolic Diseases, Beatrix Children's Hospital,
University Medical Center Groningen, University of Groningen,
The Netherlands
Filippo M. Santorelli
Molecular Medicine & Neurogenetics, IRCCS Stella Maris, Pisa, Italy
Laura Vilarinho
Genetics Department, National Institute of Health, INSA, Porto, Portugal
11 October 2012
Molecular Genetics and Metabolism 107 (2012) 764
Fig. 1. Describedmutations in theMPV17 gene.○Missensemutation;●Nonsensemutation;
Δ Small deletion;▲ Gross deletion; ◊ Small insertion;□ Splicing mutation; c.186+2T>C.
1096-7192/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ymgme.2012.10.010
Contents lists available at SciVerse ScienceDirect
Molecular Genetics and Metabolism
j ourna l homepage: www.e lsev ie r .com/ locate /ymgme
SHORT COMMUNICATION
Novel TTC19 mutation in a family with severe psychiatric
manifestations and complex III deficiency
Célia Nogueira & José Barros & Maria José Sá & Luísa Azevedo & Ricardo Taipa &
Alessandra Torraco & Maria Chiara Meschini & Daniela Verrigni & Claudia Nesti &
Teresa Rizza & João Teixeira & Rosalba Carrozzo & Manuel Melo Pires &
Laura Vilarinho & Filippo M. Santorelli
Received: 30 November 2012 /Accepted: 11 March 2013 /Published online: 28 March 2013
# Springer-Verlag Berlin Heidelberg 2013
Abstract Complex III of the mitochondrial respiratory chain
(CIII) catalyzes transfer of electrons from reduced coenzyme
Q to cytochrome c. Low biochemical activity of CIII is not a
frequent etiology in disorders of oxidative metabolism and is
genetically heterogeneous. Recently, mutations in the human
tetratricopeptide 19 gene (TTC19) have been involved in the
etiology of CIII deficiency through impaired assembly of the
holocomplex. We investigated a consanguineous Portuguese
family where four siblings had reduced enzymatic activity of
CIII in muscle and harbored a novel homozygous mutation in
TTC19. The clinical phenotype in the four sibs was consistent
with severe olivo–ponto–cerebellar atrophy, although their
age at onset differed slightly. Interestingly, three patients also
presented progressive psychosis. The mutation resulted in
almost complete absence of TTC19 protein, defective assem-
bly of CIII in muscle, and enhanced production of reactive
oxygen species in cultured skin fibroblasts. Our findings add
to the array of mutations in TTC19, corroborate the
notion of genotype/phenotype variability in mitochondri-
al encephalomyopathies even within a single family, and
indicate that psychiatric manifestations are a further
presentation of low CIII.
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Introduction
The autosomal recessive cerebellar ataxias (ARCAs) are a
heterogeneous group of neurodegenerative disorders which
can be classified according to their clinical and genetic traits
[1, 2]. The possible etiologies encompass metabolic alterations
in cellular organelles, including lysosomes, peroxisomes, and
mitochondria, and deficiency of DNA repair and chaperone
activities [2]. In this field, the development of traditional and
more sophisticated technical approaches, including exome se-
quencing [3], is leading to the identification of a growing
number of causative genes and new disease entities [1].
Ubiquinol–cytochrome c reductase (complex III, E.C.1.10.
2.2) (CIII) is the third component of the mitochondrial respi-
ratory chain (RC), and it catalyzes the transfer of electrons
from reduced coenzymeQ to cytochrome cwith a concomitant
translocation of protons across the inner membrane [4]. CIII is
made up of 11 subunits [5], only one of which (cytochrome b)
is encoded by mtDNA; the remaining proteins are encoded by
nuclear DNA genes. These include cytochrome c1, the Rieske
iron–sulfur protein (RISP), two “core” subunits (Core 1 and
Core 2), and six additional, smaller proteins (UQCR6-11),
whose functions are still largely unknown [5, 6]. Low or very
low biochemical activities of CIII [MIM 124000] are a rela-
tively rare cause of dysfunction of oxidative metabolism [7].
Mutations in MT-CYB and in the assembly factor BCS1L
account for the vast majority of cases with CIII deficiency
[8]. Less frequently, mutations in mtDNA-encoded tRNAs,
or single large-scale mtDNA deletions, may also account for
a partial reduction of the biochemical activity of CIII [8].
Recently, mutations in the human tetratricopeptide 19 gene
(TTC19), which encodes a still poorly characterized protein
thought to be important in early CIII assembly, have been
described in association with young-onset neurodegeneration
in two unrelated Italian kindred as well as adult-onset, rapidly
progressing encephalopathy in an unrelated case [5].
We here report four patients from a family found to
harbor a novel TTC19 mutation. Whilst all the patients
presented similarly reduced CIII enzymatic activity in mus-
cle and a comparable pattern on brain neuroimaging, the
onset, clinical presentation, and course of their cerebellar
ataxia and psychiatric dysfunctions varied significantly.
Patients and methods
In a Portuguese kinship (Fig. 1a), four sibs (three men and
one woman) were affected. Although formal consanguinity
was denied, both sets of grandparents originated from
neighboring villages in a relatively isolated area in northern
Portugal. The recruitment and study protocol was approved
by the medical research ethics committee of our institutes.
The participating family members in this study underwent a
thorough neurological examination. In addition, the follow-
ing workup was performed: brain and spinal MRI, complete
blood count and metabolic screen, EMG and nerve conduc-
tion studies, audiometric examination, and brainstem audi-
tory, visual, motor, and somatosensory evoked potentials.
RC complex activities in skeletal muscle homogenate and
cultured skin fibroblasts were measured using an existing
spectrophotometric method [9]. Human fibroblasts were
obtained from diagnostic skin biopsies and grown in regular
DMEM or in glucose-free medium supplemented with
5 mM galactose to induce a stress culture condition, as
reported [10], with or without the following additives: 0.
25 mM AICAR (Tocris, Bioscience, Bristol, UK), 400 μM
bezafibrate (Sigma-Aldrich, St. Louis, MO), and 1 mM
H202 (Sigma-Aldrich). Cells were analyzed 72 h post-
treatment for rate of growth and viability, total ATP produc-
tion, and amount of reactive oxygen species (ROS). Cellular
ATP content and viability were evaluated using the
CellTiter-Glo® (Promega, Madison, WI) system, according
to the manufacturers. For intracellular ROS production, cells
(2.5×105) were incubated with 5 μM CM-H2DCFDA
(Molecular Probes, Invitrogen, Paisley, UK) in 1 ml buffer
(10 mM HEPES, 142 mM NaCl, 2 mM KCl, 1.2 mM
KH2PO4, 1 mM MgSO4, 1.3 mM CaCl2, pH 7.4)
supplemented with 1 % FBS for 15 min at 37 °C. After
washing with the same buffer, the cells were incubated for
30 min with 1 mM H2O2 in 1 ml buffer. Fluorescence was
measured at excitation and emission wavelengths of 490 and
525 nm, respectively, using a Cary Eclipse Fluorescence
Spectrophotometer (Agilent, Santa Clara, CA).
Blue native gel electrophoresis (BNGE) and 2D SDS-
PAGE studies in patient II-06 and control tissues were
performed essentially as described elsewhere [11, 12]. For
SDS-PAGE and immunofluorescence analyses, we used
methodologies familiar to our laboratories [10], employing
the following monoclonal antibodies: complex I—39-kDa
subunit (NDUFA9), complex II—70-kDa subunit (SDHA),
complex III—Core 2; complex IV—subunit II (CIV-II),
anti-porin (all from Mitosciences, Eugene, OR), and a poly-
clonal antibody anti-TTC19 (Sigma-Aldrich).
Genomic DNA was purified from blood using standard
procedures. The coding exons and exon–intron boundaries
of TTC19 [NG_029806.1] were sequenced using the
BigDye v3.1 chemistry (Applied Biosystems, Foster City,
CA). MtDNA copy number in muscle was investigated by a
real-time qPCR assay [13] and results compared to levels
seen in tissue from age-matched normal controls. Total
RNA was isolated from cultured fibroblasts (RNeasy Mini
Kit, QIAGEN, Hombrechtikon, Switzerland) from the
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patient prior to cDNA synthesis (performed using a first-
strand cDNA synthesis kit [Promega, Dübendorf,
Switzerland]).
Results
Case II-01, the propositus (Fig. 1a), was a 49-year-old man
who had no clinically relevant complaints until the age of
27 years, when he manifested progressive back pain, clum-
siness, gait difficulties, and a generalized anxiety disorder.
Over the following years, additional psychiatric manifesta-
tions appeared, including major depression and visual hal-
lucinations which did not respond to antipsychotic drugs.
Neurological examination at age 37 revealed difficulties in
tandem gait; loss of balance while climbing stairs; segmen-
tal ataxia, observable as dysmetria in the nose–finger and
heel–shin tests; and interruptions in fast alternating hand
movements. Dysarthric speech, dysphagia, and slow sac-
cades were also detected. Subsequently, the patient
displayed moderate spastic paraparesis with pyramidal tract
signs affecting both the upper and the lower limbs. By the
Fig. 1 Family pedigree, brain
MRI, and molecular studies in
the new Portuguese kindred
harboring a mutation in TTC19.
a Family tree. Squaremen, circle
female, filled symbols affected
individuals. Slash indicates
deceased subjects. b Brain MRI
in three different affected
patients (II-01, II-04, II-06) in
this family. Arrows indicate
pontine atrophy. c
Electropherograms of the TTC19
gene flanking the homozygous
c.962_967delTGGC
(p.A321Afs*8) variant identified
in patient II-06. Wild-type
sequence in a control (Ctr) is also
shown. The deleted bases are
underlined. d BNGE followed
by 2D SDS-PAGE in muscle
homogenates from patient II-06
and a control (Ctrl) using
antibodies against the Core 2
subunit to detect complex III and
subunit I of cytochrome c
oxidase (CO I) for complex IV.
e A representative immunoblot
analysis of muscle homogenates
from control (Ctrl) and patient II-
06 using specific antibodies
against subunits of complex II
(SDHA), complex III (Core 2),
and TTC19. VDAC/porin was
used to control for equal loading.
Similar results were seen in
cultured skin fibroblasts.
f ROS production measured by
CM-H2DCFDA and expressed
as relative fluorescent units
(RFU) in skin fibroblasts from
control (Ctrl) and patients II-01
and II-06 incubated with or
without with 1 mM H2O2 for
30 min. Data are mean ± SD of
five different determinations.
Significance was set at p<0.05
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age of 42, he presented severe muscle atrophy and, unable to
walk or stand, was bedridden. His psychosis had worsened
as a result of the onset of visual and acoustic hallucinations.
He died of respiratory insufficiency aged 49 years.
Three additional sibs (II-04, II-05, and II-06) showed an
ataxic syndrome and psychiatric manifestations (see clinical
appendix for details). The parents and two additional sib-
lings (in their 50s), who were all asymptomatic, had no
major neuropsychiatric complaints and a normal examina-
tion. Table 1 summarizes relevant data in this family.
Brain imaging in all the patients at different ages showed
a pattern of olivo–ponto–cerebellar atrophy (Fig. 1b) and
abnormal hypersignal in the caudate, putamen, medullary
olives, cerebellar dentate nucleus, and medial midbrain on
T2-weighted MRI scans. Cortical brain atrophy (especially
in the frontal lobe) appeared at a later age in patients II-01
and II-04. No white matter changes or structural brain le-
sions were observed.
Routine histochemical stains for oxidative metabolism in
muscle biopsies were unremarkable in the four patients,
whereas measurement of RC enzymes revealed a marked
reduction of CIII activity in all of them (on average, residual
activity corresponded to 33 % of that recorded in age-
matched normal controls) (Table 1).
We identified a novel c.963_966delTGGC mutation in
TTC19 (Fig. 1c) in the propositus and three sibs. This muta-
tion predicts a frameshift and the synthesis of a truncated
protein (p.A321Afs*8), lacking about 35 % of its carboxy
terminus. The new mutation was found to be homozygous in
the four patients, heterozygous in their parents and in unaf-
fected sibs, and absent in 300 ethnicallymatched controls. The
c.963_966delTGGCwas expressed in tissues from patients II-
01 and II-06, and the amount of mRNA/TTC19 transcript
appeared to be semiquantitatively reduced in muscle from
case II-06 (not shown). Interestingly, we also observed a
moderate reduction of mtDNA copy number in II-06 (residual
mtDNA levels were, on average, 45 % of those of controls)
(supplementary Fig. 1). Using Western blotting, we found no
protein using a specific anti-TTC19 antibody in muscle and
fibroblasts from patients II-01 and II-06 (Fig. 1d). The
immunodetection pattern of the RC complexes was within
normal values in skin fibroblasts (supplementary Fig. 1).
Using BNGE followed by 2D-SDS and anti-Core 2 antibody,
there were nearly absent spots for CIII and CIII2 + IV
supercomplexes in muscle from patient II-06 compared to
control muscle (Fig. 1e), suggesting early impairment of as-
sembly of CIII, as already outlined elsewhere [8]. A less
profound defect was seen in skin fibroblasts (supplementary
Fig. 1).
ATP production in skin fibroblasts was not reduced in
either glucose or galactose medium (supplementary Fig. 1).
We also observed a statistically significant increase (p<0.
03) of ROS production in basal condition and after short-
term H2O2 treatment (Fig. 1f). Neither cellular ATP level
nor ROS production was influenced by treatment with
AICAR or bezafibrate, drugs known to enhance cellular
oxidative metabolism (not shown).
Discussion
More than 20 different ARCAs are currently documented,
and among these, the rare mitochondrial forms are increas-
ingly being recognized. The best known are Friedreich
ataxia and mitochondrial recessive ataxic syndrome (with
mutations in POLG), two progressive diseases, but more
static conditions are also described [2]. We reported herein
an additional form of mitochondrial ARCA in a family
where four siblings presented markedly reduced biochemi-
cal activities of CIII associated with overt psychiatric ill-
ness. The psychiatric component was less obvious in
previously reported cases of mutations in TTC19, although
two of those patients lacked motivation and displayed
avoidance behavior and poor social interaction [5].
Psychiatric manifestations are generally uncommon in
ARCAs [14] and more often seen in dominant forms, such
as SCA7 and SCA8 [15]. The psychotic manifestations seen
in these Portuguese TTC19 patients are also reminiscent of
the severe form of SCA17, a dominant “cerebello–olivary”
syndrome with abnormal repeat expansions in the TBP
gene. It is noteworthy that TBP has a role in the regulation
of gene expression [16] and impacts on chaperone protein
response [17]. This is also true of several members of the
TPR family of proteins [18] and possibly also of TTC19 [5].
However, given the likelihood of inbreeding in the family
we described, we cannot completely rule out the existence
of additional mutations responsible for the severe psychiat-
ric syndrome observed.
This report prompts two main considerations. First, the
Portuguese family we described is additional evidence that it
is difficult to predict the onset (timing and symptoms) and
progression of a neurodegenerative disease due to defective
oxidative metabolism [8–10] even when multiple cases have
already occurred. Mutations in TTC19 were initially linked
to severe neurodegenerative disorders in childhood and in
adult cases [5]. In the family described herein, the age at
onset and pattern of progression varied significantly, with II-
04 and II-05 manifesting symptoms in their teens and show-
ing a rapid downhill course, and II-01 and II-06 showing a
later onset with a progressive disease course. In II-06, neu-
ropsychiatric features appeared in spite of annual monitor-
ing and attempts to treat the symptoms. Reason for such
variety remains unknown, but it could be related to levels of
biochemical defects in specific brain areas or even to sec-
ondary alterations in the mtDNA. The latter is thought to
contribute to a number of neurodegenerative diseases of
156 Neurogenetics (2013) 14:153–160
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adult life [19]. Also, occurrence of psychiatric manifesta-
tions is rather unusual in disorders of oxidative metabolism,
though comorbidity between mitochondrial disorders and
psychiatric illness has been described as the presenting
features in fewer patients [20]. Second, our data add to the
relatively limited array of variants in genes related to CIII
deficiency. Like the previously described TTC19 mutation,
the new c.963_966delTGGC seems to lead to a significant
reduction of CIII holoenzyme and impairment of early as-
sembly steps, or overall stability, of the holoenzyme.
However, the mechanism by which lack of TTC19 and the
ensuing biochemical features affect cortical and deep brain
neurons and lead to the clinical manifestations seen in our
family remains largely unexplained. It is tempting to hy-
pothesize that the high levels of ROS production seen in
cells from patient II-06—and in II-01, though at a lesser
extent—are even higher in selective brain structures proba-
bly because of the lack of functional components of CIII
holoenzyme (for example, RISP) that are usually assembled
in later stages [21]. Interestingly, severe ROS damage, im-
paired motor coordination, and neurodegeneration in limbic
system structures have been observed upon ablation of RISP
in a brain-specific mouse model of CIII deficiency [22].
To summarize, we here described the first family outside
Italy with a mutation in TTC19. The novel change
manifested as a disorder characterized by degeneration of
olivary–cerebellar neurons and a progressive psychiatric
syndrome, findings that should alert clinicians while
searching for additional cases.
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Appendix—clinical data in patients harboring a new
mutation in TTC19
Case II-04 was a 33-year-old man who had displayed ob-
sessive–compulsive behavior since his teens. At the age of
24, he was hospitalized and found, on psychiatric examina-
tion, to be a healthy young man who displayed childish
behavior and frequently used “lies to communicate.” The
patient, at that time, also complained of generalized anxiety
and a sleep disorder. Medical records also contained reports
of episodes of mysticism and visual hallucinations (the
patient often said “I can see dead people talking to me”).
His neurological examination was unremarkable. A few
years later, his clinical profile also included abulia and
bradypsychism with episodes of confusion and spatial dis-
orientation. A neurological examination performed during
hospitalization at the age of 27 years revealed mild cerebel-
lar ataxia with dysarthria, pyramidal tract signs in the lower
limbs (leg stiffness, enhanced deep tendon reflexes, bilateral
Babinski sign), and generalized muscle atrophy and
wasting. The cranial nerves and peripheral nervous system
were spared. The patient's disease progressed rapidly; he
became mutacic and cachectic, and died at the age of 33
of respiratory insufficiency.
Case II-05 was a 30-year-old man who was prone to
violent behavior during his teens and had physically
attacked an officer during his compulsory military service
at age 18. Once expelled from the army, he was committed
to a psychiatric unit until the age of 22 years. When he was
23, he was reported for domestic violence and aggression in
the workplace. Medical records from that time describe a
mutacic patient with mild cognitive impairment and a com-
bination of depressive and psychotic symptoms, as well as
dysphagia and dysarthria. Neurological examination also
revealed the presence of “primitive” reflexes (sucking,
palmomental, and grasping), ataxic gait with bilateral pyra-
midal syndrome, and extrapyramidal features (bradykinesia
and hand dystonia). He died of cardiac arrest aged 30 years.
Case II-06 is a 38-year-old woman who had no significant
medical complaints until the age of 34. In view of her three
older brothers' clinical symptoms, she had been carefully
monitored since the age of 15 years and her parents had
reported only mild clumsiness and swerving while riding a
bike. At the age of 34, she began to display rude manners,
compulsory polyphagia, a major mood disorder, and auditory
hallucinations (often saying that dead relatives were inciting
her to commit suicide). Neurological examination at this time
revealed gait ataxia, bilateral finger–nose dysmetria, and in-
ability to perform tandem gait. Neuropsychological assess-
ment revealed significant impairment of attention,
psychomotor speed and language, as well as ideomotor aprax-
ia and memory loss. There were also clinical features sugges-
tive of pyramidal and extrapyramidal tract dysfunction.
Treatment with idebenone and haloperidol was attempted
without success.
All the patients were, at some time during the disease
course, screened for genetic alterations associated with
Friedreich ataxia, SCA1, SCA2, MJD1/SCA3 (Machado–
Joseph disease), SCA6, SCA7, SCA12, SCA17,
dentatorubropallidoluysian atrophy, and FXTAS. Screening
of the POLG, APTX, and SETX genes was negative in
patient II-01, as were whole mtDNA sequencing and screen-
ing of the genes encoding the structural component of CIII
(II-01 and II-04) and BCS1L (II-01 and II-06).
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Letter to the Editor
Identiﬁcation of maternal uniparental
isodisomy of chromosome 10 in a patient
with mitochondrial DNA depletion syndrome
Keywords:
C10orf2
MDS
Uniparental disomy
Chromosome 10
Twinkle
Twinkle, the mitochondrial helicase encoded by C10orf2, serves a key
function in mtDNA replication [1] and its mutations (http://www.hgmd.
cf.ac.uk/ac/gene.php?gene=C10orf2) associatewith a broad spectrum of
clinical conditions characterized by qualitative or quantitative defects of
mtDNA, including infantile-onset spinocerebellar ataxia, progressive ex-
ternal ophthalmoplegia, and the syndrome of hepatocerebralmtDNA de-
pletion (MDS) [2].
We studied a Portuguese child, born to unrelated healthy parents,
who presented hypotonia and Pierre-Robin sequence (MIM 311895)
with mandibular retrognathism, partial syndactyly of 2nd–3rd ﬁngers,
bilateral strabismus, and eyelid asymmetry. The child manifested severe
intellectual and developmental disability and nystagmus in the following
months. Brain MRI revealed brain atrophy and a thin corpus callosum
(Fig. 1A). Serum lactate levels were increased, OXPHOS activities in a
skeletal muscle biopsy were in the low normal range and there was
mtDNA depletion in muscle (~80% normal age matched controls).
In the patientwe identiﬁed two “in cis” homozygous splice sitemuta-
tions in C10orf2 ([c.1593-3TNC + c.1593-5CNT]; Fig. 1B) predicted in
silico to activate a new cryptic acceptor site and lead to missplicing. The
novelmutationswere heterozygous in themother and the healthy broth-
er whereas the father was wild-type. Once we had ruled out false pater-
nity and a multi-exon deletion on the paternal allele by MLPA, we
genotyped three microsatellite markers and 12 SNPs ﬂanking C10orf2
on chromosome 10q24. Whilst a number of markers were either
uninformative, SNP genotyping was also consistent with segmental uni-
parental isodisomic transmission (UPD) of thematernal chromosome 10
(Fig. 1C). A similar condition has already been reported for TYMP and
DGUOK [3,4] two other causes of MDS.
Description of UDP in a patient presenting mutations in Twinkle cor-
roborates the need of a full molecular examination of apparently homo-
zygous changes in MDS to deﬁne more precisely the risk of recurrence
in subsequent pregnancies.
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Fig. 1.Neuroimaging andmolecular studies in the patient harboring a maternal isodisomic inheritance of chromosome 10. A) Brain MRI (coronal and axial images). There was decreased
intensity in the posterior periventricular white matter and a thinner corpus callosum. No pathological signal changes were seen in the striatum, brainstem and dentate nuclei. B) Electro-
pherograms of the C10orf2 gene ﬂanking the homozygous splice site mutations ([c.1593-3TNC + c.1593-5CNT] identiﬁed in the patient (Pt). Wild-type sequence in a control (Ct) is also
shown. The mutated bases are indicated with an arrow. C) Segregation analysis of polymorphic microsatellite markers and single nucleotide polymorphisms ﬂanking the C10orf2 gene
suggested maternal UDP. Family tree: square, men; circle, women; ﬁlled symbol is the affected patient (arrow). M, C10orf2mutated sequences; Wt, wild-type sequence.
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Abstract 
Succinyl-CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible synthesis 
of succinate and adenosine triphosphate (ATP) from succinyl-CoA and adenosine diphosphate 
(ADP) in the tricarboxylic acid cycle. This enzyme is made up of an α and β subunits encoded by 
SUCLG1 and SUCLA2, respectively. We present a child with severe muscular hypotonia, dystonia, 
failure to thrive, sensorineural deafness and dysmorphism. Metabolic investigations disclosed 
hyperlactacidemia, moderate urinary excretion of methylmalonic acid and elevated levels of C4-
dicarboxylic carnitine in blood. We identified a novel homozygous p.M329V in SUCLA2. In 
cultured cells, the p.M329V resulted in a reduced amount of the SUCLA2 protein, impaired 
production of mitochondrial ATP, and enhanced production of reactive oxygen species (ROS) 
which was partially reduced by using 5-aminoimidazole-4-carboxamide ribonucleotide - AICAR - 
in the culture medium. Expanding the array of SUCLA2 mutations, we suggested that ROS 
scavengers have the likelihood to impact on disease prognosis. 
 
Keywords  
SUCLA2; Methylmalonic aciduria; Mitochondrial DNA depletion; Encephalomyopathy; Succinate-
CoA ligase 
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Introduction 
The encephalomyopathic form of infantile mitochondrial depletion syndrome associated with 
methylmalonic aciduria (MIM 612073) has been linked to mutations in SUCLA2 and in SUCLG1, 
the genes coding for the β and α subunits of the ADP-dependent isoform of succinyl-CoA synthase 
(SCS) (EC 6.2.1.5), respectively. SCS is a mitochondrial matrix enzyme that catalyzes the 
reversible synthesis of succinyl-CoA from succinate and coenzyme A (CoA). The reverse reaction 
occurs in the Krebs cycle, while the forward reaction may produce succinyl-CoA for activation of 
ketone bodies and heme synthesis. SCS is made of an invariant α subunit encoded by SUCLG1 and 
a β subunit that determines the enzymatic nucleotide specificity. The Adenosine triphosphate 
(ATP)-specific β subunit encoded by SUCLA2 catalyzes ATP dependent reactions, and the 
Guanosine triphosphate (GTP)-specific β subunit encoded by SUCLG2 is a component of the 
second SCS isoform (EC 6.2.1.4) which catalyzes guanosine diphosphate-dependent reactions.
1-4
 
The SUCLA2 protein is mostly expressed in brain, skeletal muscle, and heart and its pattern of 
expression may be related to the high energy demand of those catabolic tissues.
5,6
 Several studies 
have suggested that SUCLA2 forms a complex with nucleoside diphosphate kinase (NDPK), that is 
important for the salvage of deoxyribonucleotides for mitochondrial DNA (mtDNA)  synthesis and 
directly implicate the GTP-specific β subunit in control of mtDNA copy number.
6
 
A “mildly” elevated urinary methylmalonic acid (MMA) in combination with a characteristic 
metabolite profile (that is, elevated methylcitrate, lactate, carnitine esters, 3-hydroxyisovaleric acid) 
represent useful “red flag” for a SCS disorder. Other metabolic findings usually consist of elevated 
C4-dicarboxylic carnitine in blood, elevated plasma MMA and high lactate concentration. Patients 
with low enzyme activity usually die as infants (often suddenly), but some of them have a longer 
survival and present clinical features suggestive of mitochondrial encephalomyopathy, including 
psychomotor delay and, almost invariably, progressive dystonia and hearing loss.
7
 To date, 32 
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individuals harboring mutations in SUCLA2 have been described often presenting combined 
multiple deficiencies of the mitochondrial respiratory chain.
8
 
We here report an additional patient carrying a novel mutation in SUCLA2 in association with 
progressive failure to thrive, muscle weakness and deafness. We also investigated in primary cells 
the functional consequences of the mutation. 
Case Report  
Clinical and metabolic investigations were performed in a 2-year-old child presenting since birth 
with facial dysmorphism, severe muscular hypotonia with muscular atrophy and failure to thrive. 
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This is the first child born to healthy, unrelated parents. Pregnancy and delivery were uneventful. 
Apgar scores were 9 and 10 at 1 and 5 minutes, respectively. Birth weight was 3kg, height 50 cm, 
and head circumference was 34.5 cm (50
th
 centile). Since birth the baby boy presented with 
hypotonia and frequent vomiting. Growth retardation and developmental delay were noticed since 
the age of 3 months. Initial investigations disclosed a male karyotype with normal thyroid, renal and 
hepatic functions, as well as normal blood lactate levels. Plasma amino acids and urinary organic 
acid profiles showed unspecific abnormalities. Cardiac ultrasound was normal whereas brain MRI 
disclosed slight cerebral atrophy and normal myelin pattern. The patient was later referred to the 
Hospital Pediátrico de Coimbra at age 16.5 months because of a possible inherited disorder of 
metabolism. At that age, his physical examination was significant for developmental delay, failure-
to-thrive, microcephaly, muscular atrophy with dystonic posturing, recurrent vomiting and high 
ammonia level (115 µM, normal: 25-44µM) in blood. 
Genomic DNA was purified from peripheral blood using standard procedures. The coding exons 
and exon-intron boundaries of SUCLA2 [NM_003850.2] and SUCLG1 [NM_003849.3] were 
sequenced using the BigDye v3.1 chemistry (Applied Biosystems, Foster City, CA) as described 
elsewhere.
4
 Large scale, multi-exon deletions were analyzed by MLPA using commercially 
available SALSA MLPA P089 probemix (MRC-Holland, The Netherlands). 
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Human fibroblasts were obtained from a punch biopsy of skin and grown in regular Dulbecco's 
Modified Eagle's Medium (DMEM) medium unless otherwise stated. For SDS-PAGE analyses of 
cultured cells, we used methodologies familial to our laboratories, and employed the following 
monoclonal antibodies: complex I-39 kDa subunit (1:500, NDUFA9); complex II-70 kDa subunit 
(1:10.000, SDHA); complex III (1:500,  Core2); complex IV-subunit II (1:500, CoxII); complex V-
subunit alpha (1:500, ATP α); anti-porin (1:5000). All antibodies were from MitoSciences (Abcam, 
Cambridge, MA). We also used a polyclonal anti-SUCLA2 antibody (1:1000, Abcam).
9
 
For cellular studies, cultured skin fibroblasts were grown in DMEM or in glucose-free medium 
supplemented for 72 hrs with 5 mM galactose to induce a stress condition, as reported, with or 
without the following additives: 0.5 mM 5- aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) (Tocris, Bioscience, Bristol, UK) and 500 µM H2O2  (Sigma-Aldrich, St. Louis, MO).
10
 
MtDNA copy number in fibroblasts was investigated by a described qPCR assay in real-time and 
results compared to the levels seen in cells obtained from five age and sex-matched controls.
11
 
Cells (1×10
4
), incubated in a 96-well plate, were analyzed 72h post-treatment for rate of reactive 
oxygen species (ROS). After washing with respiration buffer (142 mM NaCl, 10 mM HEPES, 2 
mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1 mM MgSO4, pH 7.4) supplemented with 1% fetal calf 
serum (FBS) (ROS buffer), we added 5 µM 5-(and-6)-chloromethyl-2,7-dichlorodihydro-
flouorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular Probes, Invitrogen, Paisley, UK) in 
100 µl of ROS buffer just prior incubation (15 min at 37°C). After washing with the same buffer, 
cells were incubated 30 min at 37°C with 100 µl of ROS buffer with or without 500µM of H2O2. 
Plates were subsequently washed with the same buffer, 100 µl of ROS buffer were added and 
fluorescence detected. Fluorescence was measured at excitation and emission wavelengths of 490 
nm and 527 nm, respectively, using a Varian Cary Eclipse Fluorescence plate reader (Agilent 
Technologies, Santa Clara, CA). 
PEER REVIEW
 ONLY
Page 6 of 16
Confidential Material
Journal of Child Neurology
6 
 
Total ATP levels were measured using the Luminescence ATP Detection Assay System 
(PerkinElmer Life Sciences, Waltham, MA). Briefly, 1 x 10
4
 cells were seeded in a 96-well plate 
and incubated 48h in DMEM. Plates were then washed with ATP record buffer (156mM NaCl, 
3mM KCl, 2 mM MgSO4, 1.25mM KH2PO4, 2 mM CaCl2, 20mM HEPES, pH 7.35) and incubated 
2h in ATP record buffer with the following conditions: 10 mM glucose; 10 mM glucose plus 2.5 
µg/ml oligomycin (glycolytic ATP generation) and 5 mM 2-deoxy-Dglucose plus 5 mM pyruvate 
(oxidative ATP production). Cells were incubated with the luciferin/luciferase reagent and the ATP 
production in samples was measured using an Orion L microplate luminometer (Berthold Detection 
Systems GmbH, Pforzheim, Germany).
12
 
Results 
During hospitalization, metabolic workup in the proband revealed a compensated metabolic 
acidosis with persistently high serum lactate (2.2 to 9 mM, normal < 1.3), and elevated 
lactate/pyruvate ratio (>25, normal: <10). There were also fluctuating hyperammonemia (up to 75 
µM), high alanine, proline and glycine levels in plasma, “mildly” elevated urinary MMA and 
significantly high urinary levels of Krebs cycle intermediates. Acylcarnitine profile in blood 
showed an elevated C4-dicarboxylic carnitine (C4DC). Brainstem auditory evoked potentials 
showed a pattern suggestive of moderate sensorineural hearing loss. Based on laboratory findings, 
the patient was put on a protein restricted diet, with nasogastric tube feeding and combined vitamins 
(B1, B2, B9 and coenzyme Q10 supplementation. At the age of 18 months, the child manifested 
axial hypotonia (no head control), severe generalized dystonia, muscle wasting and constipation. 
All anthropometric parameters were below the 5
th
 centile (weight 7.1 kg, height 76.8 cm, head 
circumference 45.2 cm) in spite of adequate caloric intake. Brain MRI scans showed worsening of 
cerebral atrophy and slightly abnormal signals in deep brain (Figure 1). At age 24 months, the 
child’s global developmental quotient (DQ) was below 50 (< 1 centile), with a mental age of 6 
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months (using the Griffths scale.
13
 Since parents refused to grant permission for a diagnostic muscle 
biopsy, the child underwent a punch skin biopsy with written parental consent.  
Direct sequencing of SUCLA2 in blood DNA revealed a homozygous c.985A>G/p.M329V in 
exon 8 (Figure 2A) whereas no mutations were seen in SUCLG1 and SUCLG2. The parents were 
heterozygous carriers of the p.M329V mutation. The missense change was novel and not detected in 
a large set of in-house ethnically-matched control chromosomes and in dbSNP 
(www.ncbi.nlm.nih.gov/projects/SNP/) and Exome Variant database (evs.gs.washington.edu/EVS/). 
The mutation seems predictably deleterious after assessments in silico with Condel 
(bg.upf.edu/condel/), SIFT (sift.jcvi.org/), Mutation Taster (www.mutationtaster.org/), and 
Polyphen 2 (genetics.bwh.harvard.edu/pph2/index.shtml) and affects an amino acid that is highly 
conserved in different species (Figure 2B). A moderate reduction of mtDNA copy number (on 
average, 69% of normal controls) was observed in cultured skin fibroblasts after replacing galactose 
for glucose in the cell medium. Western blotting showed a ∼30% decrease of SUCLA2 protein in 
patient’s fibroblasts (Figure 2C) with normally expressed components of the respiratory chain 
complexes. Total and mitochondrial ATP productions in skin fibroblasts were 22% and 50% 
(p<0.03), respectively when compared to normal control values (Figure 3A). We also observed a 
statistically significant increase of ROS production in basal condition and after short-term H2O2 
treatment (Figure 3B, p<0.05). ROS production was restored to normal levels upon treatment with 
0.5 mM AICAR, a compound known to enhance cellular oxidative metabolism.
10
  
Discussion 
This case offers at least two significant points for discussion. The clinical and biochemical 
phenotype of our patient is highly similar to previously reported children harboring mutations in 
SUCLA2 and it represents the first evidence of a SCS disorder in Portugal, widening the ethnic and 
allelic presentation of the disease.
4
 The novel mutation meets several canonical criteria for 
pathogenicity. First, it was homozygous in the child and heterozygous in the parents, but absent in 
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polymorphic databases or in over 200 ethnically matched controls. Second, the mutation affects a 
residue highly conserved during evolution and it is associated with a reduced amount of protein in 
cultured primary cells. Third, the mutation affected mitochondrial production of ATP and resulted 
in low mtDNA abundance in cultured cells. Reduction of mtDNA copy number, ranging from 50% 
and 60% of control values, has been shown in previous patients carrying loss-of-function mutations 
in SUCLA2.
4
 A higher reduction is expected to occur in skeletal muscle or brain. Our data further 
confirm that the combined biochemical profile outlined in the introduction is suggestive of SCS 
disease. 
An additional observation arising from our study relies on the reduction on ROS production upon 
AICAR treatment in cells from a SUCLA2 patient. AICAR has already been shown to improve 
growth and ATP content in cells harboring mutations in genes encoding subunits of the respiratory 
chain complexes I and IV and it is said to fight the pathological mechanisms in a mouse model of 
mitochondrial encephalomyopathy.
10,14
 As a pharmacological activator of AMP activated protein 
kinase (AMPK), AICAR might play a key role in the regulation of energy homeostasis, increasing 
mitochondrial biogenesis without altering mitochondrial membrane potential.
10
 Our data suggest 
that AICAR has the possibility to raise ATP production and counteract ROS production even in 
cases with likely impaired mtDNA biogenesis. If induction of mitochondrial biogenesis has a 
“therapeutic” role, or influences mechanisms fighting apoptotic cell death, or both will require 
further investigation.
15
 
 
Page 8 of 16
Confidential Material
Journal of Child Neurology
PEER REVIEW
 ONLY
9 
 
Acknowledgments 
We thank family members who helped in retrieving old medical records and encouraged us 
throughout the study. We are also grateful to Mrs. Lurdes Lopes for professional technical support 
and Dr Catherine Wrenn for editorial assistance.  
 
Author contribution 
Study concept and design: CeN, FMS. Acquisition of data: CeN, MCM, CaN, PG, LD, CV, RiC. 
Analysis and interpretation of data: CeN, PG, LD, AV, LV, FMS. Drafting the manuscript: CeN, 
FMS. Critical revision of the manuscript for important intellectual content: PG, LD, AV, LV. Study 
supervision: CeN, LV, FMS. All authors read and approved the final manuscript. 
 
Conflict of interest 
The authors declare that they have no conflict of interest. 
 
Founding 
This work was partially supported by the National Institute of Health, INSA (to LV). Dr. 
Nogueira’s work was performed as part of her PhD thesis under the rules of the Portuguese 
Foundation for Science and Technology (SFRH/BD/45247/2008). The Transnational Cooperation 
between FCT/CAPES 2013/2014 partially supported, as well, the work of both researchers (Project 
6818). 
 
Ethical approval 
This study was approved by the Institutional ethics committee of the National Institute of Health, 
INSA, Porto, Portugal. 
 
Page 9 of 16
Confidential Material
Journal of Child Neurology
PEER REVIEW
 ONLY
10 
 
References 
1. Johnson JD, Mehus JG, Tews K, et al. Genetic evidence for the expression of ATP- and GTP-
specific succinyl-CoA synthetases in multicellular eucaryotes. J. Biol. Chem. 1998; 273:27580-
27586. 
2. Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase 
activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am. J. Hum. 
Genet. 2005; 76:1081-1086. 
3. Ostergaard E, Hansen FJ, Sorensen N, et al. Thorgrimsson, F. Wibrand, E. Christensen, M. 
Schwartz, Mitochondrial encephalomyopathy with elevated methylmalonic acid is caused by 
SUCLA2 mutations. Brain. 2007; 130:853-861. 
4. Carrozzo R, Dionisi-Vici C, Steuerwald U, et al. SUCLA2 mutations are associated with mild 
methylmalonic aciduria, Leigh-like encephalomyopathy, dystonia and deafness. Brain. 2007; 
130:862-874.  
5. Sakamoto O, Ohura T, Murayama K, et al. Neonatal lactic acidosis with methylmalonic aciduria 
due to novel mutations in the SUCLG1 gene. Pediatr Int. 2011; 53:921-925.  
6. Ostergaard E, Schwartz M, Batbayli M, et al. A novel missense mutation in SUCLG1 associated 
with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria. Eur J 
Pediatr. 2010; 169:201-205.  
7. Nogueira C, Carrozzo R, Vilarinho L, et al. Infantile-onset disorders of mitochondrial replication 
and protein synthesis. J Child Neurol. 2011; 26:866-875.  
8. Jaberi E, Chitsazian F, Ali Shahidi G, et al. The novel mutation p.Asp251Asn in the β-subunit of 
succinate-CoA ligase causes encephalomyopathy and elevated succinylcarnitine. J Hum Genet. 
2013; 58:526-530. 
Page 10 of 16
Confidential Material
Journal of Child Neurology
PEER REVIEW
 ONLY
11 
 
9. Ferreira M, Torraco A, Rizza T, et al. Progressive cavitating leukoencephalopathy  associated 
with respiratory chain complex I deficiency and a novel mutation in NDUFS1. Neurogenetics. 
2011; 12:9-17. 
10. Golubitzky A, Dan, S. Weissman P, et al. Screening for active small molecules in mitochondrial 
complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound. PLoS 
One. 2011; 6(10):e26883. 
11. Blakely E, He L, Gardner JL, et al. Novel mutations in the TK2 gene associated with fatal 
mitochondrial DNA depletion myopathy. Neuromuscul Disord. 2008; 18:557-560. 
12. McKenzie M, Liolitsa D, Akinshina N, et al. Mitochondrial ND5 gene variation associated with 
encephalomyopathy and mitochondrial ATP consumption. J Biol Chem. 2007; 282:36845-36852.  
13. Griffiths R. The abilities of young children. London: University of London press; 1984. 
14. Viscomi C, Bottani E, Civiletto G, et al. In vivo correction of COX deficiency by activation of 
the AMPK/PGC-1α axis. Cell Metab. 2011; 14:80-90.  
15. Dam AD, Mitchell AS, Quadrilatero J. Induction of mitochondrial biogenesis protects against 
caspase-dependent and caspase-independent apoptosis in L6 myoblasts. Biochim Biophys Acta. 
2013; 1833:3426-3435. 
Page 11 of 16
Confidential Material
Journal of Child Neurology
PEER REVIEW
 ONLY
12 
 
Legend to figures 
 
Figure 1 – Brain MRI scan of the patient at the age of 18 months. Imaging disclosed mild 
cerebral atrophy and a slight hyopointensity of basal ganglia. Coronal (a), sagittal (b) and axial (c) 
scans are shown. Arrows indicate deep brain structures. 
 
Figure 2 – Molecular analyses in a novel SUCLA2 patient. A) Electropherograms of the SUCLA2 
gene flanking the homozygous c.985A>G/p.M329V in the index case (Pt). The wild-type sequence 
in a control (Ct) is also shown. Arrow indicates the mutated base. B) Prediction of functional effects 
of human variations using in silico analyses with PolyPhen-2, ClustalW aligment, and Sift 
prediction. C) Representative immunoblot analysis of fibroblasts homogenates from control (Ct) 
and patient (Pt) using specific antibodies against SUCLA2 and subunits of complex III (Core 2) and 
complex I (ND39). Porin was used to control for equal loading. The histogram shows the residual 
levels in the patient as compared to controls (n= 5) whose values were arbitrarily set as 100. Data 
represents the mean ± SD of three different determinations. 
 
Figure 3 – Biochemical analyses in cells harboring the new c.985A>G/p.M329V in SUCLA2. 
A) Luminometric measurement of ATP expressed as relative luminescence units (RLU), in skin 
fibroblasts from controls (Ct) and patient (Pt) cultured in regular DMEM medium (RM) for 48 h. 
Cells were incubated 2 h in ATP record buffer supplemented with 10mM glucose (Glu), 2.5 µg/ml 
oligomycin (Oligo) and 5 mM 2-deoxy-Dglucose plus 5 mM pyruvate (2GD+Pyr). Data represents 
the mean ± SD of three different determinations. B) Reactive oxygen species (ROS) production 
measured by CM-H2DCFDA and expressed as % of relative fluorescent units (RFU) in skin 
fibroblasts from controls (Ct) and the patient (Pt). Cells were cultured in medium supplemented 
with galactose (GAL) or  Gal+5-Aminoimidazole-4-carboxamide ribotide (AICAR) 0.5mM, and 
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incubated with or without 0.5mM H2O2 for 30 min. Data are mean ± SD of three different 
determinations. Significance (*) was set at p<0.05. 
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RESUMO: 
As citopatias mitocondriais constituem um importante grupo de doenças metabólicas de 
expressão clínica heterogénea, para as quais não existe uma terapia eficaz. A maioria das 
doenças mitocondriais descritas são causadas por uma disfunção ao nível da fosforilação 
oxidativa (OXPHOS), originando consequentemente uma deficiente produção de energia. O 
correto funcionamento da OXPHOS resulta de uma interação coordenada entre o genoma 
nuclear e mitocondrial. Assim, as doenças mitocondriais podem ser causadas por defeitos 
moleculares no genoma mitocondrial, no nuclear, ou em ambos, originando doenças da 
comunicação intergenómica. Estas doenças resultam na perda ou na instabilidade do DNA 
mitocondrial (mtDNA), e podem causar quer deleções múltiplas, quer depleção do genoma 
mitocondrial.  
As doenças da comunicação intergenómica adquiriram bastante relevância nos últimos anos 
tendo sido descritos um vasto número de genes associados a estas patologias, e podem ser 
divididas em dois grandes grupos: i) o síndrome das deleções múltiplas do mtDNA, que se 
caracteriza pelo aparecimento de miopatias oculares e dos membros e ii) o síndrome da 
depleção do mtDNA, que constitui um grupo de doenças autossómicas recessivas que se 
manifestam durante a infância ou início da adolescência com três apresentações clínicas 
distintas, nomeadamente miopática, encefalomiopática e hepatocerebral. 
Neste trabalho pretendeu-se realizar uma revisão bibliográfica no sentido de apurar o 
“estado da arte” em relação às doenças de comunicação intergenómica. Serão abordados 
desde os fenótipos clínicos ao espetro mutacional e apresentado um algoritmo de 
diagnóstico, que possa ser uma ferramenta útil para os clínicos que se dedicam ao 
diagnóstico e follow-up deste tipo de patologias. 
 
 
PALAVRAS-CHAVE: depleção do mtDNA, deleções múltiplas do mtDNA, doenças da 
comunicação intergenómica. 
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Nuclear-mitochondrial intergenomic communication disorders: clinical and laboratory 
approach 
 
ABSTRACT: 
Mitochondrial dysfunction accounts for an important and heterogeneous group of inherited 
metabolic disorders with hitherto no effective therapeutic options. Most of the known 
mitochondrial disorders are caused primarily by a dysfunctional oxidative phosphorylation 
(OXPHOS) and consequently a deficient energy production. OXPHOS depends on the 
coordinated expression of both nuclear and mitochondrial genomes. Therefore, mitochondrial 
diseases can be caused by genetic defects in the mitochondrial or the nuclear genome or in 
the interplay between the two genomes, causing nuclear-mitochondrial intergenomic 
communication disorders, that result in loss or instability of mtDNA leading to either 
qualitative (multiple deletions) or quantitative (depletion) lesions of mitochondrial genome. 
The mitonuclear crosstalk has gained increased relevance in the past years and since then 
many genes have been identified as being involved in these diseases. The problems faced 
by patients with mitochondrial cross-talk disorders, and mitochondrial disorders in general, 
are particularly severe. Multiple mtDNA deletion syndrome share features such as ocular and 
limb myopathy (PEO, ptosis, proximal weakness), which are almost always associated with 
extramuscular system involvement. From a clinical point of view mitochondrial DNA depletion 
syndrome (MDS) comprises a heterogeneous group of autosomal recessive disorders 
occurring in infancy or early childhood. It can be divided into three clinical categories: 
myopathic, encephalomyopathic and hepatocerebral MDS. 
The focus of this review is to provide an overview of intergenomic communication disorders, 
a list of clinical phenotypes accompanied by their mutational spectrum and a diagnostic 
algorithm, which can be useful for clinicians when facing similar cases.  
KEY-WORDS: Mitochondrial DNA depletion syndrome, Mitochondrial DNA multiple 
deletions, Mitochondrial diseases, Intergenomic communication disorders.  
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INTRODUÇÃO 
Nos últimos 30 anos, um largo espectro de doenças multissistémicas associadas a 
disfunções da mitocôndria, designando-se globalmente de citopatias mitocondriais, têm sido 
referenciadas, com início dos sintomas desde o período neonatal até à idade adulta.1 Estas 
disfunções podem afectar qualquer órgão ou tecido do organismo, embora os músculos 
esquelético e cardíaco, e o sistema nervoso central (SNC) sejam os mais afectados, devido 
à sua elevada dependência do metabolismo energético. Assim se compreende que as 
formas de apresentação mais frequentes incluam miopatia, encefalo(mio)patia e 
oftalmoplegia externa progressiva (PEO). Aproximadamente 1:5000 indivíduos na população 
adulta e infantil possuem doenças mitocondriais ou correm o risco de as virem a 
desenvolver.2 Estes resultados revelam que estas doenças são uma causa comum de 
mortalidade e/ou morbilidade crónica, não estando disponível, até ao momento, nenhuma 
terapia eficaz. 
Desde 1988 que a investigação molecular das citopatias mitocondriais tem sido focada no 
DNA mitocondrial (mtDNA) nomeadamente na pesquisa de rearranjos do mtDNA (deleções 
simples de diferentes tamanhos e duplicações) e pesquisa de mutações pontuais quer nos 
genes estruturais quer nos 22 tRNAs e dois RNAs.3 Neste sentido, para aprofundar o 
conhecimento das citopatias mitocondriais em Portugal, implementou-se em 1993, na nossa 
Unidade, o estudo enzimático da cadeia respiratória mitocondrial (CRM) e posteriormente o 
estudo molecular do mtDNA.4,5,6,7 
Nos últimos anos a investigação destas doenças tem-se centrado na pesquisa de mutações 
no DNA nuclear (nDNA), em genes que codificam subunidades estruturais da CRM / 
fosforilação oxidativa (OXPHOS), genes necessários à montagem das mesmas ou 
envolvidos na comunicação intergenómica.  
 As doenças da comunicação intergenómica tornaram-se num foco de estudo importante, 
dado que a grande maioria das proteínas mitocondriais é codificada pelo nDNA 
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necessitando de serem importadas para a mitocôndria por mecanismos complexos, 
igualmente sob o controlo do genoma nuclear. Assim, neste trabalho efetuou-se uma revisão 
da literatura sobre este tema, focando os principais grupos de patologias, fenótipos clínicos 
e espetro mutacional.  
 
MANIFESTAÇÕES CLÍNICAS E ETIOLOGIA MOLECULAR DAS PATOLOGIAS QUE 
AFETAM A INTEGRIDADE DO MTDNA 
A integridade do mtDNA é mantida e controlada por um mecanismo complexo que envolve 
vários elementos do replissoma mitocondrial e diversas enzimas e transportadores que 
fornecem à mitocôndria os nucleótidos necessários (Fig. 1). Todos estes componentes são 
codificados pelo nDNA, logo mutações nos genes envolvidos na replicação e manutenção 
do mtDNA podem comprometer a sua integridade8 causando quer deleções múltiplas quer 
depleção do mtDNA.9 Nos últimos anos tem sido dada muito relevância à comunicação entre 
os dois genomas (comunicação intergenómica) e muitos genes têm sido identificados como 
estando envolvidos neste grupo de citopatias mitocondriais. 
A tabela 1 sumariza as principais manifestações clínicas associadas ao síndrome das 
deleções múltiplas e da depleção do mtDNA (MDS), assim como a etiologia molecular 
relacionada com cada um deles. 
 
1. Síndrome das deleções múltiplas do mtDNA 
As doenças mitocondriais associadas à presença de deleções múltiplas do mtDNA ocorrem 
mais frequentemente em adultos e podem apresentar, na sua maioria, um padrão de 
hereditariedade autossómica recessivo (AR) ou dominante (AD), sendo este último mais 
frequente.10 O tamanho das diferentes deleções do  mtDNA é variável, até mesmo em 
doentes da mesma família. O espetro mutacional do síndrome das deleções múltiplas do 
mtDNA tem vindo a aumentar devido à descoberta de cada vez mais genes associados à 
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instabilidade do mtDNA. Seguidamente será efetuada uma breve descrição das principais 
manifestações clínicas e as etiologias moleculares associadas. 
 
i) PEO (Oftalmoplegia Externa Progressiva autossómica dominante ou recessiva) 
As características clínicas mais comuns da PEO no adulto incluem a fraqueza dos músculos 
oculares externos, ptose bilateral, fraqueza muscular proximal e intolerância ao exercício. 
Sintomas como a presença de cataratas, perda de audição, neuropatia axonal sensorial, 
ataxia, depressão, hipogonadismo, e parkinsonismo também podem ocorrer. Características 
menos comuns incluem prolapso da válvula mitral, cardiomiopatia e alterações da motilidade 
gastrointestinal. Os indivíduos afetados apresentam deleções múltiplas ao nível do mtDNA 
que se encontram exclusivamente nos tecidos musculares. 
Mutações nos genes POLG, POLG2, C10orf2, SLC25A4, TK2, RRM2B, DGUOK, MGME1 
OPA1 e MFN2, encontram-se associados a PEO podendo apresentar uma hereditariedade 
AR ou AD sendo a forma AR geralmente mais grave.10,11  
Seguidamente são referidos os principais genes envolvidos na etiologia molecular de PEO 
associados ao síndrome das deleções múltiplas.  
 
POLG: a mitocôndria contêm uma única DNA polimerase, a polimerase gama (POLγ), 
imprescindível na embriogénese desde muito cedo.12 A POLγ é codificada pelo nDNA sendo 
a única polimerase exclusivamente responsável pela replicação e reparação do mtDNA e 
essencial na sua manutenção. A POLγ é composta por uma subunidade catalítica , POLγA , 
que possui atividade de polimerase e de exonuclease; e uma subunidade acessória, POLγB, 
que aumenta a ação da enzima.13 A POLγ juntamente com o mtDNA, a helicase do mtDNA 
e as diversas proteínas de ligação formam o complexo de replicação funcionante.14  
As mutações no mtDNA eram consideradas a principal causa de doenças mitocondriais 
principalmente nos adultos, no entanto tem-se vindo a verificar que as patologias 
mitocondriais estão também associados a uma deficiente replicação do mtDNA. As 
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mutações que se encontram na POLγA são uma das principais causas da doença 
mitocondrial podendo associar-se a uma grande variedade de sintomas clínicos, para além 
de PEO, tais como, Parkinsonismo, Sindrome de Alpers - Huttenlocher, encefalomiopatia 
neurogastrointestinal mitocondrial (MNGIE), neuropatia, ataxia sensorial, disartria e 
oftalmoparesia (SANDO) e ataxia espinocerebelar e epilepsia (SCAE).15,16,17 
O gene POLG está localizado no cromossoma 15 e é composto por 23 exões que se 
extendem ao longo de 18,55 Kb. O gene foi identificado em 199618, mas somente em 2001 
foi descrita a primeira mutação patogénica.19 Desde então, mais de 200 mutações foram 
publicadas sendo este gene um hot-spot para mutações em doenças mitocondriais (Human 
Gene Mutation Database- HGMD, POLG database).20 Mutações neste gene podem 
apresentar uma hereditariedade AD ou AR ou até a mesma mutação pode apresentar 
ambos os padrões de hereditariedade.21,22 
Na forma AD de PEO causada por mutações no gene POLG (mais frequente), os doentes 
apresentam geralmente disfagia grave e disfonia e ocasionalmente, Parkinsonismo e 
disfunção cerebelar. Até à data mais de 65 mutações foram descritas no gene POLG como 
estando associado com a PEO (HGMD). No entanto, mutações neste gene podem também 
ser associadas à forma hepatocerebral de MDS.15 
 
POLG2: a POLG2, a subunidade acessória da DNA polimerase gama, aumenta a eficiência 
da enzima. Alterações nesta subunidade podem causar acumulação de deleções do mtDNA. 
O gene POLG2, localizado no cromossoma 17, é composto por oito exões que se extendem 
ao longo de 19,28 Kb. Em 2006, a primeira mutação patogénica foi descrita como estando 
associada à forma AD de PEO.23 No entanto, estão descritas mais 12 mutações neste gene 
associadas a fenótipos mitocondriais inespecíficos (HGMD).  
 
C10orf2 (Twinkle): a helicase/primase mitocondrial codificada pelo gene C10orf2 também é 
responsável pela forma AD de PEO.24 Mutações neste gene estão associadas a 
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apresentações clínicas que podem apresentar PEO ''puro'', ou uma forma mais complexa de 
PEO associada a fraqueza muscular proximal dos membros e músculos faciais, disfagia e 
disfonia, ataxia, e neuropatia periférica.  
O gene C10orf2 está localizado no cromossoma 10, sendo composto por 5 exões ao longo 
de 6,38 kb. A primeira mutação patogénica, associada com PEO, foi descrita em 200124 e 
desde então mais de 40 mutações patogénicas foram descritas, das quais 39 associadas a 
PEO (HGMD). Também foram descritas mutações associadas à forma hepatocerebral de 
MDS.25,26 
 
SLC25A4 (ANT1): este gene codifica o transportador mitocondrial de adenina específico do 
músculo cardíaco (ANT1). A proteína ANT1 é a proteína mitocondrial mais abundante e, no 
seu estado funcional, é um homodímero de subunidades de 30 kD incorporados 
assimetricamente na membrana mitocondrial interna. O dímero forma um poro através do 
qual o ADP é transportado da matriz para o citoplasma. Nos mamíferos podem distinguir-se 
quatro isoformas específicas em diferentes tecidos.  
O gene SLC25A4 está localizado no cromossoma 4 e possui 4 exões distribuídos ao longo 
de 4,04 Kb. As primeiras mutações patogénicas foram descritas em 200027 e, desde então, 
apenas nove mutações estão referenciadas. Cinco destas estão associadas a AD de PEO, 
cujos doentes apresentam miopatia progressiva lenta com poucos ou nenhuns sintomas 
extra-musculares, três estão associadas a miopatia e a cardiomiopatia hipertrófica e a 
restante mutação descrita foi identificada num doente com SANDO. 
 
MGME1: o gene MGME1 foi recentemente descrito28 e localiza-se no cromossoma 20. É 
composto por quatro exões e codifica uma exonuclease mitocondrial que é essencial para 
uma síntese eficaz do mtDNA. É a primeira exonuclease mitocondrial identificada a estar 
envolvida na replicação do mtDNA, podendo ter uma função adicional de reparação, através 
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do reposicionamento da cadeia de DNA ou das estruturas de DNA-RNA durante a síntese 
do mtDNA. 
Encontram-se descritas duas mutações em três famílias distintas com PEO, que apresentam 
perda de peso severa e insuficiência respiratória.28 As biópsias musculares dos doentes 
identificados revelaram quer deleções múltiplas, quer depleção do mtDNA. 
 
ii) SANDO (neuropatia, ataxia sensorial, disartria e oftalmoparesia) 
SANDO é uma doença sistémica, autossómica recessiva, caracterizada principalmente pelo 
aparecimento de neuropatia, ataxia sensorial, disartria e oftalmoparésia em adultos. O 
fenótipo é muito variável, mesmo dentro da mesma família, e pode ainda incluir miopatia, 
convulsões e perda de audição.29 Foram descritas 14 mutações no gene POLG associadas 
a este fenótipo (HGMD).16 
 
iii) SCAE (epilepsia e ataxia espinocerebelar) 
SCAE é uma patologia semelhante a SANDO mas com uma maior frequência de 
enxaquecas e convulsões.30 Estão descritas quatro mutações no gene C10orf2 e uma no 
gene POLG associadas a esta doença. 
 
iv) MNGIE (encefalomiopatia neurogastrointestinal mitocondrial) 
MNGIE é uma doença AR com início entre a segunda e quinta décadas de vida 
caracterizada clinicamente por PEO, (pseudo)dismotilidade gastrointestinal, caquexia, 
leucoencefalopatia difusa, neuropatia periférica e morte precoce. Ao nível do mtDNA podem 
ser observadas deleções múltiplas e/ou depleção do mtDNA.31 Mutações nos genes TYMP e 
RRM2B e mais recentemente no gene POLG32 foram associados a este fenótipo. 
Seguidamente é referido o principal gene envolvido na etiologia molecular de MNGIE. 
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TYMP (ECGF1): o gene TYMP codifica a enzima timidina fosforilase (TP), que está 
envolvida no catabolismo das pirimidinas. Défices da enzima TP levam a uma acumulação 
sistémica de timidina e deoxiuridina, o que leva a um desequilíbrio da pool de 
deoxinucleótidos e consequentemente a uma instabilidade do mtDNA, originando o 
aparecimento quer de deleções múltiplas quer de depleção do mtDNA muscular.33 
O gene TYMP está localizado no cromossoma 22 e é composto por 10 exões que se 
estendem ao longo de 4,3 kb. As primeiras mutações patogénicas foram descritas por 
Nishino e colaboradores33 e, desde então, 85 mutações associadas a este fenótipo foram 
publicadas, a maioria no gene TYMP e as restantes distribuídas pelos genes RRM2B e 
POLG. 
 
 
2. Síndrome da depleção do mtDNA (MDS) 
O MDS caracteriza-se por uma redução acentuada do número de cópias do mtDNA e 
constitui um grupo de doenças raras e devastadoras que se manifestam maioritariamente 
logo após o nascimento, causando a morte prematura de muitos doentes durante a infância 
ou início da adolescência. Este síndrome é transmitido de modo AR, sendo genética e 
fenotipicamente heterogéneo e podendo apresentar-se sob três formas: miopática, 
encefalomiopática e hepatocerebral. Embora a maioria destas manifestações ocorram em 
tecidos específicos, afetando fundamentalmente o fígado, o músculo ou o cérebro, outros 
tecidos podem também ficar comprometidos com a evolução da doença.34 O seu 
mecanismo fisiopatológico está relacionado com a manutenção da pool de nucleótidos 
mitocondriais, que assume um papel crucial na replicação e integridade do mtDNA. 
Um défice múltiplo da CRM, e ainda mais crucial, o baixo rácio de mtDNA/nDNA nos tecidos 
afetados, ou seja, a depleção do mtDNA (superior a 65%), confirma o diagnóstico clínico 
deste síndrome. 
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Seguidamente é efetuada uma breve descrição das principais formas de MDS, assim como 
dos genes envolvidos na sua etiologia molecular. 
 
i) Forma Hepatocerebral 
A forma hepatocerebral é a apresentação mais comum de MDS. O aparecimento ocorre na 
infância (entre o nascimento e os 6 meses de vida) e os sintomas iniciais incluem vómitos 
persistentes, atraso de crescimento, hipotonia e hipoglicemia. As mitocôndrias do fígado 
apresentam normalmente, uma deficiência combinada dos complexos da CRM codificados 
pelo mtDNA. A morte ocorre normalmente dentro do primeiro ano de vida. Uma 
apresentação peculiar da forma hepatocerebral é o síndrome de Alpers-Huttenlocher, de 
aparecimento precoce e fatal, caracterizado por falência hepática, convulsões, evoluindo 
para epilepsia parcial contínua e deterioração neurológica global. A disfunção hepática é 
normalmente progressiva e evolui de esteatose microvesicular com proliferação dos ductos 
biliares para cirrose e falência hepática crónica. O uso de ácido valpróico como terapia para 
a epilepsia pode precipitar a falência hepática aguda. Mutações no gene POLG são uma 
causa frequente do síndrome de Alpers-Huttenlocher. Até ao momento, estão descritas 
cerca de 55 mutações associadas à forma hepatocerebral, distribuídas pelos seguintes 
genes: DGUOK, MPV17, POLG, C10orf2, TK2 e SUCLG1. Genes, como DGUOK e MPV17, 
encontram-se também associados ao síndrome das deleções múltiplas do mtDNA.35,36 Uma 
breve descrição destes genes será efetuada, com exceção dos genes POLG e C10orf2 que 
foram descritos na secção anterior e dos genes TK2 e SUCLG1 que serão descritos 
seguidamente nas formas miopática e encefalomiopática de MDS, respetivamente.  
 
DGUOK: a cinase deoxiguanosina (DGUOK) fosforila a deoxiguanosina e a deoxiadenosina, 
contribuindo para a síntese de dois nucleotídeos necessários à manutenção da pool de 
desoxirribonucleótidos trifosfato (dNTPs) mitocondrial.22,37A associação de MDS com 
mutações neste gene sugere que a manutenção desta pool de dNTPs apresenta um papel 
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crucial na replicação e integridade do mtDNA e consequentemente no seu conteúdo. Os 
doentes com mutações no gene DGUOK, localizado no locus 2p13, apresentam geralmente 
alterações hepáticas progressivas e dificuldades alimentares, associadas a disfunção 
neurológica (hipotonia, nistagmus e atraso psicomotor) por volta dos 3 meses de idade. A 
presença de neuropatia periférica e tubulopatia são raras mas, no entanto, foram descritas 
ocasionalmente.38 A depleção do mtDNA está presente maioritariamente no fígado, não se 
observando no músculo nem nos fibroblastos. A nível histológico pode-se encontrar 
esteatose microvacuolar, colestase, fibrose e cirrose. Muitos casos apresentam uma 
evolução rápida e progressiva da doença, podendo a morte ocorrer até aos 12 meses de 
idade.39 As primeiras mutações patogénicas descritas neste gene foram publicadas em 2001 
por Mandel e colaboradores.40 Atualmente, foram descritas mais de 50 mutações em cerca 
de 100 doentes (HGMD). 
 
MPV17: outro gene envolvido nesta forma clínica é o MPV17 que se localiza no locus 2p23-
p21 e codifica uma pequena proteína da membrana mitocondrial interna de função ainda 
pouco esclarecida. Estima-se que participa na manutenção da pool de dNTPs necessária 
para a síntese de mtDNA. O seu papel na patogénese do MDS é ainda desconhecido. 
Clinicamente estes doentes apresentam falência hepática severa, hipoglicemia, sintomas 
neurológicos e múltiplas lesões a nível cerebral durante o primeiro ano de vida.41 A presença 
de grande quantidade de mtDNA depletado no fígado e/ou no músculo, assim como um 
défice múltiplo dos complexos da CRM, estão normalmente presentes nestes doentes. A 
nível histológico pode-se observar esteatose microvesicular e fibrose pericelular focal e 
periportal. Foram descritos aproximadamente 30 indivíduos com mutações no gene 
MPV17.42,43 Desde a descoberta da primeira mutação neste gene 44, foram descritas mais de 
25 mutações associadas a esta forma clínica e também à neuro-hepatopatia de Navajo, uma 
doença multissistémica autossómica recessiva encontrada na comunidade de Navajo no 
sudoeste dos Estados Unidos.22 
13 
 
ii) Forma miopática 
Na forma miopática de MDS, o aparecimento de sintomas ocorre normalmente no primeiro 
ano de vida, com dificuldades alimentares, atraso de crescimento, hipotonia e fraqueza 
muscular. A creatina cinase (CK) está frequentemente aumentada, sendo um marcador 
importante para o diagnóstico, uma vez que não é muito comum em doentes com outras 
miopatias mitocondriais.9 A morte ocorre normalmente nos primeiros anos de vida devido a 
insuficiência pulmonar e infeções, mas existem casos de alguns pacientes estudados que 
sobreviveram até à adolescência.45 Estas manifestações clínicas e bioquímicas são 
acompanhadas de sinais morfológicos típicos de miopatia mitocondrial tal como a presença 
de fibras citocromo c oxidase negativas. A proliferação de mitocôndrias sob a forma de 
fibras rotas e vermelhas (RRFs) não é uma característica primária consistente mas, no 
entanto, pode aparecer mais tarde no decurso da doença. Defeitos bioquímicos em todos os 
complexos da CRM codificados pelo mtDNA estão sempre presentes nas mitocôndrias do 
tecido muscular. 
 
TK2: a timidina cinase (TK2) é uma enzima que fosforila a deoxitimidina, deoxicitosina e 
deoxiuridina, participando juntamente com a DGUOK na síntese de nucleotídeos 
necessários para a manutenção da pool de dNTPs mitocondrial.46 
O gene TK2 localiza-se no locus 16q22 e as mutações descritas neste gene estão 
especificamente associadas à forma miopática. Os sintomas aparecem durante a infância ou 
a adolescência e caracterizam-se por miopatia progressiva, culminando em falência 
respiratória e em morte, nos casos mais graves. No entanto os fenótipos menos graves 
apresentam uma evolução mais lenta da doença e um maior tempo de sobrevivência.34 
Em 2001, Saada e colaboradores47 identificaram pela primeira vez mutações neste gene. 
Depois desta primeira observação, um total de 37 mutações no gene TK2 foram já descritas 
em mais de 50 doentes.43 A maioria destas mutações estão associadas à forma miopática. 
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No entanto, existem mutações associadas a outros fenótipos, como é o caso da PEO, 
surdez neurosensorial e encefalopatia epilética (HGMD). 
 
iii) Forma Encefalomiopática 
Em 2005, Elpeleg e colaboradores48, descreveram uma forma de encefalomiopatia 
autossómica recessiva associada a depleção do mtDNA. O aparecimento dos sintomas 
ocorre igualmente na infância, e manifestam-se através de hipotonia muscular, atraso 
psicomotor grave, deterioração neurológica progressiva, surdez, perda de movimentos 
voluntários, oftalmoplegia externa, convulsões generalizadas e variável disfunção tubular 
renal. Verifica-se um aumento do lactato sanguíneo e, na ressonância magnética cerebral, 
podem-se observar lesões nos gânglios basais sugestivas de síndrome de Leigh.37 
Mutações nos genes, RRM2B, SUCLA2 e SUCLG1 estão associadas a esta forma clínica e 
encontram-se seguidamente descritas. 
 
RRM2B: o gene RRM2B localiza-se no locus 8q23 e codifica a subunidade R2 da reductase 
ribonucleotídica (RNR), uma enzima citosólica que está envolvida no passo terminal da 
síntese de novo dos dNTPs, convertendo os nucleotídeos em dNTPs durante a interfase do 
ciclo celular (fase S). A RNR está também envolvida no suplemento de dNTPs durante a 
reparação do DNA. Mutações neste gene estão associadas a hipotonia, acidose láctica, 
atraso de desenvolvimento e tubulopatia. A doença apresenta uma evolução rápida e fatal e 
manifesta-se frequentemente nos primeiros meses de vida. Verifica-se também a presença 
de grande quantidade de mtDNA depletado no músculo destes doentes.  
Em 2007, Bourdon e colaboradores49 descreveram a primeira mutação patogénica neste 
gene, estando atualmente mais de 30 mutações descritas em aproximadamente 15 
doentes.43  
 
15 
 
SUCLA2 e SUCLG1: a enzima succinil-CoA sintetase catalisa a síntese reversível do 
succinato e ATP a partir de succinil-CoA e ADP no ciclo dos ácidos tricarboxílicos (TCA). 
Esta enzima é constituída por duas subunidades, α e β, codificadas pelos genes SUCLG1 
(2p11) e SUCLA2 (13q12), respetivamente. Mutações nestes genes parecem dificultar a 
associação entre a succinil-CoA sintetase e a cinase difosfato-nucleósido mitocondrial, 
resultando num desequilíbrio na pool de dNTPs mitocondrial e consequentemente na 
depleção do mtDNA no músculo.50 Um dado importante para a suspeita do envolvimento 
destes genes é a presença de uma excreção urinária, moderada a elevada, de ácido 
metilmalónico e a presença de intermediários do TCA. Alguns doentes morrem durante a 
infância, no entanto outros apresentam uma maior sobrevivência. Clinicamente revelam 
hipotonia muscular proeminente, atraso psicomotor grave, distonia progressiva, surdez e 
convulsões generalizadas. Os doentes com mutações no gene SUCLG1 podem ainda 
apresentar dismorfias pré-natais, crises metabólicas neonatais e a morte pode ocorrer nos 
primeiros meses de vida. 
Estão descritos cerca de 30 doentes com mutações nestes genes, das quais nove no gene 
SUCLA251 e 13 no gene SUCLG1 (HGMD). 
 
 
ABORDAGENS DE DIAGNÓSTICO DAS DOENÇAS DE COMUNICAÇÃO 
INTERGENÓMICA 
Nas doenças da comunicação intergenómica a apresentação clínica pode variar entre os 
síndromes bem definidos e um fenótipo multissistémico inespecífico onde o envolvimento 
neurológico está geralmente presente. Estabelecer um diagnóstico preciso num doente com 
suspeita de patologia mitocondrial revela-se um desafio, que requer uma abordagem 
multidisciplinar a nível clínico, bioquímico e histopatológico, para além de uma história 
familiar bem documentada. É importante obter as informações bioquímicas e/ou clínicas 
para uma investigação molecular adequada que permita identificar a mutação causal.  
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A determinação da atividade enzimática dos complexos enzimáticos da CRM é importante 
para orientar a abordagem molecular, em particular em doentes sem fenótipo específico. 
Como o mtDNA codifica subunidades de vários complexos da OXPHOS (CI, CIII , CIV e 
CV), é expetável que uma depleção do mtDNA provoque um défice combinado da OXPHOS 
(com exceção do CII, o único não codificado pelo mtDNA). No entanto a atividade 
enzimática dos complexos da CRM no músculo pode ser normal, se o tecido muscular não 
se encontrar entre os tecidos afetados, como acontece nos doentes com formas 
hepatocerebrais de MDS. A análise por southern-blot ou por PCR quantitativo em tempo real 
são dois dos métodos que detetam simultaneamente as deleções múltiplas e a depleção do 
mtDNA. Independentemente da tecnologia aplicada utiliza-se um gene nuclear de referência 
específico para a análise (18S) sendo muito importante o uso de controlos da mesma idade 
e do mesmo tecido, dada a natureza dinâmica da qualidade e quantidade do mtDNA.52 
Considera-se como cut-off para o diagnóstico de depleção do mtDNA uma redução do 
número de cópias de mtDNA superior a 65% em relação aos indivíduos controlo, podendo 
esta redução atingir os 80-90% em crianças, nos casos mais graves.  
Os dados bioquímicos, tais como aumento de lactato e piruvato, quer no plasma no LCR ou 
na urina, alteração do perfil de ácidos orgânicos, aumento da alanina no perfil dos 
aminoácidos plasmáticos, assim como os dados de ressonância/tomografia cerebral são 
indicadores importantes para o diagnóstico destas patologias. Por exemplo num doente com 
mutações no gene TK2 há um aumento da CK; mutações no gene TYMP estão associadas 
a um aumento de timidina no soro e urina; nos défices de SUCLA2 e SUCLG1 verifica-se 
um ligeiro aumento de ácido metilmalónico e de ácido metilcítrico na urina.34 
O gene POLG é um hot-spot em casos de doença mitocondrial, e o seu estudo deve ser 
considerado em doentes que apresentem a sequenciação do mtDNA sem alterações e 
manifestem sinais clínicos inespecíficos tais como, hipotonia, atraso do desenvolvimento, 
epilepsia ou doença hepática. A toxicidade hepática induzida pelo ácido valproico em 
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indivíduos com mutações nos genes POLG e C10orf2 pode causar epilepsia fármaco-
resistente.53 
Com base na nossa experiência apresentamos um algoritmo para o estabelecimento de um 
diagnóstico para estas doenças da comunicação intergenómica (Fig. 2). 
 
 
CONSIDERAÇÕES TERAPÊUTICAS 
As citopatias mitocondriais não têm de momento qualquer terapia eficaz disponível, à 
exceção de um défice primário de ubiquinona (Q10) que são muito raros. O tratamento 
efectuado é meramente paliativo usando-se vitaminas, cofactores e substratos respiratórios 
que no entanto se revelaram pouco eficazes. Nos últimos anos, várias abordagens têm sido 
utilizadas e o desenvolvimento da biogénese mitocondrial (explicar melhor?) surgiu como 
uma possibilidade terapêutica.  
No entanto, verifica-se que há uma estratégia diferente para cada caso. Por exemplo, o 
transplante hepático pode ser benéfico para doentes com hepatopatia causada por 
mutações no gene DGUOK que não tenham desenvolvido sintomas neurológicos, sendo a 
presença de hipotonia atraso psicomotor ou nistagmus, contraindicações para o transplante 
hepático.54 Em doentes com mutações no gene MPV17, o transplante de fígado aumentou a 
qualidade e a expetativa de vida em alguns casos55,56, embora desenvolvam sintomas 
neurológicos. Nestes doentes, foi sugerido a instituição de uma dieta controlada de modo a 
evitar a hipoglicemia e a protelar a insuficiência hepática.57 Algumas crianças com mutações 
no gene POLG efetuaram um transplante hepático depois de insuficiência hepática induzida 
por ácido valproico, e embora o transplante tenha sido bem sucedido a evolução neurológica 
foi desfavorável.58,59 Em alguns pacientes verificou-se uma melhoria da função hepática 
após tratamento com succinato ou coenzima Q10 ao qual se associou uma dieta rica em 
lipídios.60 Nos doentes com MNGIE foi observada uma correlação entre os níveis 
plasmáticos da timidina e a gravidade do fenótipo61. Portanto, as tentativas para reduzir os 
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níveis circulantes de nucleótidos, através da infusão de plaquetas de dadores saudáveis, 
podem resultar numa melhoria da doença, restaurando parcialmente a atividade da TP. No 
entanto a semi-vida curta das plaquetas é uma limitação desta terapia.62 A diálise peritoneal 
tem sido usada para reduzir os níveis de timidina nestes doentes.63  
Apesar de atualmente não existirem tratamentos totalmente eficazes para estas patologias, 
estão a ser identificadas novas terapias.64 
 
CONSIDERAÇÕES FINAIS 
A investigação em termos de diagnóstico neste grupo de patologias não é muito diferente da 
que se aplica noutras doenças e inclui a recolha de dados como história familiar, exame 
físico e neurológico, exames laboratoriais de rotina e específicos e eventual realização de 
biópsia muscular para estudo histopatológico, bioquímico e molecular.65 Uma doença 
mitocondrial que se manifesta ao nascimento ou nos primeiros dias de vida é mais provável 
estar associada com alterações a nível do nDNA do que com alterações a nível do mtDNA. 
Os síndromes da depleção e de deleções múltiplas do mtDNA têm surgido cada vez mais 
como uma das principais causas de um amplo espetro de patologias multissistémicas de 
início na infância ou na idade adulta, respetivamente. Os avanços recentes na tecnologia de 
sequenciação, nomeadamente a utilização da sequenciação de nova geração, permitiram 
esclarecer a etiologia molecular em 55% dos doentes com suspeita de patologia 
mitocondrial, possibilitando a identificação de mutações causais em novos genes, por vezes 
não diretamente relacionados com patologias mitocondriais.66,67,68 
A caraterização molecular destes doentes é importante não só para permitir a realização de 
aconselhamento genético e diagnóstico pré-natal adequados, nos casos em que forem 
identificados mutações no nDNA, mas também para melhorar a compreensão da 
fisiopatologia da doença. Uma estratégia de diagnóstico precisa e focada irá economizar 
recursos e possibilitará avanços fundamentais na compreensão da biologia mitocondrial, 
essencial ao desenvolvimento de novas estratégias terapêuticas. 
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Tabela 1. Principais fenótipos clínicos e respetiva etiologia molecular associada às doenças 
de Comunicação Intergenómica (HGMD Professional database www.hgmd.cf.ac.uk/). 
Fenótipos Clínicos Genes Número de mutações descritas  
Oftalmoplegia Progressiva Externa (PEO) 
POLG 65 
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POLG2 1 
C10orf2 39 
SLC25A4 5 
MGME1* 2 
TK2* 1 
RRM2B 17 
DGUOK 2 
Neuropatia, ataxia sensorial, disartria e oftalmoparésia 
(SANDO) 
POLG 14 
SLC25A4 1 
Epilepsia e ataxia espinocerebelar (SCAE)  POLG 1 C10orf2 4 
Cardiomiopatia hipertrófica SLC25A4 3 
Encefalomiopatia neurogastrointestinal mitocondrial 
(MNGIE) 
TYMP* 81 
RRM2B 2 
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POLG* 1 
Síndrome da depleção do mtDNA - forma hepatocerebral  
POLG 8 
C10orf2 3 
DGUOK 51 
MPV17 28 
TK2 1 
Síndrome da depleção do mtDNA - forma miopática 
POLG 1 
TK2 34 
RRM2B 3 
DGUOK 1 
 RRM2B 14 
Síndrome da depleção do mtDNA - forma encefalomiopática TK2 1 
 SUCLA2 9 
 SUCLG1 13 
Síndrome de Alpers-Huttenlocher POLG 54 
**Presença de deleções múltiplas e depleção do mtDNA 
 
  
 
 
Fig. 1 Representação esquemática da mitocôndria e dos genes envolvidos nas doenças da 
comunicação intergenómica. Na mitocôndria podem
replicação do mtDNA (POLG e C10orf2
de nucleótidos mitocondrial (DGUOK
dos ácidos tricarboxílicos (SUCLA2
fosforilação oxidativa. Estão também representados genes envolvidos na síntese proteica 
mitocondrial (PUS1 e aminoacil-tRNA sintetases
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Fig. 2 Algoritmo de diagnóstico para as patologias da comunicação 
base em dados clínicos e bioquímicos. CRM: cadeia respiratória mitocondrial; qPCR:PCR 
quantitativo em tempo real; SB: Southern
intergenómica, com 
-Blot. 
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ABSTRACT  
Mitochondrial dysfunction accounts for a relevant group of inherited metabolic disorders in large 
part caused by a dysfunctional mitochondrial respiratory chain (MRC) and consequently a 
deficient energy production. MRC function depends on the coordinated expression of both 
nuclear (nDNA) and mitochondrial (mtDNA) genomes. Thus, mitochondrial diseases can be 
caused by genetic defects in the mitochondrial or the nuclear genome or even in the interplay 
between the two genomes, causing the so termed nuclear-mitochondrial intergenomic 
communication disorders, that result in loss or instability of the mitochondrial genome leading to 
qualitative  or quantitative lesions of mtDNA. In pediatric age, most MRC disorders are 
associated with nuclear gene defects rather than alterations in the mtDNA itself.  
Mitochondrial DNA Depletion Syndromes (MDS) are a clinically heterogeneous group of 
autosomal recessive disorders occurring in infancy or early childhood, characterized by a 
reduced number of copies of mtDNA in the affected tissues and organs. At least four clinical 
categories of MDS are recognized: hepatocerebral, myopathic, encephalomyopathic and 
neurogastrointestinal. The focus of this review is to offer an overview of MDS, presenting a list 
of clinical phenotypes, their relative frequency, mutational spectrum, and possible pathogenic 
mechanisms involved in biogenesis and replication of mtDNA.  
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INTRODUCTION 
Mitochondria are dynamic cellular organelles, present in almost all eukaryotic cells, specifically 
involved in the production of cellular energy because of the mitochondrial respiratory chain 
(MRC) and the oxidative phosphorylation (OxPhos) system. In addition to the most important 
function, ATP production, mitochondria are involved in the regulation of other cellular pathways 
such as calcium homeostasis, apoptosis and programmed cell death [1]. 
Mitochondrial disorders are a group of genetically and phenotypically pleiomorphic disorders 
with an estimated incidence between 1:5,000 and 1:10,000 live births [2], they are often 
attributable to dysfunction of the OxPhos, which leads to a deficiency in ATP production. 
The regulation of the MRC is the result of the interaction of two physically and functionally 
separate genomes: the nuclear DNA (nDNA) and the mitochondrial DNA (mtDNA) genomes. To 
carry out the OxPhos reactions mitochondria require the participation of about 1,500 genes 
encoded by both nuclear and mtDNA [3]. These genes encode for about 92 protein subunits 
forming the five multiprotein complexes embedded in the inner mitochondrial membrane. The 
mtDNA encode for 13 subunits of the  OxPhos complex, for 2 ribosomal RNA (rRNA) and 22 
transfer RNA (tRNA) that are required for initiating translation and protein synthesis [4]. 
Therefore, although human mtDNA codes for the basic machinery of protein synthesis, a 
number of nuclear encoded factors are also needed, includingthe enzymes for replication, 
repair, and transcription, to carry out protein translation. This dependency lies at the heart of 
several newly recognized human diseases that are characterized by secondary abnormalities of 
mtDNA. The cross-talk between the two genomes is crucial for the maintenance of qualitative 
and quantitative mtDNA integrity and for correct mitochondrial protein production. Multiple 
deletions, depletion, or a combination of the two in critical tissues, are the hallmarks of disease 
conditions dysregulating the communication between the two genomes. A congruous amount of 
mtDNA is required for the production of key subunits of MRC complexes and therefore mtDNA 
depletion will result in organ dysfunction due to insufficient synthesis of respiratory chain 
components needed for adequate energy production [5]. 
MtDNA depletion syndromes (MDS) embrace a heterogeneous group of autosomal recessive 
disorders, characterized by low mtDNA levels in specific tissues. The syndromes are a 
consequence of defects in mtDNA maintenance caused by mutation in nuclear genes that 
function in either nucleotide synthesis (TK2, SUCLA2, SUCLG1, RRM2B, DGUOK and TYMP) 
or mtDNA replication (POLG, C10orf2). The first group of genes produce proteins that maintain 
the mitochondrial dNTP pool. dNTPs can be synthesized via either the de novo pathway (cell 
cycle-regulated) or the salvage pathway in which they are produced by utilizing preexisting 
deoxynucleosides to synthesize DNA precursors. Given that mtDNA replicates continuously and 
independently of cell division, mutations in any of the genes responsible for the dNTP pool will 
end in an impoverishment of the mitochondria from DNA building blocks will ensuing mtDNA 
depletion. On the other hand, mutations in POLG (the DNA polymerase gamma, the only DNA 
polymerase in humans that allows for replication and repair of mtDNA) and C10orf2 (Twinkle, a 
helicase) result in impaired synthesis and incapacity to supply sufficient mtDNA to daughter 
cells during cell divisions resulting in reduction of low genome content [6]. 
 
MDS are rare, devastating diseases that manifest typically, although not exclusively, soon after 
birth, and lead usually to death in infancy or early childhood. MDS differ from more canonical 
MRC disorders, as they usually manifest as a tissue-specific disease [6,7]. However, it may 
occur that multiple organs, including the heart, brain, and kidneys, are affected [8]. 
 
The aim of this paper is to review the clinical manifestations and the molecular etiologies of 
nuclear defects involved in MDS and to provide possible insights towards best diagnostic 
strategies. 
 
MDS – CLINICAL MANIFESTATIONS 
MDS are usually classified as myopathic form (associated often with mutation in TK2), 
encephalomyopathic form (associated with changes in SUCLA2, SUCLG1,and RRM2B), 
hepatocerebral form (variants in DGUOK, MPV17, POLG and C10orf2) or  neurogastrointestinal 
form (in TYMP) [9]. In Table 1 we summarized the main clinical manifestations and molecular 
etiologies associated with MDS. 
 
 
 
Hepatocerebral MDS 
The hepatocerebral MDS are probably the best known variants of the clinical condition and so 
far 55 mutations have been associatedwith this syndrome, including mutations in the POLG, 
C10orf2, TK2, DGUOK, MPV17 and SUCLG1 genes. The onset occurs within the first 6 months 
and death usually occurs within one year. Common symptoms include persistent vomiting, 
failure to thrive, hypotonia and hypoglycemia associated with progressive neurological 
deterioration. Histological changes on liver biopsy include fatty degeneration, bile duct 
proliferation, fibrosis and collapse of lobular architecture. Reduced cytochome c oxidase (COX) 
histochemistry and combined deficiency of mtDNA-encoded MRC complexes were detected in 
the liver of infants or toddlers . A peculiar form of hepatocerebral MDS is Alpers-Huttenlocher 
syndrome (AHS), an early-onset, fatal disease, characterized by hepatic failure, intractable 
seizures evolving into epilepsia partialis continua, and global neurological deterioration. The 
liver dysfunction is usually progressive as well, evolving from microvesicular steatosis with bile 
duct proliferation into cirrhosis and organ failure [10,11]. Brain MRI includes signal abnormalities 
in the basal ganglia and thalami, irregularly widened ventricles and partial pachygyria. Patients 
usually, but not always, present MRC deficiencies and low mtDNA in liver, although both may be 
normal in skeletal muscle. The clinical picture overlaps with hepatocerebral syndrome, and is 
probably among the severest diagnosis of infancy [12]. Mutations in DGUOK, MPV17,  POLG, 
and C10orf2 cause the hepatocerebral form of MDS. 
 
i) DGUOK 
Deoxyguanosine kinase (DGUOK) is a 2-deoxyribonucleoside enzyme that catalyzes the first 
step of the mitochondrial deoxypurine salvage pathway, namely, the phosphorylation of purine 
deoxyribonucleosides into the corresponding nucleotides deoxyguanosine and deoxyadenosine 
necessary for the maintenance of mitochondrial deoxynucleotide triphosphate (dNTP) pools [8, 
13]. The typical phenotype of mutations in DGUOK is neonatal onset of progressive liver 
disease and feeding difficulties, usually associated with hypotonia, nystagmus, and 
psychomotor retardation by the age of 3 months. Most cases harbor null mutations and die 
before age 2 years. Peripheral neuropathy and renal tubulopathy have occasionally been 
reported [14]. Depletion of mtDNA has been documented mainly in the liver, where it results in 
combined reduction of complex I, III and IV; the amount of mtDNA is usually normal in other 
tissues, at least at disease onset. Histological analyses of liver biopsies show variable findings, 
including microvacuolar steatosis, and cholestasis. Progression is usually rapid with low life 
expectancy [15]. The majority of affected newborns show elevated serum concentration of 
tyrosine or phenylalanine on newborn screening. Intrahepatic cholestasis typically include 
elevation of liver transaminases, gammaglutamyltransferase and conjugated hyperbilirubinemia. 
An increased of serum concentration of ferritin is often observed [16,17]. 
Since the initial report of pathogenic mutations in 2001 [18], more than 100 affected patients 
have been reported and over 50 different DGUOK mutations have been identified (reviewed in 
[9]). 
 
ii) MPV17 
The MPV17 gene lies on chromosome 2p23-p21 and encodes a mitochondrial inner membrane 
protein of unknown function. It has been suggested that MPV17 plays a role in controlling 
mtDNA maintenance and OxPhos activities in mammals and yeast [19]. The clinical 
presentation associated with mutations in MPV17 consists of severe liver failure, hypoglycemia, 
growth retardation, neurological symptoms and multiple brain lesions during the first year of life 
[20]. Marked liver depletion associated with biochemical deficits are found, with complex I or I + 
III being the most affected. Both mildly reduced mtDNA content and defective OxPhos activities 
may also occur in muscle [21]. Histological analyses of the liver have revealed swollen granular 
hepatocytes, steatosis with focal pericellular and periportal fibrosis. Approximately 30 MPV17-
related children have been reported [9]. At least 25 different mutations have been described in 
infantile-onset hepatocerebral syndrome and also in the allelic Navajo neurohepatopathy, an 
autosomal recessive multisystem disorder typical of the Navajo community in southwestern 
United States [13]. Three main subtypes are to be considered: infantile (onset < 6 months) and 
childhood (< 5 years) forms with hypoglycemic episodes and severe progressive liver 
dysfunction requiring liver transplant, and a “classic” form with moderate hepatopathy and 
progressive motor and sensory axonal neuropathy. The three subtypes are also associated with 
variable degrees of demyelination in both the central and the peripheral nervous systems. 
 
iii) POLG 
Human mitochondria contain a single DNA polymerase, polymerase gamma (POL γ), the only 
polymerase responsible for mtDNA replication and repair in mitochondria. POL γ is composed of 
a catalytic subunit that has both polymerase and proofreading exonuclease activities, and an 
accessory subunit, which increases enzyme processivity [17]. The holoenzyme functions in 
conjunction with the mtDNA helicase and the mitochondrial single-stranded DNA- binding 
protein to form the minimal replication apparatus [22].  
The POLG gene on chromosome 15 comprises 23 exons spanning 18.55 kb. Over 200 
mutations have been reported (Human DNA Polymerase Gamma Mutation database [23]) and 
POLG is considered a hot-spot for mutations associated with mitochondrial diseases [24, 25] 
with a large variety of clinical presentations, ranging from autosomal dominantly and 
recessively-inherited forms of progressive external ophthalmoplegia (PEO) to juvenile 
spinocerebellar ataxia and epilepsy (SCAE) with or without dysarthria, to AHS [12,26]. 
Approximately 45 different point mutations in POLG cause AHS [12] whose incidence has been 
estimated to be ~1:50,000 [27]. The two most common POLG mutations detected in AHS, i.e., 
A467T and W748S, can be either homozygous or heterozygous in combination with other 
variants. Carrier frequency for these mutations is higher in Western countries than elsewhere, 
For example, it is 1:125 for W748S in Finland; or 1:50 in Norway, if both variants are combined, 
whereas; 0.6% of normal Belgium population harbor the A467T, and a single ancestral founder 
mutations being hypothesized for both variants [6].  
 
iv) C10orf2 (Twinkle) 
The mitochondrial protein Twinkle, encoded by PEO1/C10orf2 (OMIM 606075) on chromosome 
10q24, is a mtDNA helicase, active as a homohexamer and bound to mtDNA in mitochondrial 
nucleoids [28]. Mutations in C10orf2 cause dominant disorders such as pure adult-onset PEO 
with multiple mtDNA deletions, or recessive clinical conditions including severe early-onset 
hepato-encephalopathy or infantile-onset spinocerebellar ataxia (IOSCA) and low mtDNA in 
brain and liver, but not in skeletal muscle [6]. Neuroimaging can show cerebellar cortical 
atrophy; OxPhos assays show reduced complexes I, III, and IV,. 
IOSCA is a severe autosomal recessively-inherited neurodegenerative disorder that manifests 
after 9-18 months of age by progressive atrophy of the cerebellum, brain stem and spinal cord, 
ataxia during the first two years, hypotonia with sensory axonal neuropathy, optic atrophy, 
hearing impairment and ophthalmoplegia [6]. Patients usually survive to adult age. The severe 
neurological phenotype and the absences of muscle involvement observed in IOSCA suggest 
that Twinkle may play a crucial role in the maintenance and function of specific affected 
neuronal subpopulations [8].  
IOSCA represents the second most common heritable ataxia in Finland because of the founder 
effect of the Y508C variant and a carrier frequency of about 1:200. The same mutation has also 
been described in cases with severe epileptict encephalopathy and hepatic failure [29]. 
 
Myopathic MDS 
The symptoms of myopathic MDS usually appear in the first year of life and consist of feeding 
difficulties, failure to thrive, hypotonia, muscle weakness, and, occasionally, PEO. Death is often 
due to pulmonary insufficiency and recurrent infections, but some patients survive into their 
teens [30]. Muscle biopsy may show proliferation of mitochondria, and patchy or diffuse 
deficiency of COX. Biochemical defects of all mtDNA-related respiratory chain complexes are 
always present in muscle mitochondria. Serum creatine kinase (CK) levels may be variably 
elevated [31]. 
 
i) TK2 
Thymidine kinase (TK2) is an intramitochondrial pyrimidine nucleoside kinase that 
phosphorylates dNTPs, such as deoxythymidine, deoxycytidine and deoxyuridine, thereby 
participating in the salvage pathway of deoxynucleotide synthesis [32]. Mitochondrial dNTP 
pools arise either through active transport of cytosolic dNTPs or through salvage pathways. 
Both pathways are essential for the replication of mtDNA, since the mitochondrion is unable to 
synthesize dNTPs de novo. Mutations in TK2, on chromosome 16q22, primarily affect muscle 
tissue, and have little or no effect on liver, brain, heart or skin. The clinical presentation of TK2-
related MDS is variable, with a broad phenotype. Typical manifestation include a severe, rapidly 
progressing myopathy of infantile or childhood onset. Disease course is rapidly progressive, 
leading to respiratory failure and death in months or few years, although milder phenotypes with 
slower progression and longer survival have been described [6]. To date, about 50 individuals 
with TK2-related MDS have been reported [9]. Since description of the first mutation in 2001 
[33], 31 different pathogenic autosomal recessive mutations have been described, and the 
different phenotypes may be explained by variable degrees of residual activity of the mutant 
enzymes. Mutations in POLG and RRM2B are additional etiologies in myopathic presentation of 
low mitochondrial copy number. Milder presentations manifest as late onset proximal muscle 
weakness, adult-onset progressive myopathy, with or without sensorineural hearing loss [9]. 
 
Encephalomyopathic MDS 
Encephalomyopathic MDS are characterized by infantile onset of hypotonia with severe 
psychomotor retardation, high lactate levels in blood, progressive hyperkinetic-dystonic disorder, 
external ophthalmoplegia, deafness, generalized seizures and variable renal tubular 
dysfunction. Brain MRI is often affected and initially was suggestive of the pathological features 
seen in Leigh syndrome [8]. 
 
i) RRM2B 
The RRM2B gene on chromosome 8q23 encodes the small subunit of p53-inducible 
ribonucleotide reductase, a heterotetrameric enzyme responsible for de novo conversion of 
ribonucleoside diphosphates into the corresponding deoxyribonucleoside diphosphates that are 
crucial for DNA synthesis [34]. The enzyme is the main regulator of the nucleotide pools in the 
cytoplasm and its small subunit is expressed in postmitotic cells, where it probably has a key 
function in maintaining the mitochondrial dNTP pools for mtDNA synthesis. Mutations in RRM2B 
usually result in neonatal hypotonia, lactic acidosis, failure to thrive and tubulopathy. 
Psychomotor delay, sensorineural hearing loss and a profound reduction of mtDNA copy 
numbers in skeletal muscle [34] are also present. The disease has a rapid progression and 
leads to death in a few months. The associated complex phenotype suggests that the 
consequences of defective mitochondrial dNTP pools can vary dramatically depending on the 
residual amount of functional enzyme. Approximately 15 infants have been described [9]. Of the 
31 mutations thus far described, 30 are associated with major phenotypes. 
ii) SUCLA2 and SUCLG1 
Succinyl CoA synthase is a mitochondrial matrix enzyme that catalyzes the reversible synthesis 
of succinate and ATP or GTP from succinyl-CoA and ADP in the tricarboxylic acid cycle. This 
enzyme is made up of two subunits, a and b, encoded by SUCLG1 on chromosome 2p11 and 
SUCLA2 on 13q12, respectively. Mutations in SUCLA2 and SUCLG1 cause an 
encephalomyopathic form of infantile MDS, but SUCLG1 can also cause a severe disorder 
characterized by antenatal dysmorphisms, neonatal metabolic crisis, and early death 
REFERENCE HERE. Differences in presentation between patients might depend on the lower 
residual amount of the protein [35-37]. Useful diagnostic clues in succinyl CoA synthase 
disorders are the presence of ‘‘mildly’’ elevated urinary methylmalonic acid in all patients and 
the presence of tricarboxylic acid cycle intermediates (methylcitrate, lactate, carnitine esters, 3-
hydroxyisovalericacid) in most cases. Some patients die as infants (sudden infant death 
syndrome), but others show a longer survival. The clinical features include early childhood 
hypotonia, developmental delay and, almost invariably, progressive dystonia and sensorineural 
deafness. Mutations in SUCLA2 and SUCLG1 seem to disrupt the association between succinyl 
CoA synthase and mitochondrial nucleoside diphosphate kinase, resulting in an unbalanced 
mitochondrial dNTP pool and, eventually, in low mtDNA in muscle [38]. Thirty individuals, 20 
with SUCLA2 and 10 with SUCLG1 mutations, have been reported (reviewed in [9]), with a total 
of 22 mutations, 17 of which are associated with encephalomyopathic and one with 
hepatocerebral MDS. 
 
Neurogastrointestinal MDS 
The MNGIE (mitochondrial neurogastrointestinal encephalomyopathy) syndrome is an 
autosomal recessive disorder clinically characterized by onset between the first and fifth 
decades with the vast majority of cases starting with symptoms in juvenile period before age 20 
years. All affected individuals develop weight loss and progressive gastrointestinal dysmotility 
manifesting as early satiety, nausea, dysphagia, gastroesophageal reflux, postprandial emesis, 
episodic abdominal pain with distention, and diarrhea. In addition, all affected individuals have 
motor and sensory demyelinating neuropathy that may be accompanied by axonal neuropathy 
in some cases. The neuropathy typically presents with distal weakness and paresthesias 
occurring in a symmetric stocking-glove distribution. Ptosis and ophthalmoplegia are common. 
Affected individuals can have elevated CSF protein and plasma lactate. Thymidine and 
deoxyuridine are increased in plasma. Thymidine phosphorylase (TP) enzyme activity in 
leukocytes is usually less than 10 % of the control mean. Neuroimaging typically demonstrates 
diffuse white matter changes  [9]. 
In MNGIE, abnormalities of mtDNA can include depletion, multiple deletions and point mutations 
[39]. Mutations in TYMP and RRM2B have been linked to MNGIE, though recent varints in 
POLG have been described in MNGIE-like syndromes [40].  
Skeletal muscle generally shows ragged-red fibers and defects in single or multiple OxPhos 
complexes, especially COX. However, MNGIE has been reported without skeletal muscle 
involvement at the morphological, enzymatic, or mtDNA content level. Life expectancy is 
reduced (ranging from 25–60 years) [9]. 
 
i) TYMP  
The TYMP gene encodes the cytosolic enzyme TP, which catalyzes the conversion of thymidine 
to thymine and deoxyuridine to uracil, and is therefore essential for pyrimidine catabolism. 
Defects of TP cause systemic accumulation of thymidine and deoxyuridine; this leads to 
deoxynucleotide pool imbalance and mtDNA instability, resulting in the presence of multiple 
deletions and partial depletion of muscle mtDNA [41]. 
TYMP is located at chromosome 22 and comprises 10 exons spanning 4.3 kb DNA. The first 
pathogenic mutations were described in 1999 [41] and since then over 70 mutations have been 
described, most of all associated with MNGIE. 
MDS - DIAGNOSTIC APPROACHES 
Suspicion of MDS is usually based on clinical presentation, which may range from well-defined 
syndromes to non-specific multisystem phenotypes, where neurological involvement is usually 
present. Establishing a specific MDS diagnosis is challenging and requires the integration of 
clinical assessments, family history, biochemical testing and histopathological examination in 
affected tissues. It is important to obtain the appropriate biochemical and clinical information 
before starting any molecular investigations in order to increase the chances of a successful 
molecular diagnosis. Biochemical determination of MRC complexes is also important, but can 
be normal, if skeletal muscle is not among the affected tissues. Quantitative real-time PCR 
quantification of total mtDNA content in affected tissues, using a nuclear gene as reference, 
represents a prerequisite for correct interpretation of the amount of mtDNA, though it is 
important to select the appropriate age-matched control materials [42] considering the dynamic 
nature of mtDNA copies in different ages and tissues. A reduction in mtDNA copy number to 60-
65% of average age-matched controls is the empirical cut-off level for a diagnosis of primary 
MDS, but the reduction may be greater (80-90%) especially in children. Biochemical data, such 
as lactate, pyruvate, alanine and organic acid profiles, as well as neuroimaging findings, are 
also important clues to propose a diagnosis. Serum CK is especially elevated when mutations 
occur in TK2 mutations, serum thymidine is impaired in TYMP, and a mild elevation of urinary 
methylmalonic acid and methylcitrate occur in disorders linked to SUCLA2 or SUCLG1 [6]. 
Reaching a full molecular definition is also important in adopting the appropriate therapies: 
identification of changes in POLG and C10orf2 should prompt consideration for the risk of 
valproate (VPA)-induced liver toxicity in toddlers with severe drug-resistant epilepsy [43].   
 
MDS - THERAPEUTIC CONSIDERATIONS 
The management of mitochondrial disease is largely supportive as no “magic pill” is available 
[44]. Palliative treatments with vitamins, cofactors and respiratory substrates have been used, 
but showed poor efficacy. In recent years several approaches have been adopted mostly 
through a modulation of the different pathways regulating mitochondrial biogenesis [25], but 
they have not yet being applied translationally. In the meantime, therapeutic possibilities have 
been adopted, though none has an evidence based efficacy. 
For example, liver transplantation may be beneficial to patients with hepatopathy caused by 
DGUOK mutations if no neurological symptoms have developed. However, significant 
hypotonia, psychomotor retardation or nystagmus would be contraindications for transplantation 
[16]. In patients with MPV17,and in VPA-induced organ failure, transplantation has increased 
quality and expectation of life in some patients [5,45], but children may later develop 
neurological symptoms [46,47]. A controlled diet avoiding hypoglycemia has been proposed to 
slow down disease progression and for supportive care [48]. Some improvement was 
suggested with succinate or coenzyme-Q10 together with a lipid-rich diet [49]. Also folate levels 
may be deficient in the cerebrospinal fluid (CSF) of some patients and recognition of low folate 
in the CSF may prompt replacement therapy [50]. Levocarnitine, creatine monohydrate, 
coenzyme Q10, B vitamins, and antioxidants, such as alpha lipoic acid, vitamin E, and vitamin 
C, have been often used as pro-energetic supplements in mitochondrial disorders in general 
and in MDS in particular but longer follow-up is necessary to appraise whether dietary 
interventions should be recommended [44]. In MNGIE, correlation between plasma thymidine 
levels and the severity of the phenotype has been observed [51]. Therefore, attempts to reduce 
the circulating nucleotide levels could result in disease improvement. Enzyme replacement 
therapy has been used in MNGIE: infusions of platelets from healthy donors reduced circulating 
thymidine and deoxyuracile levels and partially restored TP activity. The limitation of this therapy 
is the short half-life of the platelets [52]. Allogeneic stem cell transfusions have been given to 
two patients with MNGIE [53,54] and although more experience is needed to illustrate the 
clinical benefit of this treatment, it opens up a therapeutic possibility for disorders of the 
nucleoside metabolism. Finally, continuous ambulatory peritoneal dialysis has also been used in 
MNGIE to reduce thymidine levels, and this treatment improved symptoms during a three-year 
follow-up [55].  
 
CONCLUDING REMARKS 
A mitochondrial disease manifesting at, or soon after, birth is more likely to be associated with 
nDNA than with mtDNA mutations [25] but until very recently our profound ignorance regarding 
the mechanisms underlying mitochondrial gene transcription and translation and the complex 
interaction between the “two genomes” has limited our diagnostic power.   
MDS have become an increasingly important cause of a wide spectrum of infantile and 
childhood-onset tissue-specific and multisystem disorders and could result from any imbalance 
of the mitochondrial nucleotide pool available for mtDNA replication, as well as abnormalities in 
mitochondrial replication machinery [56]. Consistent with the different phenotypes, mtDNA 
depletion may affect a specific tissue (most commonly brain and muscle or liver) or multiple 
organs, including heart and kidney. More than 75% of MDS patients manifest a full-blown 
condition during the first year of life, and the disease is rapidly fatal in most [57,58]. Identifying 
the causative genes is important not only to allow adequate antenatal options, family planning 
and prenatal diagnosis, but also to improve understanding of the disease pathophysiology and, 
therefore, improve therapeutic options. Thus, the recent advances in the clinical use of next 
generation sequencing (NGS) technologies will likely facilitate the molecular diagnosis in 
forthcoming years [59-61]. Since NGS is becoming a feasible option in several mendelian 
disorders and inborn error of metabolism [62], it also holds the promise to identify a greater 
number of patients with mitochondrial disorders as well [63,64]. This would likely resolve some 
of the open issues emerging from the clinic practice, including difficult diagnosis, uncertain 
counseling and, hopefully, unpredictable prognoses. An accurate and focused diagnostic 
workup will also save health-related resources and family distress. Only by achieving a full 
understanding of the molecular basis of MDS we will gather insights towards novel and effective 
therapeutic strategies. 
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 Figure 1. Schematic overview of the mitochondrion and the mitochondrial disease genes 
involved in MDS disorders. A “magnifying lens” focus on genes (namely, POLG and C10orf2- 
Twinkle) thought to be involved in replication of mitochondrial DNA (mtDNA), on those trusted 
important in the metabolism of the mitochondrial deoxynucleotide (dNTP) pool (via progressive 
phosphorylations of deoxythymidine, deoxycytidine, deoxytadenine, and deoxiguanosine); and 
on those belonging to the tricarboxylic acid cycle and secondary OxPhos involvement.  
 
 
Table 1. Relative frequency of mutations associated with the different forms of 
Mitochondrial DNA Depletion (source: HGMD Professional database www.hgmd.cf.ac.uk/). 
 
 
 
Clinical Manifestations Genes Number of mutations 
Hepatocerebral mtDNA depletion syndrome 
POLG 8 
C10orf2 3 
DGUOK 51 
MPV17 28 
TK2 1 
Alpers-Huttenlocher syndrome POLG 54 
Myopathic mtDNA depletion syndrome 
POLG 1 
TK2 34 
RRM2B 3 
DGUOK 1 
 RRM2B 14 
Encephalomyopathic mtDNA depletion syndrome 
TK2 1 
SUCLA2 9 
SUCLG1 13 
Mitochondrial Neurogastrointestinal Encephalomyopathy 
TYMP 81 
RRM2B 2 
POLG 1 
